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General introduction: a preface to the 
role of surgery in synchronous
metastatic colorectal cancer patients
Introduction
Colorectal cancer is a disease of all time and place. The first 
known description of the disease can be found in the Corpus 
Hippocraticum (± 400 BC). Although its existence has been 
recognised for a long time, it has only been in the last century 
that steps forward are made in its prevention, early diagnosis 
and treatment. Treatment modalities used for colorectal cancer 
include surgery, radiation and systemic therapy. The gold standard 
for localised colorectal cancer is radical surgical resection, with 
(neo)adjuvant therapy in case of local advanced disease. For 
patients who present with unresectable metastatic disease, 
surgery can be indicated to fight symptoms. However, as modern 
systemic palliative treatment may also relieve symptoms as well 
as improve survival significantly, it is commonly considered the 
first therapeutic option. In the last decades, it has also been 
recognized that surgery could be deployed as life-prolonging 
or even curative treatment when the primary tumour and all 
metastases are being removed. This thesis focuses on the role of 
surgery in patients with metastatic colorectal cancer.
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Epidemiology, staging and survival of metastatic colorectal cancer
Worldwide, colorectal cancer is the third most common type of cancer, with 
an estimated incidence of 1,36 million cases in 2012.1 In The Netherlands, 
more than 15,500 new patients (90 per 100,000; 15% of all cancer cases) were 
diagnosed with colorectal cancer in 2015. In approximately 4,500 patients the 
cancer originates in the rectum. The absolute number of patients diagnosed 
with colorectal cancer has doubled since 1990, partly due to growth and 
ageing of the population. In 2014, the bowel cancer screening programme was 
introduced in The Netherlands, which lead to another increase in incidence 
of 12% with reference to 2013. The life-time risk to develop colorectal cancer 
is 7% for men and 5% for women.2 
Approximately 20% of all colorectal cancer patients present with distant 
metastases at the time of first diagnosis 3, and another 20% will develop 
metastases during follow-up 4. The incidence of metastases varies between 
different stages, where patients with locally advanced or node positive 
tumours have a higher risk of metastatic disease compared to patients with 
early tumours. In general, the liver is the predominant site of colorectal 
cancer metastases with 80% of all patients presenting with metastatic lesions 
in the liver. Liver metastases are often asymptomatic, but can coincide with 
aspecific symptoms, such as general discomfort, fatigue or weight loss. More 
specific symptoms, such as jaundice or ascites, only present in late stage 
disease. Nowadays, nearly all colorectal cancer patients are staged with 
computed tomography (CT) of the thorax, abdomen and pelvis; where in 
the past only abdominal ultrasound and chest x-rays were performed. Other 
diagnostic tools include magnetic resonance (MR) imaging and positive 
emission tomography (PET) scanning. MR imaging has a higher sensitivity and 
comparable specificity as CT scanning for the diagnosis of liver metastases.5 
In 40-50% of patients with liver metastases, extrahepatic metastases are 
also present, most commonly situated in the lungs, lymph nodes and the 
peritoneum. The risk and pattern of metastases is also highly dependent on 
location of the primary tumour. Rectal cancer frequently metastasizes to the 
lungs and bones, whereas  colon cancer often primarily presents with hepatic 
metastases.  Metastatic patterns are also related to the histological subtype, 
with a higher rate of peritoneal metastases in mucinous adenocarcinoma, 
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whereas signet ring cell tumour patients more often have metastases in the 
distant lymph nodes.6
Synchronous versus metachronous disease
The TNM Staging System of the American Joint Committee on Cancer (AJCC) 
/ Union for International Cancer Control (UICC) is currently considered to 
be the strongest prognostic factor in outcome prediction for patients with 
colorectal cancer.7 Within this classification, patients with distant metastases 
are classified as “Stage IV”, independent of the size and invasive depth of 
the primary tumour or the presence of lymph nodes metastases. It is called 
synchronous disease if distant metastases are present  when the cancer is 
first diagnosed. If patients are diagnosed with non-metastatic disease, but 
develop metastases during follow-up – it is called metachronous disease. 
There is no international consensus of what constitutes synchronicity. The 
AJCC Staging System (7th edition) states that staging should be done as part 
of definitive surgery or primary treatment, or within 4 months of diagnosis. 
However, various definitions are used in clinical studies.7, 8  A start towards 
a more uniform definition of ‘synchronicity’ was made recently, when an 
international multidisciplinary expert panel agreed that ‘synchronous liver 
metastases’ should be defined as ‘synchronously detected liver metastases’, 
detected at or before diagnosis of the primary tumour.9
It is unclear if metachronous and synchronous disease represent two different 
entities of disease. Several studies indicate that synchronous presentation 
is associated with unfavourable clinical and biological characteristics, and 
might therefore be associated with a poorer prognosis compared to patients 
with metachronous disease.8, 10-13 The number of synchronous disease has 
been slowly increased over time, which is often attributed to earlier diagnosis 
due to an improvement in imaging techniques.14
Prognosis
Relative five-year survival for colorectal cancer has been steadily increased 
from 50-55% in 1989-1993 to 60% in 2008-2012. In The Netherlands, 
approximately 5,000 patients die of colorectal cancer annually (30 per 
100,0000). In 2013, it was the second cause of cancer-related death (11.6% of 
17
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all cases)1. Although five-year survival rates for stage IV colorectal cancer are 
still below 10%, survival has been improving as well. For patients diagnosed 
between 1995-1999 median overall survival was 7.1 months, whereas for 
patients diagnosed between 2005-2007 this has improved to 11.6 months 
in the general population in The Netherlands. In the same period, two-year 
survival rates doubled from 14% to 28%.3
Treatment of metastatic colorectal cancer
Due to the abdominal vasculature, colorectal cancer is pre-eminently a type 
of cancer in which cure can be provided, even when metastases are present. 
Circulating tumour cells originating from the colorectum first enter the liver 
via the portal vein. Therefore, colorectal metastases often occurs initially in 
the liver, before spreading to the rest of the body.  
As a result of the improved imaging techniques, patients with colorectal 
cancer and distant metastases are now more accurately staged and 
appropriate treatment regimens can be applied to each patient. Treatment 
of patients who present with rectal cancer and distant metastases depends 
primarily on the condition, age and frailty of the patients; and obviously 
resectability of the primary tumour and the metastases. It is recommended 
that a treatment plan for patients with metastatic colorectal cancer should 
be achieved through consensus of a multidisciplinary team, consisting 
of the involved medical and surgical specialists.15 The involvement of a 
multidisciplinary team leads to optimal decision-making in the diagnosis 
and treatment, and improves the prognosis of colorectal cancer patients.16-18 
The Dutch standard requires the presence of at least one surgical, medical 
and radiation oncologist, as well as a gastroenterologist, a radiologist, a 
pathologist and a case manager at the multidisciplinary team, with the 
possibility of weekly consultation with the referral centre.19
Metastatic disease can be categorized into three different subgroups: 
resectable disease, potentially resectable disease and unresectable disease. 
Resectable metastatic colorectal cancer
The majority of stage IV patients who undergo treatment of both the primary 
tumour and metastases have liver metastases. When metastatic disease is 
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isolated to the liver, surgical resection of all metastatic lesions can provide 
long-term survival.20 Overall five-year survival rates for patients undergoing 
resection of liver metastases vary between 30-60%, depending on the study 
population.20-23 Various factors for the selection of patients who benefit 
most of resection have been described. The most well-known clinical criteria 
are those established by Fong, which contain the following risk factors: 
a carcinoembryonic antigen (CEA) level >200 ng/ml, the node positivity 
of the primary tumour, multiple liver metastases, a metastatic tumour of 
over 5 centimetres and a disease-free interval between the primary tumour 
and metastases shorter than 12 months.24 With regard to this last item, it 
is understood that survival of these patients with synchronous or ‘early 
metachronous’ metastases is slightly lower compared to ‘late metachronous’ 
disease, although the literature on this subject is contradictory.12, 24-26 
At present, metastasectomy should be considered for all patients with 
colorectal liver metastases when the patient is fit for surgery, when the 
expected remnant liver is at least 20% of the preoperative volume, if 
resection is possible with regard to vascular and biliary structures and if no 
unresectable extrahepatic metastases are present.27-29 Age should not a be 
selection criterion by itself, as long-term outcomes in elderly patients are 
comparable to those of younger patients, and should thus only be considered 
in combination with other risk factors, such as the existence of comorbidity 
or tumour load.28 As the criteria for resectability are evolving fast and 
the number of patients undergoing surgery are increasing 30, determining 
resectability is challenging. Even in high-volume centres (UK cancer 
network), almost two-thirds of patients with tumours deemed unresectable 
by non-liver surgeons were considered potentially resectable by a panel of 
specialist liver surgeons.31 Therefore, patients with liver metastases should 
be discussed in hospitals with liver surgeons. On the other hand, it should be 
remarked that there is considerable inter-individual variation in the decision-
making process between liver-surgeons 29, 32, which highlights the importance 
of multidisciplinary liver tumour boards to optimize timing of surgical 
intervention and multidisciplinary treatment. Several studies from different 
countries have demonstrated that there is still a considerable variation in the 
utilization of liver resection, which might indicate that further optimizing the 
evaluation of resectability will potentially lead to an important improvement 
in the identification of patients.21 The optimal timing for surgical treatment 
is still controversial: metastasectomy can be timed either before (liver-first), 
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during (one-staged) or after (classical) resection of the primary tumour. The 
different strategies have different considerations, and no survival benefit 
has been demonstrated for any of these approaches. Timing should be 
individualized, based on technical and oncological considerations.33 
In recent years, the use of metastasectomy has evolved to include resection 
of limited extrahepatic metastases as well.34, 35 Patients with extrahepatic 
metastases have a poorer prognosis than patients with liver-only metastases. 
However, in selected patients, and especially those patients with single-
site extrahepatic disease, surgery can lead to long-term survival. Although 
evidence is limited and mainly retrospective of nature, surgical resection is 
increasingly done for patients with lung metastases, with increased long-
term survival compared to systemic treatment only.36, 37 For patients with 
peritoneal dissemination, cytoreductive surgery of peritoneal metastases 
in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) 
improves survival, depending on the number of affected regions and the 
completeness of cytoreduction.38, 39
For patients who undergo resection of hepatic metastases, the addition 
of systemic therapy does not lead to a survival benefit, although a minor 
positive impact was observed on the progression-free survival.40-42 Two 
retrospective studies demonstrated only a potential benefit for (neo)
adjuvant chemotherapy for high risk patients according to the Fong 
criteria.43, 44 Because of these limited benefits of adjuvant chemotherapy, it 
is not considered standard care in The Netherlands for all resected patients. 
To identify specific subgroups that do benefit from adjuvant treatment more 
data are warranted.  
Potentially resectable metastatic colorectal cancer
In recent years, various treatment modalities have been introduced to convert 
unresectable metastases into resectable disease. Besides the use of surgical 
techniques, such as portal embolization and different ablation techniques, 
systemic treatment is nowadays frequently used to convert unresectable 
metastases into resectable lesions due to downsizing effects of neoadjuvant 
chemotherapy.32, 45-48 Combination regimens produce higher conversion 
rates compared to monotherapy, and patients with liver metastases who are 
treated with induction systemic treatment and can be secondarily resected 
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have an overall survival comparable to primary resectable patients.49 Tumours 
might become resectable in 15-60% of cases, and with excellent long term 
results.32, 46 Again, criteria for resectability prior to or after neoadjuvant 
chemotherapy are poorly defined, and there is no consensus on the optimal 
systemic therapy regimen. A nationwide trial with a liver expert panel, and 
various induction therapy regimens, is currently ongoing in The Netherlands 
to study and determine the optimal treatment.50 
Other treatment options to provide curative treatment to patients with 
unresectable liver metastases have been developed, such as cryosurgery, 
microwave ablation and radiofrequency ablation (RFA). Of these different 
modalities, RFA is currently the most used. Despite the higher rate of local 
recurrence, 5-year overall survival of patients with limited hepatic metastases 
treated with RFA is reported around 40%. When, even after induction 
systemic therapy, metastases are not surgically resectable, RFA provides an 
increased survival compared to palliative chemotherapy and can be used in 
clinical practice on a case-by case basis.51-53
Unresectable metastatic colorectal cancer
Unfortunately, the majority of patients with metastatic colorectal cancer do 
not qualify for curative therapy, because their metastases have spread in 
such a way that no curative options are available. Non-curative treatment, 
or palliative care, is commonly defined as an approach that improves or 
maintains quality of life through the prevention and relief of pain and other 
physical, psychosocial and spiritual problems.54 Besides counselling and 
social support, palliative care for cancer patients can consist of systemic 
therapy, radiation, surgery and non-invasive pain relief methods. Although 
not in the original definition, palliative treatment in metastatic colorectal 
cancer also aims at controlling the disease in such a way that it prolongs 
survival without compromising the aforementioned quality of life.
The increasing use of palliative systemic therapy during the past two 
decades has led to a remarkable increase in overall survival.55 The optimal 
chemotherapeutic treatment consists of a combination regimen of a 
fluoropyrimidine with irinotecan or oxaliplatin 56-58 in combination with 
targeted therapy (anti-VEGF or anti-EGFR treatment). Triple therapy (with all 
three cytotoxic agents) has been shown to be a promising treatment option, 
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with a median overall survival of 30 months, and acceptable toxicity.59 Little 
research has been done to determine the optimal duration of treatment, but a 
recent study showed a survival benefit for maintenance treatment, compared 
to a treatment-free interval.60 The last decades, several new agents have 
been added to the treatment possibilities of metastatic colorectal cancer, 
including monoclonal antibodies. When surgery is considered, treatment 
with these targeted therapies does not increase perioperative risks, although 
a six week interval between the final administration of bevacizumab and a 
surgical intervention is advised.61
Traditionally, primary tumour resection was preferred in patients with 
incurable stage IV colorectal cancer to prevent, or treat, complications 
such as severe blood loss, a mechanical ileus and intestinal perforation.62 
When such complications do already exist, the indication for surgery 
seems obvious. However, in some cases the tumour might be unresectable, 
or surgery is not feasible for other reasons (e.g. because of the patient’s 
physical condition). In such cases, stenting could provide adequate palliation 
for patients with bowel obstruction.63 Furthermore, prophylactic resection 
of the primary tumour in patients with few or absent symptoms has become 
more controversial over the last few decades. 
At first glance, resection of the primary tumour provides unmistakable 
benefits. Elective removal of the tumour does not only diminish the chance of 
obstruction, perforation of haemorrhage; but also has a lower perioperative 
morbidity compared to the same procedure in an emergency setting. Second, 
resection of the primary tumour can lead to more accurate staging. Tumour 
invasion in adjacent organs or visceral peritoneum (T4) is a predictor of poor 
survival, even when metastases are present.64 Also, peritoneal carcinomatosis, 
another poor prognostic factor, is often only identified by visual exploration, 
as sensitive imaging tools to diagnose this form of metastases are still 
lacking.65 Thus, resection of the primary tumour can lead to a more reliable 
evaluation of the prognosis of a patient, which can assist in determining 
the optimal treatment strategy, as well as in counselling the patient. Finally, 
in other cancer types, such as renal cell cancer, a survival benefit has been 
demonstrated when the primary tumour is surgically removed; and it has 
been hypothesized that cytoreduction might attribute to a better response 
to systemic treatment.66-68 Several retrospective analyses and population-
based studies have demonstrated a possible association between improved 
22
GENERAL INTRODUCTION
overall survival and resection of the primary tumour in colorectal cancer as 
well.13, 69-71
However, a survival benefit has never been proven in a randomized 
controlled trial for colorectal cancer, and currently no prospective data on 
the subject are available. In fact, in murine models resection of the primary 
tumour has led to an accelerated growth of metastases. FDG-PET scanning 
and consecutive biopsies of liver metastases before and after resection of 
the primary tumour in humans also showed increased metabolic activity, 
increased vascularisation and a decrease in the number of apoptotic cells 
after removal of the intestinal tumour.72, 73 Although there are no studies 
that provide clinical relevance to these observations, it does indicate that 
resection of the primary tumour may have a stimulating effect on the growth 
of distant metastases. Furthermore, life-prolonging systemic treatment is 
postponed when it is decided to perform a surgical intervention first.74 For a 
large proportion of patients with synchronous colorectal cancer, local control 
might be reached with systemic treatment and/or radiation.75-77 Indeed, when 
no resection is performed, only a small proportion of patients who receive 
upfront systemic therapy require palliative surgery for complications of the 
primary tumour.78-80 Finally, 30-day mortality rates after elective surgery of 
the primary tumour in patients with stage IV disease range between 1.3-
11.7%, which is lower than in case of emergency surgery, but higher than 
reported after surgery in patients with non-metastatic disease 81; and more 
than 20% of patients develop postoperative complications.3, 82 
In conclusion, the available evidence does not provide outright support for 
either opting for or refraining from primary tumour resection. Despite rapid 
developments in curative treatment, and the expected earlier detection of 
colorectal cancer due to the introduction of the screening program, many 
patients are still awaiting a definitive outcome of the debate on whether to 
resect an asymptomatic primary tumour or not.
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This thesis focuses on several subjects with regard to the surgical treatment 
of stage IV colorectal cancer.
Part 1: Defining the concept of synchronous metastatic colorectal 
cancer
In Chapter 1 the results of a systematic review are presented in which the 
different definitions of synchronous metastatic disease are studied in both 
medical and surgical studies. The difference in overall survival between 
synchronous and metachronous metastases is also evaluated; as well as trends 
in the ratio synchronous versus metachronous disease. Chapter 2 reports 
the results of a nationwide population-based study to determine trends 
in incidence, treatment and survival of colorectal cancer with synchronous 
metastases between 1996 and 2011. For this study, data from the Dutch 
Cancer Registry was used: a database containing information of all cancer 
patients in The Netherlands.
Part 2: How to reach optimal utilization of liver resection
Resection of the primary tumour and all metastases remains the only option 
for curative treatment. Especially liver metastasectomy has shown great 
results. In Chapter 3 it is investigated whether there are differences in the 
utilization of liver resection among hospitals. For this study, the Eindhoven 
Cancer Registry was used, which covers over 2 million inhabitants in the south 
of The Netherlands, and is representative for the general Dutch population. 
To confirm these findings and to investigate the influence of type, volume 
and region of the hospital of diagnosis on the chance of undergoing a liver 
resection, an analysis of nationwide data is described in Chapter 4. 
Part 3: Palliative resection of the primary tumour: an ongoing debate
In Chapter 5 the possible benefit of palliative resection of the primary 
tumour is investigated in a nationwide population-based registry. To correct 
for immortal time bias and selection bias, we performed a propensity-score 
based analysis as well as a landmark analysis. Differences in postoperative 
morbidity and mortality between metastatic and non-metastatic cancer are 
investigated in Chapter 6 using data from the Dutch Surgical Colorectal Audit 
– a database containing information of all patients undergoing colorectal 
surgery in The Netherlands. This chapter also provides a preoperative risk 
score to identify patients with high chance of postoperative mortality and/
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or admittance to the intensive care unit. In Chapter 7, a retrospective 
study of patients’ files is presented aiming to identify predictive factors for 
postoperative mortality in stage IV patients, including important biochemical 
characteristics that are commonly not available in large databases. To put an 
end to the ongoing debate of the benefit of palliative resection of the primary 
tumour in asymptomatic patients, Chapter 8 contains the study protocol of a 
randomized controlled trial investigating this issue.
This thesis is completed by a General discussion summarizing the results 
and conclusions of the presented studies, as well as discussing their added 
value to the available literature and possible implications for the future.
Defining the  concept of synchronous 
metastatic colorectal cancer
Part 1|

European Journal of Cancer, 2016; 69:166-177
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Significant increase of synchronous 
disease in first-line metastatic 
colorectal cancer trials: Results of a 
systemic review
1
Background. Although synchronous and metachronous 
metastases are considered as separate entities of metastatic 
colorectal cancer (mCRC) with different outcomes, its proportion 
is reported infrequently. We compared inclusion rates and 
survival of synchronous versus metachronous mCRC in different 
types of studies investigating initial systemic therapy or surgical 
treatment of mCRC. 
Methods. We searched PubMed and EMBASE (January 2004 - 
February 2016) for mCRC studies investigating first-line systemic 
therapy or surgical treatment of mCRC including information on 
synchronous versus metachronous metastases. Outcomes were 
the proportion of synchronous mCRC, and estimated median 
overall survival (OS) of the total study population. Spearman 
analysis (rs) was used to study correlations between outcomes 
and median year of study enrolment.
Results. We included 46 articles, reporting data from 23 phase 
3 randomised controlled trials (RCTs), twenty cohort and three 
population-based studies (total: 25,941 patients). Seventeen 
different definitions for synchronous mCRC were identified. In 
systemic therapy RCTs, we observed an increased proportion of 
synchronous mCRC during recent years (rs .77, p < .001). In these 
trials, estimated median OS slightly improved over time (rs .48, p 
= .03). No significant inclusion or survival trends were observed 
in included cohort and population-based studies.
Conclusions. In recent years, the proportion of patients with 
synchronous compared with metachronous mCRC enrolled in 
first-line systemic therapy RCTs increased. Estimated median OS 
of the total study population in these RCTs slightly increased over 
time. Many different definitions of synchronous disease were used. 
Uniform definitions and consistent reporting of the proportion 
of synchronous versus metachronous metastases could improve 
cross-study comparisons and interpretation of reported data in 
all mCRC studies. 
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Introduction
Approximately half of all colorectal cancer (CRC) patients develop distant 
metastases during the course of their disease.1-3 Metastases can either present 
at the time of initial diagnosis (synchronous) or develop during follow-up 
(metachronous). Until recently, there has been no international consensus on 
the definition of synchronous and metachronous metastases. Several studies 
reported that patients with synchronous metastases have unfavourable clinical 
and biological characteristics compared with metachronous metastases.4-6 
Survival differences for these groups were found in particular when resection 
of the primary tumour was taken into account, with best survival outcomes 
in patients with metachronous metastases and better outcomes in patients 
with synchronous metastases who underwent a primary tumour resection 
compared with those with a primary tumour in situ.4, 7, 8 Despite these 
observations, the distribution and prognostic impact of synchronous versus 
metachronous disease is not routinely reported in metastatic CRC (mCRC) 
trials.9 Furthermore, population-based studies reporting on incidence and 
trends of synchronous and metachronous mCRC are scarce, and their results 
are conflicting.10-12
During the last decade, availability of new effective drugs together with 
increased possibilities and use of metastasectomy have improved the 
prognosis of mCRC patients.2, 13 As patients with stage I-III disease are 
being monitored more closely and high-quality diagnostic tools to detect 
metastases have become available, metachronous metastases are probably 
detected in an earlier stage during follow-up.14, 15 Nowadays, treatment with 
metastasectomy has a clear survival benefit compared with palliative systemic 
therapy, which used to be the standard treatment of mCRC.16 The impact 
of these progresses on the proportion and survival of mCRC patients with 
synchronous versus metachronous disease included in randomised controlled 
trials (RCTs), cohort and population-based studies has not been studied thus 
far. The aim of this systematic review was to investigate recent trends in 
inclusion and survival of synchronous versus metachronous mCRC in different 
types of studies investigating first-line systemic therapy or initial surgical 
treatment of mCRC. 
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Methods
Search strategy and selection criteria
We searched PubMed and EMBASE on February 22, 2016 to identify mCRC 
studies published in English between January 2004 and February 2016. The 
following keywords were used in our search strategy: ‘metastasis’, ‘colorectal’, 
‘cancer ’, ‘synchronous’ and ‘metachronous’. We conducted a separate search 
to identify all phase 3 mCRC studies with synonyms of ‘metastasis’, ‘colorectal’, 
‘cancer ’ and ‘phase 3 trial’. A detailed literature search strategy is listed in 
Supplementary Table 1. Subsequently, reference lists from selected articles 
were cross-searched for additional relevant studies.
We included full-text articles containing data of randomised phase 3 trials 
(RCTs), cohort or population-based studies that investigated first-line 
systemic therapy (i.e. chemotherapy and/or targeted therapy) or initial 
surgical treatment (i.e. metastasectomy) in adult mCRC patients and included 
information on synchronous and metachronous metastases. Since stage IV 
disease is often used interchangeably with synchronous disease, studies 
categorising mCRC as stage I-III versus stage IV disease were considered 
eligible. If articles categorised time from initial diagnosis to randomisation 
into different time intervals, the time interval closest to randomisation was 
considered as synchronous disease. If articles evaluated the same data set, 
only the most recent publication with data on synchronous and metachronous 
mCRC was included.
Exclusion criteria were: translational studies; studies limited to specific age 
groups, ethnicity or molecular subgroups (e.g. KRAS wild-type); studies 
focussing on specific metastatic sites (other than liver and lung; e.g. cerebral 
metastases only); studies investigating beyond first-line systemic therapy or 
repeat metastasectomy; studies investigating local interventional techniques 
(e.g. local ablation, embolisation, precision radiotherapy); studies investigating 
simultaneous surgery of two metastatic organs; studies investigating CRC 
together with other cancer type(s); and editorials, commentaries, letters, 
(systematic) reviews or meta-analyses.
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Data extraction
All steps in the screening and data extraction process were performed by 
two independent reviewers (KG, JtL). Disagreements were solved through 
discussion with a third reviewer (MK or MvO). Study design, patient 
characteristics and outcomes were extracted from the selected articles. For 
RCTs, we also obtained inclusion and exclusion criteria, and randomisation 
technique. Guidelines by the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) statement were followed.17 
Outcomes
The primary outcome was the proportion of patients with synchronous 
versus metachronous metastases, irrespective of the definition used in the 
included studies. In addition, when provided, median overall survival (OS) 
data were collected, as well as the different definitions of ‘synchronous’ and 
‘metachronous’ metastases. The included studies reported a variety of survival 
outcomes (e.g. progression-free survival, disease-specific survival or OS), as 
well as a variety of outcome parameters (e.g. median OS, survival rates or 
hazard ratios). Since we were particularly interested in the overall prognosis 
of the different study populations, we have selected median OS as end-point 
of interest. When OS was only given for separate cohorts or treatment arms, 
median OS of the total study population was estimated by calculating the 
sample-size weighted mean of the median OS for separate groups (estimated 
median OS).
Statistical analysis
Three types of mCRC studies were identified: RCTs, cohort studies and 
population-based studies. Within these groups, studies were subdivided 
according to the type of intervention studied: systemic therapy, surgery (i.e. 
metastasectomy), surgery combined with perioperative systemic therapy, or 
all interventions (i.e. no focus on specific intervention type). Mean proportions 
of synchronous disease between different study types and different types 
of interventions were compared using the Kruskal-Wallis test. To investigate 
trends in time, we performed correlation analyses between median year 
of study enrolment and (1) the proportion of synchronous mCRC; and (2) 
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estimated median OS of the total study population. Correlation analyses 
were performed using the Spearman’s rank correlation test (rs) in case of a 
minimum sample size of four studies. Data from RCTs, cohort and population-
based studies were analysed both combined and separately; as were data 
from studies investigating systemic and/or surgical treatment. Two-sided 
p-values <.05 were considered statistically significant. Statistical analyses 
were performed using IBM SPSS Statistics for Windows, version 21.0 (Armonk, 
NY: IBM Corp).
Results
Literature search
A flow chart of the literature search is shown in Figure 1. The systematic 
search identified 6,905 unique publications, of which 6,660 were excluded on 
the basis of title or abstract. After full-text revision of 245 articles, 46 studies 
were retained, including 10 eligible studies identified by cross-referencing. 
In total, 46 studies met the predefined inclusion criteria, reporting data from 
23 RCTs7, 18-40, 20 cohort studies6, 41-58, and three population-based studies.59-61 
General characteristics
Study characteristics and survival data are presented in Table 1. The included 
studies comprised data of a total of 25,941 patients (RCTs: n = 15,461; cohort 
studies: n = 5,934; population-based studies: n = 4,546). Sample sizes ranged 
from 40 to 2,502 patients. Type of interventions studied were: systemic 
therapy (n = 24), surgery (n = 6), surgery combined with perioperative 
systemic therapy (n = 14), or all types of interventions (n = 2). In studies 
reporting on gender, age, colon as primary tumour site (as opposed to rectum 
or rectosigmoid), prior adjuvant chemotherapy or primary tumour resection 
in their baseline characteristics, distribution of these variables did not differ 
significantly between study types or intervention types. 
Considering all included studies, the proportion of patients with synchronous 
mCRC varied from 20% to 81% (Figure 2A). Analysed by study type, there was 
no significant difference in the mean proportion of synchronous mCRC patients 
included in RCTs (63%), cohort (56%) and population-based studies (69%, p 
= .37). The mean proportion of synchronous mCRC in studies investigating 
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systemic therapy, surgery or surgery combined with perioperative systemic 
therapy was 64%, 54% and 57%, respectively (p = .32). Thirty-five out of 46 
studies (76%) reported median OS, of which 29 studies reported median OS 
for separate treatment arms or cohorts, while six studies only reported median 
OS of the total study population.41, 45, 48, 49, 58, 60 Five studies reported median OS 
for synchronous and metachronous disease separately6, 45, 53, 57, 61, of which three 
studies demonstrated a significant OS difference in favour of metachronous 
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Figure 1. PRISM flow chart of literature search.
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mCRC45, 57, 61. One study only showed inferior OS in synchronous compared 
with metachronous mCRC patients in case of no perioperative chemotherapy 
or unfavourable response to chemotherapy53 and one study reported no 
significant OS difference between synchronous versus metachronous mCRC.6 
RCTs
Out of the 23 eligible multicentre RCTs, 20 trials investigated first-line systemic 
treatment7, 18-23, 25, 26, 28-30, 32-39, and three trials investigated metastasectomy 
combined with perioperative systemic therapy.24, 31, 40 Eleven trials investigated 
a targeted therapy containing regimen7, 18, 19, 25, 26, 29, 32-34, 37, 39 (Table 1). Sixteen 
trials included only patients with unresectable metastases18-20, 22, 27-30, 33, 35-
38, whereas three trials enrolled only patients with resectable or resected 
metastases24, 31, 40. Four trials did not specify resectability of metastases in 
their eligibility criteria.21, 23, 26, 34 The percentage of synchronous mCRC in all 
RCTs varied from 30% to 85% (Figure 2B). The proportion of patients with 
synchronous mCRC significantly increased during the last decades (rs .78, p 
<.001). This observation remained significant when analysing only systemic 
therapy RCTs (n = 20, rs .77, p < .001). Median OS was reported in 22/23 (96%) 
RCTs (Figure 2C). In RCTs investigating surgery combined with perioperative 
systemic therapy, estimated median OS varied from 44.8 to 57.8 months (n = 
2).24, 31 Estimated OS in systemic therapy RCTs varied from 15.1 to 28.4 months 
and slightly increased during the last decades (n = 20, rs .48, p = .03). 7, 18-23, 
25, 26, 28-30, 32-39
Cohort studies
Twenty cohort studies were considered eligible, which investigated first-
line systemic therapy (n = 4)49, 50, 55, 58, metastasectomy (n = 4)6, 43, 57, 62, 
metastasectomy combined with perioperative systemic therapy (n = 11)41, 42, 44, 
46-48, 51-54, 56 and one study considered all types of interventions45. The majority 
of the cohort studies were retrospective (n = 17)6, 42, 43, 45-49, 51-58, 62; single centre 
(n = 18)6, 41-49, 51-55, 57, 58, 62; and conducted in a tertiary care facility (n = 15)6, 41-43, 
46-49, 52-55, 57, 58, 62 (Table 1).
The proportion of patients with synchronous mCRC in the cohort studies 
varied from 38% to 76% (Figure 2D). No significant differences in the inclusion 
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of synchronous mCRC patients over time were found; neither when all cohort 
studies were analysed (rs .12, p = .60), nor when differentiating between studies 
investigating first-line systemic therapy (rs -.32, p = .68), metastasectomy 
(rs -.80, p = .20) or metastasectomy combined with perioperative systemic 
therapy (rs .36, p = .29).
Median OS was reported in 11/20 (55%) cohort studies (Figure 2E). In cohort 
studies investigating systemic therapy, metastasectomy or metastasectomy 
combined with perioperative systemic therapy, estimated median OS ranged 
from 20.3 to 24.3 months, 22.2 to 44.5 months and 31.5 to 47.8 months, 
respectively.6, 41, 42, 44, 45, 48-50, 53, 57, 58 There was no significant correlation between 
estimated median OS and median year of study enrolment when analysing 
cohort studies investigating metastasectomy combined with perioperative 
systemic therapy (n = 5, rs .10, p = .87).
Population-based studies
Out of the three observational population-based studies, two studies mainly 
focused on surgery of liver metastases59, 60 and one study investigated 
different intervention types in all kind of CRC metastases 61. The percentage 
of synchronous mCRC patients included in these studies varied from 64% 
to 72% (Figure 2A). Due to the small number of included population-based 
studies, no correlation analyses were performed for this study type.
Definitions
Definitions and terminology used to describe synchronous versus metachronous 
metastases varied among the different studies. In total, 17 different definitions 
to report synchronous versus metachronous metastases were found (Table 2). 
The terms ‘synchronous’ versus ‘metachronous’ metastases were reported in 
36 studies. In 18/36 (50%) studies, no specific description of synchronous 
metastases was given. To distinguish ‘synchronous’ versus ‘metachronous’ 
metastases, some authors used the initial CRC diagnosis as a reference point 
in time 7, 24, 39, 43, 45, 57, 59, while others incorporated the timing of colorectal 
surgery in their definition 6, 52, 53, 62. In these studies, inclusion of patients in 
the ‘synchronous’ group varied from 0, 3, 6 to 12 months after the initial 
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Treatment details 
RCTs – First-line systemic therapy 
Adams, 2011 18 2005-2008 UK, Ireland 1,630 (69) 53 15.1 
Continuous vs intermittent FOLFOX / 
CAPOX 
Cassidy, 2011 19  2003-2005 Multi 2,034 (60) NR 19.7 
CAPOX ± B/placebo vs FOLFOX ± 
B/placebo 
Chibaudel, 2009 20 2004-2006 France 202 (72) NR 21.6 
mFOLFOX followed by 5FU/LV vs 
mFOLFOX followed by 
chemotherapy-free interval 
Comella, 2005 11 2001-2003 Italy 276 (62) 78 17.3 FOLFIRI vs FOLFOX 
Comella, 2009 10 2004-2007 Italy 322 (58) 74 16.6 CAPOX vs FOLFOX 
Díaz-Rubio, 2007 14 2002-2004 Spain 342 (69) 82 
c 19.5 CAPOX vs FUOX 
Hegewisch-Becker,  
  2015 22 2009-2013 Germany 
472 
(82) 74 21.7 FP-B vs B vs observation 
Hoff, 2012 23 2006-2010 Multi 860 (66) NR 19.4 
FOLFOX/CAPOX + cediranib vs 
FOLFOX/CAPOX + placebo 
Koopman, 2007 26, b 2003-2004 Netherlands 803 (50) 82 16.9 
Sequential CAP, IRI, CAPOX vs CAPIRI 
followed by CAPOX 
Loupakis, 2014 30 2008-2011 Italy 508 (80) NR 28.4 FOLFIRI-B vs FOLFOXIRI-B 
Masi, 2011 33 2001-2005 Italy 244 (65) NR 20.1 FOLFOXIRI vs FOLFIRI 
Passardi, 2015 45 2007-2012 Italy 370 (24) 76 21.1 FOLFIRI or FOLFOX4 ± B 
Pectasides, 2012 46 2006-2009 Greece 285 (69) 83 22.6 CAPIRI-B vs FOLFIRI-B 
Schmoll, 2012 48 2006-2009 Multi 1,422 (71) NR 22.1 
mFOLFOX6 + cediranib vs 
mFOLFOX6-B 
Seymour, 2007 49 2000-2003 UK, Cyprus 2,135 (56) 75 15.0 
5FU followed by IRI vs 5FU followed 
by FOLFIRI/FOLFOX vs FOLFIRI/ 
FOLFOX 
Simkens, 2015 50 2007-2012 Netherlands 557 (74) 59 19.9 CAP-B vs observation 
Souglakos, 2006 36 2000-2004 Greece 283 (46) NR 20.5 FOLFOXIRI vs FOLFIRI 
Tol, 2011 11, b 2005-2006 Netherlands 736 (61) 78 19.9 CAPOX-B vs CAPOX-B + cetuximab 
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Tournigand, 2006 10 2000-2002 Multi 620 (30) NR 20.2 
Continuous FOLFOX4 vs 
FOLFOX7/5FU-LV + intermittent 
oxaliplatin 
Tournigand, 2015 9 2007-2011 Multi 452 (85) 62 23.5 B vs erlotinib-B 
RCTs – Metastasectomy with/without perioperative systemic therapy 
Hebbar, 2014 24 2004-2010 France 284 (67) 52 44.8 
FOLFOX4 vs FOLFOX7 followed by 
FOLFIRI (after hepatectomy) 
Nordlinger, 2013 31 2000-2004 Multi 364 (35) NR 57.8 Hepatectomy ± FOLFOX4 
Ychou, 2009 40 2001-2006 Multi 306 (62) 100 NR 
5FU-LV vs FOLFIRI (after 
hepatectomy) 
Cohort studies – First-line systemic therapy 
Kronborg, 2015 49 2007-2011 Denmark 314 (63) 
56 20.9 Intermittent FLIRI-based chemotherapy 
Marschner, 2015 50 2006-2012 Germany 605 (62) 87 24.3 FP chemotherapy with OX or IRI 
Ohhara, 2015 55 2007-2010 Japan 185 (48) 85 NR 
FOLFOX4-B vs mFOLFOX6-B vs 
CAPOX-B 
Yoshino, 2007 58 2002-2004 Japan 46  (74) 70 20.3 mFOLFIRI 
Cohort studies – Metastasectomy  
Bredt, 2014 43 2006-2010 Brazil 101 (38) 100 NR Hepatectomy 
John, 2013 62 2000-2011 UK 432 (60) NR NR Hepatectomy 
Van der Pool, 
  2010 6 2000-2008 Netherlands 
272 
(39) 100 44.5 Hepatectomy 
Xu, 2009 57 2000-2007 China 669 (57) 100 22.2 PT resection ± hepatectomy 
Cohort studies – Metastasectomy with/without perioperative systemic therapy 
Barone, 2007 41 2000-2003 Italy 40  (68) NR 31.5 Hepatectomy + mFOLFIRI 
Boostrom, 2009 42 2000-2005 USA 99  (48) 100 55.6 Hepatectomy ± FOLFOX/FOLFIRI  
Capussotti, 2006 44 2000-2003 Italy 150 (42) NR 47.8 Hepatectomy ± chemotherapy  
Faron, 2014 46 2000-2010 France 179 (58) NR NR 
Hepatectomy ± perioperative 
FOLFOX 
Galizia, 2013 47 2006-2011 Italy 48  96 NR Hepatectomy + chemotherapy 
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(73) 
Gur, 2013 48 2003-2011 USA 157 (50) NR 42.8 
Hepatectomy ± perioperative 
systemic therapy  
Mehta, 2008 51 2003-2005 UK 173 (39) NR NR 
Hepatectomy vs OX + hepatectomy 
vs other chemotherapy + 
hepatectomy  
Nakayama, 2015 31 2007-2013 Japan 88  (58) NR NR 
Adjuvant OX-based chemotherapy 
after curative metastasectomy 
Ng, 2009 30 2002-2008 China 55  (64) 100 36.1 Hepatectomy 
Nozawa, 2011 28 2000-2009 Japan 207 (56) 100 NR Hepatectomy ± 5FU-LV / FOLFOX 
Rong, 2014 56 2002-2012 Multi 501 (76) 100 NR 
Hepatectomy + FOLFOX vs 
hepatectomy + FOLFOX-B 
Cohort studies – All interventions 
Dexiang, 2012 45 2000-2010 China 1,613 (66) 
NR 23.1 All interventions 
Population-based studies 
Hackl, 2014 59 2002-2007 Germany 1,426 (71) NR NR Hepatic resection (main focus) 
Ksienski, 2010 60 2002-2004 Canada 618 (72) NR 15.2 Hepatic resection (main focus) 
Kumar, 2014 61 2006-2012 Australia 2,502 (64) NR 15.8 All interventions 
5FU = 5-fluorouracil; 5FU-LV = 5-fluorouracil + leucovorin; CAP = capecitabine; CAPIRI = 
capecitabine + irinotecan; CAPOX = capecitabine + oxaliplatin; B = bevacizumab; FLIRI = 5- 
fluorouracil + leucovorin + irinotecan; FP = fluoropyrimidine; FOLFIRI = 5 -fluorouracil + 
leucovorin + irinotecan; FOLFOX = 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI = 5- 
fluorouracil + leucovorin + oxaliplatin + irinotecan; FUOX = 5-fluorouracil + oxaliplatin; IRI = 
irinotecan; Multi = multinational, conducted in several countries; NR = not reported; OX = 
oxaliplatin; PT = primary tumour; UK = United Kingdom; USA = United States of America  
a Sample size as described in baseline characteristics of included study.  
b Data on synchronous and metachronous mCRC and PT resection were described in 
publication Venderbosch et al.  8 
c Described as ‘previous surgery’; no differentiation between PT resection or 
metastasectomy. 
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diagnosis or colorectal surgery. One study used two different definitions of 
synchronous disease.57
Ten publications did not report on the terms ‘synchronous’ and ‘metachronous’ 
metastases. In four of these articles, authors distinguished ‘stage I-III’ and 
‘stage IV’ disease 8, 23, 32, 33; three articles reported ‘time from initial diagnosis 
to randomisation’ with the first interval ranging until 3 or 6 months after 
initial 
diagnosis 26, 30, 34; two articles reported ‘metastatic disease at first diagnosis’ 
19, 55 and one article reported ‘delay in diagnosis of metastasis after primary 
tumour resection’ with the first interval ranging until 12 months after primary 
tumour resection 40. 
Discussion
This first systematic review on trends in the proportion and survival of 
patients with synchronous versus metachronous metastases included in 
mCRC studies shows a significant increase in the proportion of patients with 
synchronous compared to metachronous mCRC enrolled in first-line systemic 
therapy trials, with a slight increase in estimated median OS of the total study 
 
Table 2. Terminology and definitions of synchronous CRC.  
Terminology Definition Studies  References 
Synchronous metastases N  
 No further definition given  18  
Detected by preoperative imaging or during resection of primary tumour 1  
Diagnosed within 3 months of primary diagnosis  1  
Diagnosed before, at the same time or within 3 months after colectomy  1  
Diagnosed within 3 months, reference point not specified 1  
Diagnosed within 6 months of primary diagnosis  3  
Diagnosed within 6 months after resection primary tumour 1  
Diagnosed up to 6 months after treatment of primary tumour 1  
Based on the existing LiverMetSurvey definition of 6 months 1  
Disease-free interval from primary tumour to metastases ≤ 6 months 1  
Diagnosed within 12 months of primary diagnosis 2  
Diagnosed within 12 months after resection primary tumour  1  
Stage IV at initial diagnosis 4  
Other a 
 Stage IV at initial diagnosis, ‘synchronous’ not reported 4  
Stage at first diagnosis: metastatic 2  
Time from initial diagnosis to random assignment, < 3 months 1  
Time from initial diagnosis to random assignment, < 6 months 2  
Delay in diagnosis of metastasis ≤ 1 year after primary tumour resection 1  
a Terminology ‘synchronous’ versus ‘metachronous’ metastases not reported. 
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population over time. The association between survival and the proportion 
of synchronous versus metachronous mCRC could not be analysed, since the 
included RCTs did not differentiate between synchronous and metachronous 
mCRC in median OS results. No significant trends could be observed in the 
included cohort or population-based studies.
Figure 2. Proportion of synchronous versus metachronous mCRC and estimated median OS of 
total study population in different study types, plotted against median year of study enrolment. (A) 
All included studies - proportion synchronous versus metachronous mCRC; (B) RCTs - proportion 
synchronous versus metachronous mCRC; (C) RCTs - estimated median OS over time; (D) Cohort 
studies - proportion synchronous versus metachronous mCRC; (E) Cohort studies - estimated 
median OS over time. Dot size represents sample size. All = all interventions; PB = population-
based; ST = systemic therapy; Surg = surgical treatment.
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Prognostic value
Synchronous metastases are considered to be of worse prognostic value 
compared with metachronous metastases, particularly synchronous disease 
without a resection of the primary tumour, as is currently being investigated 
in several RCTs, e.g. the phase 3 CAIRO4 study.7, 8, 63-65 Another explanation 
for the worse prognosis of synchronous disease may be found in biological 
differences between metastases of synchronous and metachronous origin.5 
Only five studies in our systematic review reported median OS for synchronous 
and metachronous disease separately and only 26/46 (57%) studies reported 
the primary tumour resection status. Therefore, no firm conclusions can be 
drawn on the prognostic value of synchronous versus metachronous mCRC 
and the resection status of the primary tumour.
In addition, the prognosis of mCRC is highly dependent on whether metastases 
are resectable. A few studies have reported that an increasing proportion of 
the mCRC population is eligible for metastasectomy.2, 3 Most of the systemic 
therapy RCTs included in our systematic review enrolled patients with 
unresectable metastases only. Our results suggest an increasing amount of 
patients with synchronous metastases included in first-line systemic therapy 
RCTs with a possible selection bias of patients with unresectable metastases, 
both indicating a poor prognosis. This did not seem to have a detrimental 
effect on estimated median OS of the total study population over time, 
possibly partly due to the positive influence of advances in systemic therapy, 
including targeted agents. However, we can only hypothesise on this subject, 
as the heterogeneity of the included studies with different prognostic groups 
and the use of different treatments does not justify a clear conclusion.
Cohort and population-based studies
In cohort studies, we found no significant correlations between median year 
of study enrolment versus proportion of synchronous disease or estimated 
median OS of the total study population. However, most of the included 
cohort studies were small, retrospective, single-centre studies conducted in 
tertiary care facilities. Given these methodological limitations, our results 
regarding these cohort studies should be interpreted with caution. 
We hypothesised an increased percentage of patients with synchronous 
metastases over time in population-based studies, attributable to earlier 
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detection of metastases due to improved quality of imaging techniques, as 
previously reported in two population-based studies.2, 3, 13-15 However, due 
to the small number of included population-based studies, we could not 
perform correlation analyses for this study type.
Limitations
Given the extensive literature search with strict adherence to standards 
of study selection and data extraction, we believe to have selected the 
most relevant studies in order to answer our research question. The main 
limitation of this systematic review concerns the infrequent reporting of 
the proportion of synchronous and metachronous disease in mCRC studies, 
resulting in only 46 eligible studies in a literature search covering a period of 
more than a decade. Furthermore, cross-study comparisons were hampered 
by heterogeneity in study designs, types of intervention and outcomes. In 
addition, definitions used to describe synchronous versus metachronous 
metastases varied widely among the included studies. Moreover, most of the 
studies in which synchronous and metachronous metastases were reported, 
lacked description of these terms. This supports previous findings that until 
recently there has been no consensus on what constitutes ‘synchronous’ and 
‘metachronous’ metastases.4, 66-68
Uniform definitions
Recently, a multidisciplinary expert panel used a modified Delphi method to 
develop recommendations for managing synchronous CRC liver metastases. 
The panel recommended that synchronous liver metastases should be defined 
as metastases detected at or before diagnosis of the primary tumour, and to 
make a distinction between ‘early metachronous’ and ‘late metachronous’ 
metastases, detected within (early) or after 12 months (late) post-surgery 
of the primary tumour.66 We support the use of these uniform definitions 
to facilitate cross-study comparisons and to gain more insight into the 
prognostic value of synchronous versus metachronous mCRC.
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Conclusion
In first-line systemic therapy RCTs we observed a marked, significant increase 
of mCRC patients with synchronous compared with metachronous metastases 
during the last decades. In these RCTs, the estimated median OS of the 
total study population slightly increased over time. Due to methodological 
limitations and a restricted number of included studies, our results concerning 
cohort and population-based studies should be interpreted with caution. 
Uniform definitions and consistent reporting of the proportion of synchronous 
and metachronous CRC metastases are essential to gain more insight into 
differences in clinical outcome and to enable cross-study comparisons in all 
types of mCRC studies.
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Supplementary Materials 
 
Supplementary Table 1. Search strategy in PubMed and EMBASE 
Date of search: February 22, 2016 
PubMed 
Search for all mCRC studies reporting on synchronous versus metachronous disease 
1 Synchronous [tiab] OR synchronic [tiab] OR synchronicity [tiab] OR synchronously [tiab] OR Stage 
IV [tiab] OR stage 4 [tiab] OR stage four [tiab] 
2 Synchronous [tiab] OR synchronic [tiab] OR synchronicity [tiab] OR synchronously [tiab] OR Stage 
IV [tiab] OR stage 4 [tiab] OR stage four [tiab] 
3 #1 OR #2 
4 Neoplasm Metastasis [MESH] OR neoplasm metastasis [tiab] OR Metastatic [tiab] OR metastases 
[tiab] OR metastasis [tiab] OR metastasize [tiab] OR metastasized [tiab] OR metastasised [tiab] OR 
Disease Progression [MESH] OR disease progression [tiab] OR advanced [tiab] 
5 Intestine, large [MESH] OR Colorectal [tiab] OR Colon [tiab] OR colonic [tiab] OR Rectal [tiab] OR 
rectum [tiab] 
6 Colorectal Neoplasms [MESH] OR Cancer [tiab] OR cancers [tiab] OR Neoplasms [MESH] OR 
neoplasm [tiab] OR neoplasia [tiab] OR neoplasms [tiab] OR Tumour [tiab] OR tumours [tiab] OR 
tumor [tiab] OR tumors [tiab] OR Malignant [tiab] OR malignancy [tiab] OR malignancies [tiab] OR 
Carcinoma [MESH] OR carcinoma [tiab] OR carcinomas [tiab] 
7 #3 AND #4 AND #5 AND #6 
8 Filters: NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]) AND English[lang] AND 
("2004/01/01"[PDAT] : "2016/02/22"[PDAT]) 
Additional search for phase 3 trials on mCRC: 
9 Phase 3 [tiab] OR phase III [tiab] OR phase three [tiab] OR Randomized Controlled Trial [tiab] OR 
Randomized Controlled Trials as topic [MESH] OR Clinical Trials, phase III as topic [MESH] 
10 #4 AND #5 AND #6 AND #9 
11 Filters: NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]) AND English[lang] AND 
("2004/01/01"[PDAT] : "2016/02/22"[PDAT]) 
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EMBASE 
Search for all mCRC studies reporting on synchronous versus metachronous disease 
1 Synchronous:ab,ti OR synchronic:ab,ti OR synchronicity:ab,ti OR synchronously:ab,ti OR ‘stage 
IV’:ab,ti OR ‘stage 4’:ab,ti OR ‘stage four’:ab,ti 
2 Metachronous:ab,ti OR metachronic:ab,ti OR metachronicity:ab,ti OR metachronously:ab,ti�  
3 #1 OR #2 
4 ‘metastasis’/exp OR ‘neoplasm metastasis’:ab,ti OR metastatic:ab,ti OR metastasis:ab,ti OR 
metastases:ab,ti OR metastasize:ab,ti OR metastasized:ab,ti OR metastasised:ab,ti OR 
advanced:ab,ti OR ‘disease progression’:ab,ti 
5 ‘large intestine’/exp OR colorectal:ab,ti OR colon:ab,ti OR colonic:ab,ti OR rectal:ab,ti OR 
rectum:ab,ti OR rectum:ab,ti 
6 ‘large intestine tumor’/exp OR ‘malignant neoplastic disease’/exp/mj OR cancer:ab,ti OR 
cancers:ab,ti OR neoplasm:ab,ti OR neoplasms:ab,ti OR neoplasia:ab,ti OR tumor:ab,ti OR 
tumors:ab,ti OR tumour:ab,ti OR tumours:ab,ti OR malignant:ab,ti OR malignancy:ab,ti OR 
malignancies:ab,ti OR carcinoma:ab,ti OR carcinomas:ab,ti 
7 #3 AND #4 AND #5 AND #6 
8 Quick limits: Humans; Publication types: Article; Source: Embase; Date limits: Records added to 
Embase from 01-01-2014 to 22-02-2016; Language: English 
Additional search for phase 3 trials on mCRC: 
10 ‘phase 3 clinical trial’/exp OR ‘randomized controlled trial’/exp OR ‘phase 3’:ab,ti OR ‘phase iii’:ab,ti 
OR ‘phase three’:ab,ti OR ‘randomized controlled trial’:ab,ti 
11 #5 AND #6 AND #7 AND #10 
12 Quick limits: Humans; Publication types: Article; Source: Embase; Date limits: Records added to 
Embase from 01-01-2014 to 22-02-2016; Language: English 
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Nationwide trends in incidence 
treatment and survival of colorectal 
cancer patients with synchronous 
metastases
The aim of this study was to determine trends in incidence, 
treatment and survival of colorectal cancer (CRC) patients with 
synchronous metastases (Stage IV) in the Netherlands. 
This nationwide population-based study included 160,278 
patients diagnosed with CRC between 1996 and 2011. We 
evaluated changes in stage distribution, location of synchronous 
metastases and treatment in four consecutive periods, using Chi 
square tests for trend. Median survival in months was determined, 
using Kaplan-Meier analysis. 
The proportion of Stage IV CRC patients (n = 33,421) increased 
from 19% (1996-1999) to 23% (2008-2011, p < 0.001). This was 
predominantly due to a major increase in the incidence of lung 
metastases (1.7-5.0% of all CRC patients). During the study period, 
the primary tumour was resected less often in Stage IV patients 
(65-46%) and the use of systemic treatment has increased (29-
60%). Also an increase in metastasectomy was found in patients 
with one metastatic site, especially in patients with liver-only 
disease (5-18%, p < 0.001). Median survival of all Stage IV CRC 
patients increased from 7 to 12 months. Especially in patients 
with metastases confined to the liver or lungs this improvement 
in survival was apparent (9-16 and 12-24 months respectively, 
both p < 0.001). 
In the last two decades, more lung metastases were detected 
and an increasing proportion of Stage IV CRC patients was 
treated with systemic therapy and/or metastasectomy. Survival 
of patients has significantly improved. However, the prognosis of 
Stage IV patients becomes increasingly diverse.
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Introduction
Colorectal cancer (CRC) is one of the most frequently diagnosed cancer types 
in the Western world, and second leading cause of cancer-related death in 
The Netherlands.1 Approximately 15-25% of all CRC patients have distant 
metastases (TNM Stage IV) at the time of the primary diagnosis.2-4 Although 
metastases are predominantly located in the liver, little is known about 
patterns of metastatic spread. 
Curative treatment is possible when resection of the primary tumour is 
accompanied by resection of all metastases. About 20-30% of patients 
with liver metastases would have potentially resectable disease;5 however, 
observational studies have reported resection rates of liver metastases around 
5-15%3, 6, and 5 years overall survival rates of curatively operated patients up 
to 50%.7 Although most Stage IV CRC patients present with liver metastases, 
also patients with a limited number of metastases (oligometastases) in the 
lungs8 or peritoneum9 can be treated with curative intent when all metastatic 
lesions are removed.
However, for patients with unresectable metastatic disease, best supportive 
care with or without palliative systemic therapy is the only option. In the 
past decades, randomized controlled trials have shown that palliative 
chemotherapy improves survival of CRC patients with metastatic disease, 
especially after the introduction of combination regimens of fluorouracil with 
oxaliplatin or irinotecan.10-12 Further improvement of survival was obtained 
with the addition of targeted therapies.13 The additional value of systemic 
treatment was also found in population-based studies.2-4
Resection of the primary tumour is indicated in patients with curative 
treatment options, or in the palliative setting when the primary tumour 
becomes symptomatic. However, resection of an asymptomatic primary 
tumour is currently under debate.14, 15 Whether discussion about resection of 
the primary tumour has influenced treatment patterns is largely unknown. 
In addition, little is known about treatment patterns according to metastatic 
sites.
The aim of this nationwide population-based study was to determine trends 
in incidence, metastatic spread, treatment and survival of CRC patients with 
synchronous metastases in the Netherlands.
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Methods
Patients
Population-based data were selected from the nationwide Netherlands 
Cancer Registry (NCR), which covers over 16.7 million inhabitants. In the NCR, 
data on all newly diagnosed malignancies in the Netherlands are registered. 
Main sources of notification are the automated pathology archive (PALGA) 
and the National Registry of Hospital Discharge Diagnoses. Following 
notification, specially trained registration clerks collect data on patient, 
tumour and treatment characteristics from the medical records in all hospitals. 
Completeness of the NCR is estimated to be at least 95%. Topography and 
morphology were coded according to the International Classification of 
Diseases for Oncology (ICD-O).16 Stage of disease was defined according to 
the tumour-lymph node-metastasis (TNM) classification.17
For this paper, all patients with colorectal carcinoma in the period 1996-2011 
were selected. Patients with CRC diagnosed at autopsy or without histological 
confirmation were excluded. Tumour location was categorized as colon 
(including recto sigmoid: C18-19) or rectum (C20). Date of diagnosis was 
divided into four periods: 1996-1999, 2000-2003, 2004-2007, and 2008-2011. 
Synchronous metastases were defined as metastases detected before the 
start of initial treatment and/or during surgical exploration. Data on the 
location of distant metastases at organ level (with a maximum of three sites) 
were registered in four out of nine NCR-regions in 1996-1999, increasing to 
national coverage from 2008 onwards. From each region, we have included 
those years with a (nearly) complete registration of location of distant 
metastases, resulting in 3.5% missing locations of metastases of included 
Stage IV patients (0.7% of included patients).
Treatment after diagnosis included the treatment modalities as mentioned in 
the treatment plan and provided to the patient. Treatment was categorized as 
resection of primary CRC tumour, metastasectomy (surgical resection of one 
or more metastatic sites) and systemic treatment (chemotherapy, targeted 
therapy). Follow-up on vital status (deceased or alive) was obtained from the 
national Municipal Personal Records Database, which contains information 
on vital status of all Dutch inhabitants.
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Statistical analysis
Chi square tests for trend were used to assess the trends in stage distribution 
in the consecutive periods, as well as trends in the location of distant 
metastases (denominator: CRC all stages) and trends in treatment of Stage 
IV CRC patients. Due to a change in the TNM-classification of lymph node 
metastases from 2003 onwards,17 sensitivity analyses were performed with 
all distant lymph node metastases categorized as non-distant (regional), 
showing similar trends over time. 
Survival time was defined as the time from first histological diagnosis to 
death. Patients who were still alive at January 1st, 2014 were censored. In 
consecutive periods, median survival times with 95% confidence intervals 
were computed of Stage IV CRC patients according to age and location of 
the primary tumour and locations of distant metastases, using Kaplan-Meier 
analyses. Differences in survival between subgroups were tested using the log 
rank test. All analyses were performed using STATA/SE (version 12.0; STATA 
Corp., College Station, Texas, USA).
Results
Between 1996 and 2011, 160,278 new patients were diagnosed with CRC. The 
proportion of patients with synchronous metastases gradually increased from 
19% in 1996-1999 to 23% in 2008-2011 (p < 0.001). Within this period, the 
proportion of patients with Stage II disease decreased (from 33% to 28%, p 
< 0.001). This pattern was found in both colon and rectal cancer patients, as 
shown in Figure 1. Compared to Stage I-III CRC patients (n = 126,857), Stage 
IV CRC patients (n = 33,421) were younger (median age 69 vs. 71 years, p < 
0.001), more often male (55 vs. 53%, p < 0.001), and the primary tumour was 
more often localized in the colon (76 vs. 71%, p < 0.001). Over time, median 
age of Stage IV patients remained stable (69 years), the primary tumour 
more often was found in the rectum (22-26%, p < 0.001), the proportion of 
patients with a T3 or T4 primary tumour decreased (73-67%, p < 0.001) and 
patients more often were diagnosed with positive lymph nodes (51-60%, p 
< 0.001). Seventy-two percent of all CRC patients were included in analyses 
of metastatic spread (Table 1), patient and tumour characteristics of Stage IV 
patients in this subgroup did not differ from those of all Stage IV patients 
(data not shown).
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Synchronous metastases
The most common site of distant metastases in CRC patients was the liver, 
followed by the peritoneum and the lungs (Table 1). Over time, an increasing 
percentage of patients was diagnosed with metastases in more than one organ 
(from  3.6% of all patients in  1996-1999 to  8.0% in 2008-2011,  p < 0.001). 
The proportion of patients with liver metastases increased from 14% to 17% 
(p < 0.001) and with peritoneal carcinomatosis from 3.7 to 4.7% (p < 0.001), 
while the proportion of patients with lung metastases more than doubled, 
from 1.7% to 5.0% (p < 0.001). The largest increase was seen especially in 
patients with lung metastases only (0.4-1.1%) and in patients with liver and 
lungs affected (from 1.1 to 3.4%). 
Compared to rectal cancer patients, colon cancer patients were more often 
diagnosed with peritoneal metastases (4.5 vs. 1.7% in 1996-1999 and 6.0 vs. 
1.7% in 2008-2011, both p < 0.001) and less often with lung metastases (1.4 
vs. 2.5% in 1996-1999 and 4.4 vs. 6.3% in 2008-2011, both p < 0.001).
Figure 1. Stage distribution (TNM-stage) of patients diagnosed with colon or rectal 
carcinoma, by period of diagnosis.
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Table 1. Percentage of patients diagnosed with colorectal carcinoma and synchronous distant 
metastases (stage IV) in 1996-2011 in the Netherlands, by location of metastases and period of 
diagnosis. 
 
 1996-1999 
N= (%) 
2000-2003 
N= (%) 
2004-2007 
N= (%) 
2008-2011 
N= (%) 
Chi2 for trend 
p-value 
All patients diagnosed with CRC  33,206 36,730 42,924 47,418  
Number of patients included a  
(% of all CRC patients) 
15,531 (47) 18,814 (51) 34,278 (80) 47,415 (100)  
Number of metastatic sites a 
   No distant metastasis 
   Single site 
   Multiple sites 
   Distant metastasis, site unknown 
 
12,688 (82) 
2,128 (14) 
5541 (3.6) 
161(1.0) 
 
15,171 (81) 
2,634 (14) 
870 (4.6) 
139(0.7) 
 
26,910 (79) 
4,700 (14) 
2,260 (6.6) 
408(1.2) 
 
36,749 (78) 
6,825 (14) 
3,796 (8.0) 
45(0.1) 
<0.001 
Most common metastatic sites a, b 
Liver 
Lung 
Peritoneum 
Bone 
Brain   
Lymph nodes   
 
2,143 (14) 
258 (1.7) 
580 (3.7) 
45 (0.3) 
21 (0.1) 
87 (0.6) 
 
2,799 (15) 
392 (2.1) 
785 (4.2) 
74 (0.4) 
14 (0.1) 
152 (0.8) 
 
5,436 (16) 
1,259 (3.7) 
1,528 (4.5) 
192 (0.6) 
49 (0.1) 
604 (1.8) 
 
8,123 (17) 
2,358 (5.0) 
2,234 (4.7) 
334 (0.7) 
74 (0.2) 
1,278 (2.7) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Location(s) of distant metastases a  
   No distant metastasis 
   Liver-only 
   Lung-only 
   Peritoneum-only 
   Other single organ site  
   Liver + no-lung 
   Liver + lung 
   No-liver + lung  
   No-liver + no-lung (Other multiple) 
   Distant metastasis, site unknown 
 
12,688 (82) 
1,665 (11) 
68 (0.4) 
291 (1.9) 
104 (0.7) 
313 (2.0) 
165 (1.1) 
25 (0.2) 
51 (0.3) 
161(1.0) 
 
15,171 (81) 
2,048 (11) 
96 (0.5) 
349 (1.9) 
141 (0.8) 
484 (2.6) 
267 (1.4) 
29 (0.2) 
90 (0.5) 
139(0.7) 
 
26,910 (79) 
3,503 (10) 
241 (0.7) 
666 (1.9) 
290 (0.9) 
1,018 (3.0) 
915 (2.7) 
103 (0.3) 
224 (0.7) 
408(1.2) 
 
36,749 (78) 
4,880 (10) 
515 (1.1) 
917 (1.9) 
513 (1.1) 
1,614 (3.4) 
1,629 (3.4) 
214 (0.5) 
339 (0.7) 
45(0.1) 
<0.001 
a Selection of cancer regions with (nearly) complete data on metastatic sites.  
b Proportions of all CRC patients, including patients with missing data on location of metastasis 
Treatment
Between 1996 and 2011 the percentage of Stage IV CRC patients undergoing 
metastasectomy increased from 4% (1996-1999) to 12% (2009-2011, p < 
0.001), with higher median age in the last period (64 vs. 62 years). Analysed 
separately, this increased metastasectomy rate was only found in patients 
with metastatic disease isolated to one organ (Table 2). The most markedly 
increase was found in patients with isolated liver metastases (5-18%, p 
< 0.001). We also found an increase in the use of systemic treatment for 
Stage IV patients (29-60%, p < 0.001), which was combined with targeted 
therapies in 28% of patients in 2008-2011. Especially in patients with isolated 
liver metastases and in patients with multiple organs affected, the use of 
systemic treatment was high. The median age of patients receiving systemic 
treatment gradually increased over time (from 61 to 65 years). The proportion 
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of patients undergoing resection of the primary tumour decreased over time 
from 65 to 46% (p < 0.001). The largest decrease was seen in patients with 
multiple-organ metastases, followed by patients with  metastases confined 
to the liver. Median age of patients undergoing resection of their primary 
tumour remained stable (68 years).
 
Table 2. Percentage of patients diagnosed with colorectal carcinoma and synchronous distant 
metastases (stage IV) receiving cancer treatments, by location of distant metastases and period of 
diagnosis. 
 1996-1999 2000-2003 2004-2007 2008-2011 
Chi2 for 
trend 
p-value 
All patients N=6,206 (%) N=7,337 (%) N=9,211 (%) N=10,667 (%)  
Metastasectomy a 4 5 7 12 <0.001 
Resection primary tumour 65 50 53 46 <0.001 
Systemic therapy 29 41 53 60 <0.001 
Liver metastases only b N=1,665 (%) N=2,048 (%) N=3,503 (%) N=4,880 (%)  
Metastasectomy 5 5 10 18 <0.001 
Resection primary tumour 70 66 57 53 <0.001 
Systemic therapy 32 46 57 65 <0.001 
Lung metastases only b N=68 (%) N=96 (%) N=241 (%) N=515 (%)  
Metastasectomy 4 3 7 10 0.006 
Resection primary tumour 53 65 58 57 0.72 
Systemic therapy 29 38 41 42 0.05 
Peritoneum metastases only b N=291 (%) N=349 (%) N=666 (%) N=917 (%)  
Metastasectomy 2 3 6 7 0.002 
Resection primary tumour 58 54 61 56 0.91 
Systemic therapy 22 24 36 46 <0.001 
Other single organ metastases b N=104 (%) N=141 (%) N=290 (%) N=513 (%)  
Metastasectomy 10 6 14 14 0.06 
Resection primary tumour 64 61 62 59 0.23 
Systemic therapy 25 23 43 44 <0.001 
Multiple organ sites of metastases b N=554 (%) N=870 (%) N=2,260 (%) N=3,796 (%)  
Metastasectomy a 5 6 4 5 0.99 
Resection primary tumour 56 51 42 32 <0.001 
Systemic therapy 33 46 58 62 <0.001 
a No information available whether one or all metastatic sites were treated. 
b Selection of cancer regions with (nearly) complete data on metastatic sites. 
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In the last period (2008-2011), 8% of patients received a combination of 
above mentioned treatment modalities (systemic treatment, resection primary 
tumour, metastasectomy) and 21% of patients had both systemic treatment 
and resection of the primary tumour, compared to 1 and 19% respectively 
in the first period (p  < 0.001). Over time, an increasing proportion of these 
patients have received systemic treatment prior to resection of the primary 
tumour (from 3% in 1996-1999 to 21% in 2008-2011, p < 0.001).
 
Table 3. Median survival in months with 95% confidence interval of patients with colorectal carcinoma and 
synchronous distant metastases, according to site(s) of distant metastases, by period of diagnosis. 
 1996-1999 2000-2003 2004-2007 2008-2011 
Log rank 
p-value 
Overall (stage IV) 7.2 (6.9-7.5) 8.5 (8.2-8.9) 10.3 (9.9-10.6) 12.0 (11.6-12.4) <0.001 
Age < 75 years 8.7 (8.3-9.1) 10.5 (10.2-11.1) 13.1 (12.5-13.7) 15.2 (14.6-15.8) <0.001 
Age ≥ 75 years 4.6 (4.4-5.1) 4.7 (4.3-5.1) 5.7 (5.2-6.0) 6.8 (6.4-7.2) <0.001 
Colon-rectosigmoid 6.8 (6.6-7.1) 8.0 (7.7-8.4) 9.7 (9.3-10.1) 10.9 (10.6-11.4) <0.001 
Rectum  8.9 (8.1-9.6) 10.4 (9.7-11.3) 12.2 (11.5-12.9) 15.5 (14.5-16.5) <0.001 
No. of metastatic sites a      
Single metastatic site 8.6 (8.0-9.2) 10.2 (9.5-10.9) 12.1 (11.5-12.8) 14.9 (14.1-15.6) <0.001 
Multiple metastatic sites 5.5 (4.4-6.5) 6.1 (5.5-6.8) 7.5 (7.0-8.1) 8.5 (8.1-9.0) <0.001 
Most common sites a      
Liver 7.9 (7.2-8.5) 9.0 (8.4-9.6) 10.4 (9.9-10.9) 12.1 (11.8-12.6) <0.001 
Lung  8.3 (7.2-10.0) 9.9 (8.8-11.2) 9.9 (9.0-10.8) 11.5 (10.7-12.2) <0.001 
Peritoneum 5.6 (4.8-6.6) 6.2 (5.4-6.8) 7.5 (6.9-8.2) 8.2 (7.6-8.7) <0.001 
Location(s) of metastases  a      
Liver-only 8.8 (8.1-9.4) 10.4 (9.7-11.2) 12.5 (11.8-13.1) 15.6 (14.8-16.4) <0.001 
Lung-only 11.7 (8.3-17.5) 15.9 (11.9-20.5) 17.1 (13.6-20.3) 24.1 (21.9-26.3) <0.001 
Peritoneum-only 6.7 (5.5-8.2) 7.4 (6.1-9.1) 9.1 (7.8-10.4) 9.0 (8.2-10.1) <0.001 
Other single organ site 10.7 (6.2-13.0) 9.4 (7.2-13.0) 12.0 (9.9-14.5) 12.8 (11.12-15.5) 0.04 
Liver + lung 8.9 (7.2-11.0) 10.2 (8.8-11.5) 10.3 (8.9-11.7) 11.4 (10.4-12.6) 0.01 
Other multiple organ sites 4.4 (3.7-5.6) 5.1 (4.4-5.7) 6.6 (6.0-7.2) 7.5 (6.9-8.0) <0.001 
a Selection of cancer regions with (nearly) complete data on metastatic sites. 
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Figure 2. Crude survival of CRC patients diagnosed with synchronous distant metastases in the period 
1996-2011 in the Netherlands, by period of diagnosis of CRC: (A) all patients (log rank test p < 
0.0001), (B) patients treated with metastasectomy (long rank test p < 0.0001).
NATIONWIDE TRENDS IN INCIDENCE, TREATMENT AND SURVIVAL
2
75
Figure 3. Crude survival of CRC patients diagnosed with synchronous distant metastases in 
the period 1996-2011 in the Netherlands, by period of diagnosis of CRC: (C) patients receiving 
systemic therapy without metastasectomy (log rank test p < 0.0001) and (D) patients receiving 
supportive care (no metastasectomy, no systemic therapy) (long rank test p < 0.0001).
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Survival
As shown in Table 3, median survival of Stage IV CRC patients has gradually 
increased from 7.2 months (95% Confidence Interval [CI] 6.9-7.5) to 12.0 
months (95%CI 11.6-12.4) (Figure 2a). Compared to elderly patients and colon 
cancer patients, patients younger than 75 years and rectal cancer patients 
showed a higher median survival and a larger progress over time. Improvement 
of survival was largest in patients with metastatic disease confined to the 
liver (8.8-15.6 months) or the lungs (11.7-24.0 months). Patients with bone 
or brain metastases had the worst median survival, and showed little or no 
progress over time.
Survival was highest in patients who underwent metastasectomy (with or 
without other treatments). These patients also  showed the largest improvement 
in survival, from median 25.0 months (95%CI 22.1-31.8, 1996-1999) to 46.2 
months (95%CI 40.5-52.4, 2008-2011, Figure 2b). In patients who received 
systemic treatment without undergoing metastasectomy, median survival 
increased from 12.1 months (95%CI 11.5-12.7) to 15.3 months (95%CI 14.8-
15.8, Figure 2c), while survival of patients receiving neither metastasectomy 
nor systemic treatment (best supportive care) decreased from 5.1 months 
(95%CI 4.9-5.4) to 3.4 months (95%CI 3.1-3.6, Figure 2d). Furthermore, 
patients with lung-only metastases who underwent metastasectomy (median 
56.1 months [95%CI 31.1-90.3], n = 77) showed a similar median survival 
compared to patients who underwent resection of liver-only metastases 
(median 51.4 months [95%CI 48.1-56.8], n = 1422, period 1996-2011, p = 
0.69).
Discussion
This nationwide population-based study in the Netherlands showed that 
the proportion of CRC patients diagnosed with Stage IV disease increased 
between 1996 and 2011. The largest increase was found in the incidence of 
lung metastases only and combined lung and liver metastases. In Stage IV 
patients, a decrease was found in resection of the primary tumour, while the 
use of systemic treatment increased, as well as the use of metastasectomy. 
The highest rate of metastasectomy and the largest increase over time were 
found in patients with isolated liver metastases. Survival of Stage IV CRC 
patients has gradually increased, especially in patients with isolated liver or 
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lung metastases, and in patients who underwent surgical resection of their 
metastases. 
The increasing proportions of Stage IV CRC patients are in line with earlier 
reports from the Netherlands.2-4 In the absence of a national screening 
program, the shift in stage distribution can be attributed to more accurate 
staging, due to improved pathological detection of lymph node involvement 
in the resection specimen18, and improved detection of metastatic disease. 
An increased use and improved quality of computed tomography (CT) of the 
chest and magnetic resonance imaging (MRI) of the liver have potentially led 
to an increased detection rate for lung and liver metastases.19, 20
The present study showed that the incidence of synchronous lung metastases 
more than doubled, which is in line with a French population-based study21, 
and the incidence of lung metastases became slightly higher than that 
of peritoneal metastases. In earlier years, patients with small lung-only 
metastases might have been diagnosed as non-metastatic CRC. The improved 
detection of lung metastases also explains the increase of patients with both 
liver and lung metastases. Our data suggest that improvements in detecting 
lung and other non-liver metastases have surpassed an improvement in the 
detection of liver metastases, since a ‘decrease’ in the proportion of patients 
with liver metastases was found within the subset of patients with Stage IV 
disease (from 80 to 76%). Considering all CRC patients (Stage I-IV), however, 
the incidence of liver metastases has increased from 14 to 17%. As the NCR 
has no data available on the number of detected metastases per organ, it is 
possible that the absolute number of diagnosed liver metastases per patient 
did increase. The minor changes in bone, brain and other more atypical 
metastases probably reflect the fact that diagnostic imaging for these sites 
is not performed routinely. However, when curative treatment is considered, 
positron emission tomography (PET) scanning has additional value in the 
detection of extra-hepatic metastases.22
Consistent with several other studies2-4, 7, 23, an increased use of systemic 
treatment in Stage IV CRC patients was found. Simultaneously, the percentage 
of patients undergoing resection of the primary tumour decreased over time, 
especially in patients with multiple organ metastases. This decrease may 
reflect the recent debate about the added value of palliative resection of the 
primary tumour.15, 24-26 However, it also may reflect an increased preference for 
chemotherapy as the treatment of first choice27, 28, as we found in this study.
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The present study showed an increase in metastatic surgery for patients with 
metastatic disease confined to one site. It is plausible that the majority of 
these patients were treated with curative intent. The largest increase was 
found in patients with liver-only metastases, which is potentially due to the 
introduction of new treatment possibilities and improved surgical techniques.7 
These improvements, together with the increasing efficacy of systemic therapy 
to make secondary resection possible, are expected to further increase the 
proportion of patients undergoing liver surgery. Therefore, close collaboration 
with centres of expertise in liver surgery is essential to select patients 
eligible for treatment with curative intent.29 Although less pronounced, we 
also observed an increase in surgical treatment of metastases in patients 
with lung or other single organ metastases. The proportion of patients with 
advanced metastatic disease undergoing metastasectomy did not change 
over time. However, there is some evidence that curative resection is possible 
in selected patients with multiple organ metastases.9, 30, 31
In the Netherlands, median overall survival in the total group of CRC patients 
diagnosed with synchronous Stage IV disease increased from 7.2 months in 
1996-1999 to 12.0 months in 2008-2011. Consistent with reports from other 
countries23, 32, the largest improvement in survival was seen in patients below 
the age of 75. These patients are more often eligible for surgical and systemic 
treatment, and they can better withstand the complications and side effects 
of treatment. However, median age of systemic treated patients increased 
over time and median survival of elderly patients improved especially in 
recent periods. Therefore, increasing numbers of elderly patients receiving 
curative or palliative cancer treatments may have contributed to a slowed 
survival improvement in the last period. The increasing survival gap between 
patients with colon cancer and patients with rectal cancer is remarkable. This 
survival gap may to some extend be explained by differences in patterns 
of metastatic spread. Peritoneal metastases are more frequently found in 
colon cancer patients, whereas lung metastases are more common in rectal 
cancer patients.33 Survival is found to be less favourable in patients with 
peritoneal carcinomatosis than in patients with lung metastasis34, 35, as was 
also confirmed in this study.
The survival benefit for patients with single-organ metastasis can easily 
be explained, as they will more often be eligible for curative surgery than 
patients with multiple organs affected. In patients who received palliative 
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systemic treatment, survival was lower than reported in randomized trials10-12, 
which is partly because the general population encompass elderly and frail 
patients who are usually not included in those trials. This is reflected by the 
fact that only 28% of the patients in this population based study received 
modern, expensive, systemic targeted treatment which might also explain 
the lower overall survival. A recent study showed that patients with Stage IV 
CRC not fulfilling eligible criteria for the original trial had a worse outcome 
while eligible non-trial patients showed a similar outcome compared to trial 
participants.36
The remarkable improvement in survival for patients with lung metastases, 
especially patients with lung-only metastases, can partly be contributed to 
improvements in systemic therapy and surgical intervention. However, to some 
extent it will also reflect earlier diagnosis as a result of improved imaging 
techniques.20, 21, 37 Probably, this phenomenon has influenced other survival 
outcomes as well. With regard to survival of CRC patients who underwent 
metastasectomy of lung metastases, results in this study are in line with a 
recent review of 25 retrospective series reporting a median survival between 
18.5 and 72 months.8
A limitation in this study is the amount of lacking data on location of 
metastasis for patients diagnosed between 1996 and 2007. With careful 
selection of included data, missing values were limited to a minimum without 
compromising representativeness. Furthermore, in the literature several 
definitions are used for distinguishing synchronous and metachronous 
metastases. Because the NCR does not provide information on the date of 
diagnosis of distant metastases, we cannot select distant metastases that 
were diagnosed within a predefined period of date of diagnosis of the 
primary tumour (e.g. 3, 6 or 12 months) to analyse possible differences in the 
incidence of distant metastases.
In conclusion, an increase in the proportion of Stage IV CRC patients was 
observed over the last two decades. This increase can mainly be explained by 
an improved detection of non-liver metastases, especially lung metastases. In 
upcoming years, further increase of survival is expected, when more patients 
will undergo metastatic surgery and the efficacy of systemic treatment 
increases further by the developments in personalized medicine. Optimizing 
the use of personalized medicines justifies an extensive tracking system of 
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treatment and treatment results. However, treatment and survival patterns 
may further diverge according to metastatic spread.
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Large variation in the utilisation of liver resections 
in stage IV colorectal cancer patients with 
metastases confined to the liver
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Background. Surgical resection of both the primary tumour and 
all metastases is considered the only chance of cure for patients 
with stage IV colorectal cancer. The aim of this study was to in-
vestigate change over time in the utilization of liver resections, 
as well as possible institutional variations.
Patients and methods. All patients diagnosed with stage IV 
colorectal cancer with metastases confined to the liver (n = 
1,617) between 2004 and 2012 were selected from the popu-
lation-based Eindhoven Cancer Registry. The proportion of pa-
tients undergoing liver resection was investigated. Institutional 
variation in the period 2010-2012 was analysed using logistic 
regression. Kaplan-Meier and Cox regression analyses were used 
to analyse overall survival.
Results. The proportion of patients undergoing liver metasta-
sectomy increased over time from 8% in 2004 to approximately 
24% in 2012. There was a wide inter-hospital variation in the 
proportion of patients that underwent a liver resection (range: 
14-34%) in the period 2010-2012. Liver resection was more of-
ten performed in younger patients and in rectal cancer patients. 
Median overall survival in patients undergoing liver resection 
was 55 months. Adjusted for potential confounders, resection of 
liver metastases was strongly associated with improved overall 
survival (HR 0.32, 95%CI 0.25-0.40).
Discussion. This study shows that despite the excellent long-
term prognosis for patients with stage IV colorectal cancer after 
liver resection, there is still a large institutional variation in the 
utilization of this potentially curative therapy.
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Introduction
Colorectal cancer (CRC) is one of the most frequently diagnosed cancer types 
worldwide. In the Netherlands, approximately 2,500 patients are diagnosed 
with colorectal cancer and synchronous metastases (stage IV) each year.1, 2 
The prognosis of patients with stage IV disease has improved significantly 
over the last two decades, mainly because of an improved survival in patients 
with isolated liver metastases.1-4
For these patients surgical resection of the primary tumour and all 
metastases leads to a significant increase in long-term overall survival. Some 
twenty years ago, less than 5% of stage IV CRC patients underwent a liver 
metastasectomy.3, 4 Nowadays, this number has increased up to 15-20%.3, 
4 It is estimated that resection of all liver metastases is possible in 20-30% 
of all stage IV CRC patients.5 Resection of liver metastases is safe and can 
potentially cure patients, demonstrated by 30-day postoperative mortality 
of less than 2% in high volume centres, and five year survival rates are around 
50% in selected patient groups.5-7
In recent years, the criteria for resectability of hepatic metastases have 
expanded.8 Currently, curative treatment is considered if the expected 
remnant liver is at least 30% of the preoperative volume, there are no 
unresectable metastases outside the liver, liver resection is anatomical 
possible with regard to vascular and biliary structures and the patient is 
fit for surgery.9, 10 New techniques, such as portal vein embolization and 
radiofrequency ablation, show promising long-term results.11, 12 The benefit 
of neoadjuvant systemic therapy in downsizing unresectable colorectal liver 
metastases has also been shown in various studies.13
A treatment plan is commonly achieved through consensus of a 
multidisciplinary team, consisting of the involved medical and surgical 
specialists. Nevertheless, it seems possible that depending on experience 
and knowledge the criteria on what constitutes resectable disease are 
interpreted differently by different specialists. Indeed, Young et al. showed 
that large differences in referral practice existed between hospitals in 
the United Kingdom for patients with liver metastases.14 There was also 
a considerable difference in patients deemed operable between local 
colorectal specialist teams and a tertiary liver specialist team.14 Even among 
liver specialists there seems to be a substantial inter-individual variation in 
PART II: OPTIMIZING UTILISATION OF LIVER RESECTION
90
3
the decision on whether or not metastases are resectable, highlighting the 
complexity of the decision making process.15, 16
We hypothesized that this differences in referral practice and interpretation 
of resectability, might lead to a considerable variation in the proportion of 
patients with colorectal liver metastases who undergo a metastasectomy. 
The aim of this population-based study was to investigate the association 
between hospital of diagnosis and the utilization of liver resection in the 
south of the Netherlands in recent years.
Patients and methods
Patient selection
Population-based data were extracted from the Eindhoven Cancer Registry 
(ECR). This database includes all newly diagnosed cancer patients from ten 
hospitals in the south of the Netherlands. The ECR was founded in 1955 
and currently covers a population of 2.4 million inhabitants. Registration 
is primarily based on notification by the nationwide automated pathology 
registry PALGA and the National Registry of Hospital Discharge Diagnosis. 
Data are retrieved from patient files by specially trained registration clerks 
from the Netherlands Comprehensive Cancer Organisation. Classification 
of tumour characteristics is done according to the TNM Classification 
of Malignant Tumours and International Classification of Diseases for 
Oncology. Follow-up consists of linking the ECR to the Municipal Personal 
Records database to retrieve information on vital status and date of death. 
At the time of data extraction, follow-up was completed up to December 31, 
2013. As the ECR only registers data on primary tumours and their primary 
treatment, information on metachronous metastases is not recorded and 
thus also not included in this study. 
Data selection
For this study, we selected all patients who were diagnosed with stage 
IV colorectal cancer with liver-only metastases between 2004 and 2012. 
The extracted data include patient, tumour and treatment characteristics. 
Socioeconomic status was estimated based on postal code of patients’ 
residence at time of diagnosis, using data on income and education from the 
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Netherlands Institute for Social Research. Location of the tumour was divided 
in colon (C18-C19) and rectum (C20). Year of diagnosis was defined as the 
year of first histological confirmation (most often from endoscopic biopsy). 
In the Netherlands, liver surgery is centralized in specific referral centres 
to ensure the best quality of care. When liver metastases is considered a 
possibility by the local multidisciplinary colorectal teams, patients from the 
general hospitals are referred to the multidisciplinary liver teams in these 
expert centres to assess eligibility. Two out of ten hospitals in the region 
included in this study are referral centres, these hospitals are indicated as 
‘liver centre’ in the analyses. The ECR only provides information on whether 
or not a patient underwent a liver resection, but does not register if a patient 
was referred to a multidisciplinary liver team and considered not eligible for 
liver surgery.
Data analysis
All patients were classified according to surgical treatment strategy: (1) 
patients who underwent neither a resection of the primary tumour nor a 
metastasectomy, (2) patients who underwent only resection of the primary 
tumour, and (3) patients who underwent resection of both the primary tumour 
and metastases. The ECR does not provide information on the number of 
metastases, nor on treatment per metastatic lesion; thus, in patients with 
multiple liver metastases, it cannot be confirmed with complete certainty that 
metastasectomy was performed for all metastases. Patients who received 
radiofrequency ablation as stand-alone treatment for metastases were not 
included in the ‘resection of both primary and metastases’ category. Because 
of the small number of patients, patients who underwent metastasectomy 
without resection of the primary tumour were excluded from the patient 
characteristics table and all analyses.
The primary endpoint of this study is the utilization of liver resection. 
Utilization of liver resection was defined as the proportion of stage IV 
patients with liver-only metastases who underwent liver resection, before 
or after undergoing resection of the primary tumour. Institutional variation 
was analysed by calculating the utilization of liver resection per hospital of 
first diagnosis. To provide the closest reflection of the current situation, only 
patients diagnosed between 2010 and 2012 were included in these analyses. 
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Each hospital The chi-square test was used to compare patients, tumour and 
therapy characteristics between the three treatment groups. To determine 
factors associated with liver resection, a multivariable logistic regression 
analyses was performed including various baseline characteristics for patients 
who underwent resection of the primary tumour with or without resection of 
liver metastases. Overall survival (OS) was defined as the interval between 
date of diagnosis of the primary tumour until date of death from any cause, 
or censored at date of end of follow up (December 31, 2013). OS curves 
were rendered according to the Kaplan-Meier method. A multivariable Cox 
proportional hazard model, including all available potential confounders, 
was performed to determine the association between treatment strategy 
 
Table 1. Patient, tumour and treatment characteristics of 1,603 patients with stage IV colorectal  cancer 
and liver-only metastases according to surgical therapy. 
 Total No  
resection 
Resection 
primary tumour 
Resection of 
primary and liver 
metastases a 
χ² test 
N % N % N % N %  
All 1,603 100% 729 45% 652 41% 222 14%  
Gender          
 Male 973 61% 437 45% 391 40% 145 15%  
 Female 630 39% 292 46% 261 41% 77 12% 0.32 
Age          
 0-44 37 2% 11 30% 6 16% 20 54%  
 45-59 295 18% 129 44% 111 38% 55 19%  
 60-74 772 48% 327 42% 322 42% 123 16%  
 75+ 499 31% 262 53% 213 43% 24 5% <0.0001 
Location primary          
 Colon 1,063 66% 424 40% 512 48% 127 12%  
 Rectum 540 34% 305 56% 140 26% 95 18% <0.0001 
Period of diagnosis          
 2004-2006 463 29% 179 39% 241 52% 43 9%  
 2007-2009 522 33% 263 50% 202 39% 57 11%  
 2010-2012 618 39% 287 46% 209 34% 122 20% <0.0001 
Comorbidity          
 No comorbidity 626 39% 268 43% 243 39% 115 18%  
 1 comorbidity 404 25% 181 45% 170 42% 53 13%  
 2+ comorbidity 566 35% 278 49% 237 42% 51 9%  
 Not recorded in ECR 7 <1% 2 29% 2 29% 3 43% <0.001 
Socioeconomic status          
 Low 372 23% 183 49% 158 42% 31 8%  
 Medium 589 37% 269 46% 229 39% 91 15%  
 High 509 32% 209 41% 211 41% 89 17%  
 Institutionalized 71 4% 43 61% 26 37% 2 3%  
 Missing 62 4% 25 40% 28 45% 9 15% <0.001 
Systemic treatment          
 No 602 38% 303 50% 262 44% 37 6%  
 Yes 1,001 62% 426 43% 390 39% 185 18% <0.0001 
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and OS for patients who underwent resection of the primary tumour with or 
without resection of liver metastases.
To ensure anonymity, the hospitals are coded differently for each analysis. 
The numbers and letters representing the hospitals do not correspond with 
each other. In the multivariable logistic regression analysis on association 
with liver resection, the hospital with the highest chance on univariable 
analysis will be taken as the reference. Likewise, in the multivariable Cox 
regression model, the hospital with the highest survival on univariable 
analysis will be used as a reference value. In all statistical tests, p-values 
below 0.05 were considered as significant. For all statistical analysis, SAS 
(Statistical Analysis System, Cary, NC) was used.
Results
Patient characteristics
Of the total of 1,617 patients diagnosed with stage IV colorectal cancer and 
liver-only metastases between 2004 and 2011, 729 patients (45%) did not 
undergo resection of the primary tumour nor metastases, 652 patients (40%) 
Figure 1. Proportion of patients with stage IV colorectal cancer and liver-only metastases 
undergoing liver resection over time.
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underwent only resection of the primary tumour, 14 patients (1%) underwent 
only a metastasectomy and 222 patients (14%) underwent both a resection 
of the primary tumour and metastases (Table 1).
Systemic therapy was significantly lower in the non-resection group (58%, n 
= 429) and the primary tumour resection group (60%, n = 390), compared to 
the group of patients who underwent resection of both the primary tumour 
and metastases (83%, n = 185; p < 0.001). In the nonsurgical group patients 
were significantly older (p < 0.0001), had significantly more comorbidity (p 
< 0.0001), had a lower socioeconomic status (p < 0.001) and the primary 
tumour was more often located in the rectum (p < 0.0001). Over time we saw 
a shift towards more resections of the primary tumour in combination with 
liver resection, and less resections of the primary tumour alone (p < 0.0001).
Utilization of liver resection
The proportion of patients who underwent a liver resection increased over 
time from 9% in 2004 to 24% in 2012 (Figure 1). In the period 2010-2012, liver 
utilization per hospital of diagnosis varied from 14% to 34% (Figure    2). 
One    of    the    two specialized liver centres had the highest proportion of 
patients undergoing liver resection (34%). However, in the other specialized 
centre only 17% of patients underwent liver resection. 
In 2010-2012, a total of 874 patients underwent resection of the primary tumour 
with or without resection of liver metastases. Five patients for whom no data 
were available on comorbidity 
were excluded from the 
regression analyses; thus 869 
patients were included in the 
univariable and multivariable 
logistic regression 
models to investigate the 
association between various 
clinicopathological factors 
and liver metastasectomy. The 
multivariable analysis showed a 
significantly decreased chance 
of liver resection for patients 
Figure 2. Proportion of patients with stage IV colorectal 
cancer and liver-only metastases undergoing liver 
resection per hospital of diagnosis in the period 2010-
2012.
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Table 2. Univariable and multivariable logistic regression modelling the chance of liver resection among 
patients with stage IV colorectal cancer and liver-only metastases who underwent resection of the 
primary tumor (n = 869). 
 Univariable Multivariable 
 OR 95% CI OR 95% CI 
Gender     
 - Male 1.25 0.91-7.73 1.10 0.76-1.58 
 - Female 1.00  1.00  
Age     
 - 0-44 6.92 2.62-18.24 5.44 1.86-15.89 
 - 45-59 1.00  1.00  
 - 60-74 0.80 0.54-1.18 0.74 0.48-1.14 
 - ≥75 0.22 0.13-0.39 0.26 0.14-0.47 
Location primary tumor     
 - Colon 0.37 0.26-0.51 0.38 0.26-0.56 
 - Rectum 1.00  1.00  
Period of diagnosis     
 - 2004-2006 1.00  1.00  
 - 2007-2009 1.58 1.02-2.44 1.73 1.07-2.79 
 - 2010-2012 3.19 2.15-4.74 4.04 2.61-6.28 
Comorbidity a     
 - No comorbidity 1.00  1.00  
 - 1 comorbidity 0.66 0.45-0.96 0.68 0.44-1.05 
 - 2+ comorbidity 0.46 0.31-0.66 0.62 0.40-0.96 
Socioeconomic status     
 - Low 1.00  1.00  
 - Medium 2.01 1.33-3.34 1.63 0.97-2.72 
 - High 2.11 1.33-3.34 1.91 1.14-3.20 
 - Institutionalized 0.39 0.09-1.74 0.37 0.08-1.83 
 - Missing 1.64 0.70-3.81 0.38 0.54-3.58 
Hospital of diagnosis     
 - A 0.47 0.21-1.06 0.50 0.21-1.20 
 - B 0.51 0.27-0.93 0.43 0.22-0.86 
 - C (liver center) 0.63 0.37-1.07 0.60 0.33-1.09 
 - D 0.47 0.23-0.95 0.46 0.21-1.00 b 
 - E 0.46 0.21-0.99 0.41 0.18-0.97 
 - F 0.85 0.48-1.50 0.71 0.37-1.36 
 - G 0.64 0.36-1.16 0.57 0.30-1.10 
 - H 1.14 0.58-2.21 1.54 0.72-3.31 
 - I 1.02 0.54-1.95 1.04 0.49-2.20 
 - J (liver center) 1.00  1.00  
a Patients for whom comorbidity was not recorded (n = 5) were excluded from this analysis.  
b 1.00 outside 95% confidence interval. 
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primarily diagnosed in hospital B, D or E, compared to hospital J; Table 2). 
Furthermore, age above 75 years (OR 0.26 [0.14-0.47], compared to age 45-
59), a tumour located in the colon (OR 0.38 [0.26-0.56], compared to rectal 
cancer) and multiple comorbidity (OR 0.62 [0.40-0.96], compared to no 
comorbidity) were all associated with a decreased chance of liver resection. 
In contrast, patients with a high socioeconomic status were more likely to 
undergo liver resection. No association was found between the volume of 
hospitals (i.e. the number of patients diagnosed per year) and the utilization 
of liver resection (data not shown).
Survival
Median OS was 8 months in the non-resection group, 18 months in patients 
who underwent only primary tumour resection and 53 months in patients 
undergoing resection of both the primary tumour and liver metastases (p 
< 0.0001, Figure 3). Multivariable Cox regression analysis, confirmed the 
association between liver resection and improved OS (HR 0.32 [95%CI 0.25-
0.40], Table 3). Patients aged 60e74 years, and above 75 years had a decreased 
OS compared to patients aged 45e59 years (HR 1.28 [1.02-1.61] and HR 1.71 
[1.30-2.24], respectively). Colon cancer patients had a lower OS (HR 1.39, 
95%CI 1.16-1.68), compared to rectal cancer patients. After adjustment for 
confounders hospital of diagnosis was not significantly associated with OS.
Discussion
This large population-based study shows that despite an overall increase 
in the proportion of stage IV colorectal cancer patients with liver-only 
metastases undergoing liver resection over the last ten years, there is a large 
institutional variation in the utilization of liver resection between hospitals 
in the south of the Netherlands. This institutional variation was confirmed in 
a multivariable analysis including many potential confounders to correct for 
case-mix. Survival was strongly associated with liver resection, but did not 
depend on hospital of diagnosis.
This study shows that patients diagnosed in one hospital may be twice as 
likely to undergo liver surgery as patients diagnosed in another hospital. 
This variety between hospitals in the proportion of patients undergoing 
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liver surgery is not restricted to the Netherlands.14, 17 In the United Kingdom, 
an audit of referral patterns for liver resection showed a large variation in 
resection rates between different hospitals. However, after the introduction 
of guidelines for referral, resection rates standardized for four of the five 
hospitals.17
It has been previously demonstrated that a resection rate of at least 20% 
can be attained in patients with liver metastases.5 In the current study, five 
hospitals showed resection rates over 20% and one centre had a resection 
rate as high as 34% in stage IV colorectal cancer patients with liver-only 
metastases. Improvement of referral practice may lead to a remarkable 
increase in the amount of patients undergoing liver surgery and consequently 
survival, and possibly even larger than can be expected from any surgical or 
medical development in the upcoming years. 
Although inter-hospital variations are often considered synonymous with 
variation in quality, there may be other reasons to explain these differences 
as well. Variation between hospitals can be simply based on chance. This 
may be especially the case in the smaller hospitals, where the numbers of 
Figure 3. Overall survival of patients with stage IV colorectal cancer and liver-only metastases 
according to surgical  therapy.
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patients are low. However, all hospitals included in this study diagnosed at 
least 34 patients in the period 2010-2012. Furthermore, differences in case-
mix can potentially bias inter-hospital variation; this is a common form of 
bias when evaluating tertiary referral centres. Case-mix variation also is a 
plausible explanation of the below average resection rate of 17% in one of the 
tertiary liver centres. Nevertheless, a multivariable analysis including many 
important case-mix factors, confirmed the association between hospital of 
diagnosis and utilization of liver resection.
Despite other influencing factors, the inter-hospital variation will be partly 
due to differences in (quality of ) care. Although it is common practice to 
discuss patients with liver metastases in a multidisciplinary team, and the 
benefit of such a team has been demonstrated in multiple studies17-19, the 
choice for liver resection highly depends on the skills and experience of the 
responsible surgeon.15, 16 Currently, patients are only referred to the regional 
multidisciplinary liver teams after they have been discussed in the local 
multidisciplinary colorectal teams. However, hospitals may maintain different 
strategies in referring patients between hospitals: where some hospitals 
might  refer all patients diagnosed with liver metastases to an expert centre, 
others might only refer those patients who are deemed eligible for surgery 
by the local specialists. This way, patients who are marginally eligible for 
resection, or are candidates for down staging with neoadjuvant systemic 
therapy, can be overlooked. The simplest solution to this problem would be 
to discuss all patients with liver metastases in a multidisciplinary liver team. 
As previous research has also shown a substantial inter-individual variation 
among liver specialists, we advocate that this multidisciplinary team would 
include at least two hepatobiliary surgeons.
Besides hospital of primary diagnosis, this study showed an association 
between liver resection and age, location of the primary tumour, presence 
of comorbidity and socioeconomic status. Patients aged over 75 years were 
less likely to undergo liver resection as has also been demonstrated for 
metachronous CRC and other liver tumours.20 However, mortality rates have 
proven acceptable in elderly patients, with 3-year survival rates that are 
comparable to younger patients.21 Therefore, these patients should not 
automatically be denied liver resection. Furthermore, rectal cancer patients 
were more likely to undergo liver resection than colon cancer patients. 
This difference between rectal and colon cancer is not clear, although new 
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strategies such as ‘liver first’ resection might especially be suitable for rectal 
cancer patients.22
Last, we found a significant association between high socioeconomic status 
and treatment with liver resection. This association was sustained in the 
multivariate analysis, and thus cannot be explained by the association between 
socioeconomic status and comorbidity alone. Possibly, these patients are 
more aware of their treatment options, do more often seek second opinions, 
or are more self-assertive and concerned with their treatment strategy.23 
These socioeconomic inequalities in treatment decisions have previously 
also been demonstrated in other cancer types, such as prostate cancer and 
breast cancer in the Netherlands.24, 25
This study confirms that patients with liver metastases due to stage IV 
colorectal cancer who undergo liver resection have an excellent long-term 
prognosis, as demonstrated in previous studies.7, 9, 13 Despite the lack of 
randomized trials, this remarkable survival benefit has assured that liver 
metastasectomy is now widely accepted in clinical practice. Other studies 
have demonstrated that survival rates can be further increased by both 
careful patient selection and centralizing liver surgery in dedicated centres.26, 
27
In contrast to the association between hospital of diagnosis  and the chance 
of undergoing a liver resection, no association was found between hospital 
of diagnosis and survival. This might indicate that hospitals use different 
criteria to select patients for liver resection. It could be that centres with lower 
resection rates managed to select more accurately those patients who do in 
fact benefit from surgery. This finding reinforces our hypothesis that there 
is non-uniformity in the utilization of liver resection; and it strengthens our 
recommendation that all patients with liver metastases should be presented 
to a multidisciplinary liver team.
As with most observational studies, confounding by indication cannot be 
avoided in the current study. Data on rationale for individual treatment 
choices are not available within the Eindhoven Cancer Registry. It is also 
plausible that patients, who were selected for surgery, were more physically 
fit than patients who did not undergo surgery. The Eindhoven Cancer 
Registry does not provide information on the amount of metastases per 
organ. However, extensive tumour load is often considered an important 
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prognostic factor and can be a reason to renounce liver metastasectomy.28 
To create a more homogenous group with regard to extensiveness of disease, 
this study concentrated on stage IV patients with metastatic disease isolated 
to the liver. Therefore, one should be careful in extrapolating the reported 
survival rates to all stage IV CRC patients with liver metastases.
With only 122 liver resections in two hospitals in three years, it could be 
commented that these number are too low to speak about dedicated centres; 
and thus question the quality of care within this centres. However, absolute 
number of liver resection will be much higher, as these numbers do not 
include liver resections performed for metachronous colorectal metastases, 
non-colorectal metastases and primary liver tumours.
In conclusion, this study shows a large variation between hospitals and 
social economic status in the utilization of liver resection in the south of the 
Netherlands. As there seems to be a clear survival benefit of liver resection 
for patients with hepatic metastases due to stage IV colorectal cancer, we 
advocate that all these patients are assessed by a regional multidisciplinary 
liver team including at least two hepatobiliary surgeons, without pre-
selection by a local multidisciplinary colorectal team. We believe that such a 
change in referral practice could lead to an important increase in the amount 
of eligible patients identified, potentially resulting in an overall survival 
benefit for patients with stage IV CRC.
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Regional and inter-hospital differences 
in the utilisation of  liver surgery for 
patients with synchronous colorectal 
liver metastases in The Netherlands
4
Background. The objective of this study was to map referral 
patterns in patients with synchronous colorectal liver metasta-
ses (SCLM) and to investigate if type, volume and location of the 
hospital of diagnosis are associated with whether or not patients 
underwent liver resection.
Methods. This population-based study includes all patients di-
agnosed with SCLM between 2008 and 2012, based on the Neth-
erlands Cancer Registry. To study inter-hospital variation, the 
proportion of patients undergoing liver surgery was calculated 
per  hospital of diagnosis. Multivariable multilevel logistic re-
gression analysis was used to investigate the association be-
tween hospital characteristics and liver resection.
Results. Of 10,520 patients with SCLM, 12% (n = 1259) under-
went liver surgery. Of these patients, 58% (n = 733) were re-
ferred to another hospital to undergo liver surgery. In 53% of the 
patients (n = 647), liver resection was performed in a university 
hospital, in 39% (n = 482) in a dedicated liver centre and in 8% 
(n = 102) in a general hospital. There was a large inter-hospital 
variation in the proportion of patients undergoing liver resection 
(2e26%). In a multilevel logistic regression model, the odds of 
undergoing liver surgery were higher when patients were diag-
nosed in hospitals where liver surgery was performed compared 
with the general hospitals (dedicated liver centre: odds ratio 1.36 
[95% confidence intervals 1.08-1.70], university hospital: odds 
ratio 1.69 [95% confidence intervals 1.22-2.34]).
Conclusion. There is a large inter-hospital and inter-regional 
variation in the utilisation of liver resection. Patients diagnosed 
with SCLM in expert centres had a higher chance of undergoing 
liver resection.
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Introduction
Colorectal cancer (CRC) is the third most common type of cancer worldwide. In 
2014, more than 15,000 patients were diagnosed with CRC in the Netherlands. 
metastases  occur in a substantial number of patients, depending on the 
histological subtype of colorectal cancer (i.e. mucinous, signet ring cell or 
adenocarcinoma).1 Approximately, 20% of patients present with synchronous 
distant metastases (stage IV disease), and another 20% of patients develop 
metastases during follow-up (metachronous metastases).2, 3 Colorectal liver 
metastases (CLMs) are present in three out of four patients with stage IV 
disease and in the majority no extrahepatic metastases are found.3, 4 
Surgical resection of the primary tumour and all metastases offers a potential 
cure for patients with CLM; in particular for patients without extrahepatic 
metastases.5 The five-year survival rates for patients undergoing liver 
resection are nowadays between 20% and 60%, depending on clinical risk 
factors.5-8 As the criteria for resectability are evolving, the proportion of 
patients undergoing liver resection is increasing.9 At present, metastasectomy 
is considered for patients with colorectal liver metastases if the patient is fit 
for surgery, if there is an expected remnant liver of at least 20-30% of the 
preoperative volume, if liver resection is anatomically possible with regard to 
vascular and biliary structures, and if no unresectable extrahepatic metastases 
are present.10, 11 
In the Netherlands, inter-hospital variation in the proportion of patients 
undergoing curative treatment has been demonstrated for various types of 
cancer.12-14 A survey among surgeons showed a wide variety in the diagnostics 
and therapeutic work-up for patients with metastatic CRC.15 Recently, a 
regional study demonstrated variation in the utilisation of liver resection in 
the south of the Netherlands.8 This implies that substantial differences in the 
utilisation of liver surgery might exist on a national level as well. Previous 
research has demonstrated that involvement of a hepatobiliary surgeon in 
the multidisciplinary colorectal cancer team improves overall survival.16-18 
Therefore, we hypothesise that patients with CLM diagnosed in a dedicated 
liver centre more often undergo liver surgery.
The objective of this study was to determine the variation between hospitals 
in the proportion of patients with CLM undergoing liver resection, using the 
Netherlands Cancer Registry (NCR). Because only synchronous metastases 
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can be identified by the NCR, we focused on stage IV patients only. Moreover, 
we analysed referral patterns for liver surgery and investigated if type, volume 
and region of the hospital of diagnosis were associated with the probability 
that a patient will undergo liver resection.
Methods
Netherlands Cancer Registry
Nationwide population-based data were extracted from the NCR. This database 
registers all newly diagnosed cancers since 1989. Identification of patients is 
primarily based on notification by the national automated pathology archive 
and hospital discharge notes.19 Patient, tumour and treatment characteristics 
were retrieved from patient files by specially trained registration employees 
of the Netherlands Comprehensive Cancer Organisation. Classification of 
tumour characteristics occurs according to the current versions of the TNM 
Classification of Malignant Tumours20 and the International Classification of 
Diseases for Oncology21. Information on metachronous metastases is not 
registered in the NCR. Follow-up of vital status is obtained by annually linking 
the Registry to the Municipal Personal Records Database, which contains 
information on vital status of all Dutch inhabitants.
Data selection
All adult patients (18 years or older) who presented with SCLM between 2008 
and 2012 were selected for this study. Patients diagnosed with SCLM during 
autopsy were excluded. Synchronous metastases were defined as metastases 
detected before the start of initial treatment and/or during surgical exploration. 
The extracted data included patient, tumour and treatment characteristics, as 
well as overall survival (OS). OS was defined as the interval between date of 
diagnosis of the cancer until date of death from any cause, or censored at 
date of end of follow-up (December 2015). Year of diagnosis was defined as 
the year of first histological confirmation. Hospital of diagnosis was defined 
as the hospital where the first histological confirmation of malignant disease 
was obtained: most often as the result of endoscopic biopsy of the primary 
tumour. Liver resection was defined as any removal of liver metastases 
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(including surgical diagnostic biopsies, not including percutaneous biopsies 
or percutaneous treatments such as radiofrequency ablation).
Organisation of Dutch hospital health care
Hospital health care in the Netherlands during the studied time period 
comprised of 91 hospitals. These are commonly divided into general hospitals, 
teaching hospitals and university hospitals. University hospitals (n = 8) are 
allied with the Dutch universities and function as tertiary referral centres. 
There are 42 teaching hospitals that offer a surgical residency in collaboration 
with the university hospitals. General hospitals are often smaller and provide 
less complex care in high volume or diseases with a high incidence. 
However, because not all teaching hospitals provide liver surgery, within 
this article, we scored type of hospital as university hospital, dedicated liver 
centre (i.e. teaching hospitals where liver surgery in performed) and general 
hospital (i.e. teaching or general hospitals not providing liver surgery). In 
the Netherlands, liver surgery may be performed if a hospital meets specific 
requirements set by the medical professional associations. These requirements 
state that a centre should employ at least two hepatobiliary surgeons, have 
access to specific interventions (e.g. radiofrequency ablation, endoscopic 
retrograde cholangiopancreatography) and meet a volume requirement of 
at least twenty oncologic liver resections annually.22 The number of surgical 
procedures presented in this study does not include liver resections performed 
for metachronous colorectal metastases, non-colorectal metastases or 
primary liver tumours. Volume of hospital of diagnosis was divided in low (<20 
diagnoses), medium (20-35 diagnoses) and high (>35 diagnoses) according 
to the mean number of patients diagnosed with stage IV CRC annually in 
the studied time period. Regional differences were analysed using the nine 
regions of the Netherlands Comprehensive Cancer Organisation. 
These nine regions, covering the whole of the Netherlands and all including 
rural and urban areas, are also the basis for regional collaboration between 
hospitals.
Data analysis
Patient, tumour and treatment characteristics were presented or the total 
population. Any trend in the utilisation of liver resection over time was studied 
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using chi-square tests. The number of hospitals performing liver resections 
was calculated per year. For each type of hospital, the proportion of patients 
diagnosed with SCLM undergoing liver resection was calculated. To identify 
factors associated with liver resection, a multivariable multilevel logistic 
regression analysis was performed, taking into account the hierarchical 
structure of patients clustered within hospitals of diagnosis. The multivariable 
analysis included those factors that showed a p-value below .1 on univariable 
analysis. Regions of diagnosis were alphabetically numbered to ensure 
anonymity. The region with the lowest rate of liver resection was taken as the 
reference value in multivariable analysis. For all statistical analyses, STATA 
version 12.0 was used.
Results
Patient characteristics
Patient, tumour and treatment characteristics are presented in Table 1. A total 
of 10,520 patients were diagnosed with SCLM in the Netherlands between 
2008 and 2012. Over the years, there was a small increase in the number 
of diagnosed patients (from 1,954 to 2,173). The majority of patients was 
diagnosed in a general hospital (67%, n = 7,036). Metastatic spread was 
limited to the liver in 60% (n = 6,263) of the patients. Liver surgery was 
performed in 12% of patients (n = 1,259). Most patients were treated with 
preoperative and/or postoperative systemic therapy (65%, n = 6,869). Of 6,263 
patients with metastases confined to the liver, 19% underwent liver surgery 
(n = 1,213). Over the years, the proportion of all patients undergoing liver 
resection increased from 9% to 15% (p < .001). Patients with colorectal liver 
metastases who underwent liver surgery had a 5-year OS of 46%, compared 
with 4% in patients who did not undergo liver surgery. For patients with 
metastases confined to the liver specifically, this difference in 5-year OS was 
47% versus 6%, respectively. 
Concentration of care and referral patterns
Between 2008 and 2012, there were a total of 91 hospitals in the Netherlands, 
divided into 9 university hospitals, 16 dedicated liver centres and 66 general 
hospitals. Table 2 shows that there was some variation in the number 
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of hospitals performing at 
least one liver resection 
for synchronous colorectal 
metastases. This was mainly due 
to a variation in the number of 
hospitals performing only one 
(incidental) resection per year 
(varying from 3 to 14). 
Table 3 shows the referral 
patterns for patients 
undergoing liver surgery. Of the 
1,259 patients who underwent 
liver surgery, 527 patients 
(42%) did so at the hospital 
of primary diagnosis. This 
number varied between the 
types of hospital of diagnosis: 
in university hospitals, only 
4% of patients were referred 
to another centre before 
undergoing liver surgery; in 
dedicated liver centres, 16% 
of patients underwent liver 
surgery at another hospital 
than the hospital of  diagnosis; 
and in the general hospitals 
this number was 88%.
Utilisation of liver resection
Figure 1 shows the proportion 
of patients undergoing liver 
resection for each hospital of diagnosis. Overall, 12% of patients with SCLM 
underwent a liver resection. This proportion varied between hospitals from 
2% to 26%. The variation was largest in general hospitals (2-26%), followed 
by the dedicated liver centres (4-24%) and the university hospitals (10-22%). 
 Table 1. Characteristics of patients with synchronous 
colorectal liver metastases (n = 10,520). 
 Total Liver resection 
 N (%) N (%) 
Year of diagnosis   
2008 1,954 (19) 172 (14) 
2009 2,020 (19) 191 (15) 
2010 2,178 (21) 269 (21) 
2011 2,195 (21) 315 (25) 
2012 2,173 (21) 312 (25) 
Gender   
Male 6,136 (58) 798 (63) 
Female 4,384 (42) 461 (37) 
Age   
Mean 68 63 
<60 2,347 (22) 398 (32) 
60-75 5,316 (51) 714 (57) 
75+ 2,857 (27) 147 (12) 
Hospital of diagnosis   
General hospital 7,036 (67) 720 (60) 
Dedicated liver centre 2,869 (27) 402 (32) 
University hospital 615 (6) 97 (8) 
Location primary   
Colon 7,402 (70) 787 (63) 
Rectosigmoid 384 (4) 48 (4) 
Rectum 2,734 (26) 424 (34) 
Other metastatic locations 
None (liver-only) 6,263 (60) 1,213 (96) 
1 3,097 (29) 42 (3) 
2 918 (9) 3 (0) 
>2 242 (2) 1 (0) 
Liver resection  
(+/- other treatment)  
Yes 1,259 (12) 1,259 (100) 
No 9,136 (87)  
Unknown 125 (1)  
Radiofrequency ablation  
(+/- other treatment) 
Yes 302 (3) 147 (12) 
No 10,218 (97) 1,112 (88) 
Perioperative systemic therapy  
(+/- other treatment) 
Chemotherapy 3 705 (35) 654 (52) 
Targeted therapy 30 (0) 1 (0) 
Combination therapy 3 134 (30) 357 (28) 
None 3 651 (35) 247 (20) 
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The proportion was significantly higher in the university hospitals (16%) and 
the dedicated liver centres (14%), compared with the general hospitals (11%, 
p < .001).
In univariable logistic regression analysis, no association was found between 
volume of hospital of diagnosis and liver resection (p = .12). Type and region 
of hospital, as well as several other clinicopathological factors were associated 
with liver resection and were thus included in the multivariable analysis.
As shown in Figure 2, patients diagnosed in a dedicated liver centre or in a 
university hospital were significantly more likely to undergo liver resection 
(odds ratio 1.36 [95% confidence intervals 1.14-1.62] and 1.64 [95% confidence 
intervals 1.25-2.14], respectively). There was an association between region 
of diagnosis and liver resection, with patients diagnosed in six out of 
nine regions (region B, C, F, G, H and I) being more likely to undergo liver 
resection  compared with the reference region with the lowest probability 
of this treatment (region A). With regard to chemotherapy, variation was 
smaller between type of hospital, as well as region. Only 6% of patients 
treated with chemotherapy were referred to another hospital for treatment. 
 
Table 2. Number of hospitals performing treatment in patients with SCLM. 
 Total 2008 2009 2010 2011 2012 
Hospitals where liver resection 
was performed 
53 30 42 34 37 30 
Number of liver resections per 
hospital per year (%) 
      
      1 resection   4 (13%) 14 (33%) 5 (15%) 9 (24%) 3 (10%) 
      2-10 resections  21 (70%) 22 (52%) 23 (68%) 16 (43%) 15 (50%) 
      >10 resections  5 (17%) 6 (14%) 6 (18%) 12 (32%) 12 (40%) 
Abbreviation: SCLM, synchronous colorectal liver metastases. 
 
Table 3. Referral patterns of patients undergoing liver resection (n = 1,259) with type of hospital. 
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General 95 (13) 4 (1) 136 (18) 499 (66) 26 (3) 760 (100) 
Dedicated 339 (84) 3 (1) 4 (1) 54 (13) 2 (0) 402 (100) 
University 93 (96) 0 (0) 3 (3) 0 (0) 1 (1) 97 (100) 
Total 527 (42) 7 (1) 143 (11) 553 (44) 29 (2) 1259 (100) 
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60% to 69%.
Discussion
This nationwide population-based study shows that the rate of liver resection 
in patients with synchronous colorectal liver metastases (SCLMs) varies 
considerably between hospitals in the Netherlands. Patients diagnosed in 
general hospitals were less likely to undergo liver surgery, compared with 
patients diagnosed in a dedicated liver centre or in a university hospital. 
Besides this inter-hospital variation, an inter-regional variation in the 
utilisation of liver  resection was also found, which was sustained after 
correction for several confounders in a multivariable analysis.
Similar to these results, studies from the United Kingdom and Sweden showed 
considerable inter-hospital variation in the utilisation of liver resection.7, 
23 Although patients included in the study by Morris et al. were diagnosed 
between 1998 and 20047, our study showed comparable results in more 
recent years, as did the study by Noren et al.23 In the Netherlands, inter-
hospital variation was also found in the utilisation of curative treatment for 
oesophageal cancer, lung cancer and gastric cancer.11, 16, 22, 24, 25 Similar to the 
Figure 1. Proportion of patients undergoing liver resection (whether or not after referral to another 
hospital) per hospital of primary diagnosis.
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treatment of colorectal liver metastases, curative treatment for these cancer 
types is also concentrated in dedicated centres.
According to The Dutch National Guidelines on Colorectal Cancer, all 
patients who are diagnosed with colorectal cancer should be discussed by a 
multidisciplinary team (MDT).26 In the general hospitals, this colorectal MDT 
also identifies patients who should be presented to a tertiary liver MDT at one 
Figure 2. Forest plot of the probability to undergo liver resection, as found in a multilevel multivariable 
logistic regression analysis.
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of the dedicated liver centres or university hospitals. An explanation for the 
lower resection rate among patients diagnosed in the general hospitals could 
be that the local MDTs are less proficient in identifying all patients potentially 
eligible for curative treatment. Previous studies showed that a large number 
of patients, who were initially diagnosed with unresectable liver metastases, 
were still considered potentially resectable by a hepatobiliary surgeon.27, 28 
Therefore, an obvious solution to reduce inter-hospital variation could be to 
involve a hepatobiliary surgeon in the local colorectal MDTs.
As there was also a substantial inter-hospital variation in the hospitals where 
liver resection was performed – with a range of 4-24% in the dedicated liver 
centres and 10-22% in the university hospitals – involving a hepatobiliary 
surgeon in the local MDTs would not disperse these inter-hospital and inter-
regional variations completely. Folprecht et al. showed that even between 
hepatobiliary specialists considerable inter-individual variation in the decision 
of resectability existed.29 This could also account for the inter-hospital and 
interregional variation. The variation in treatment with chemotherapy was 
remarkably smaller, with an inter-regional variation of 60-69%. An important 
difference between chemotherapeutic treatment and liver surgery is that 
patients were seldom referred to another hospital – as there is no centralisation 
of chemotherapeutic treatment in the Netherlands.
A possible solution to this problem was recently put forth in the design 
of a new trial investigating treatment strategies in patients with initially 
unresectable colorectal liver-only metastases: the CAIRO5 study and the 
CHARISMA study.30, 31 To prevent bias caused by inter-individual variation, 
a nationwide expert panel was appointed, that first reached consensus on 
the criteria of resectability.  Second, a web-based system was developed 
where physicians can upload diagnostic imaging, which are then assessed by 
a radiologist on quality, and subsequently evaluated by at least three expert 
liver surgeons on resectability.31 Although this expert panel is currently only 
operating as part of a clinical trial, it shows that establishing a nationwide 
expert panel is logistically and financially possible. It should therefore be 
advocated that this panel will be maintained for daily practice as well, as 
this will probably contribute to more consensus on resectability, as well as a 
reduction in inter-hospital and inter-regional variation.
Besides type and region of hospital of diagnosis, other predictors to undergo 
liver resection included location of the primary tumour, the absence of 
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extrahepatic disease and the year of diagnosis. The latter shows that the 
utilisation of liver resection is still increasing, implying that the rates of liver 
resection might increase even further in the nearby future.9 The association 
between a more distal location of the primary tumour and an increased 
probability to receive curative treatment is remarkable and has been 
previously demonstrated; however, no clear explanation for this phenomenon 
is available [8]. It might be that patients with distal tumours are more often 
eligible for resection of the primary tumour, due to the beneficial effect of 
neoadjuvant therapies; or that new strategies such as the ‘liver first’ resection 
are more suitable for rectal cancer patients.32
Although it is tempting to consider the presented inter-hospital and inter-
regional differences as a direct reflection of differences in quality of care, this 
would not be correct. Several other factors might attribute to these differences 
as well.33 First, liver resection rates might vary simply because of chance. A 
variation in case-mix between the hospitals can also lead to a variation in 
treatment strategies.33 To minimise this potential bias, a multivariable analysis 
including various clinicopathological factors was performed. Several factors, 
such as comorbidity, number and size of liver metastases, were not available. 
Because information on these prognostic factors was missing, multivariable 
analysis to investigate the influence of the inter-hospital and inter-regional 
variation in treatment utilisation on overall survival could not be performed. 
Another limitation of this study is that no information is available on the 
accuracy of clinical staging. Recent studies demonstrate that PET-CT imaging 
does not have an impact on resectability or prognosis of patients with 
colorectal liver metastases.32, 34 Hence, despite these possible differences, 
the variation shown in this study should at least be partially contributed to 
differences in (quality of ) care. This study does not include data on variation 
n overall survival, and future studies should investigate how inter-hospital 
and inter-regional differences influence survival. 
In conclusion, there is a considerable variation in the utilisation of liver 
resection for patients with SCLM in the Netherlands. As liver resection offers 
the only potential cure, it is very important that all eligible patients are 
identified by dedicated specialists. The formation of a national expert panel, 
including hepatobiliary surgeons, dedicated radiologists as well as dedicated 
medical oncologists, evaluating resectability in all patients with SCLM, will 
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potentially lead to an important improvement in the identification of patients; 
and might even lead to an improvement in overall survival.
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Palliative resection of the primary 
tumour is associated with improved 
overall survival in incurable stage 
IV  colorectal cancer: a nationwide 
population-based propensity-score 
adjusted study in The Netherlands
5
As the value of palliative primary tumour resection in stage IV 
colorectal cancer (CRC) is still under debate, the purpose of this 
population-based study was to investigate if palliative primary 
tumour resection as the initial treatment after diagnosis was as-
sociated with improved overall survival. All patients with stage IV 
colorectal adenocarcinoma (2008-2011) were selected from the 
Netherlands Cancer Registry, and patients undergoing treatment 
with curative intent (i.e., metastasectomy, radiofrequency abla-
tion and/or hyperthermic intraperitoneal chemotherapy), or best 
supportive care were excluded. After propensity-score matching, 
a multivariable Cox proportional hazard model was performed to 
determine the association between treatment strategy and mor-
tality. 
From a total group of 10,371 patients with stage IV CRC, 2,746 
patients (26%) underwent an elective palliative resection of the 
primary tumour, whether or not followed by systemic therapy, 
and 3,345 patients (32%) were initially treated with palliative 
systemic therapy. After propensity score matching, median overall 
survival in these groups was 17.2 months (95% CI 16.3-18.1) and 
11.5 months (95% CI 11.0-12.0), respectively. In Cox regression 
analysis, primary tumour resection was significantly associated 
with improved overall survival (hazard ratio of death 5 0.44 [95% 
CI 0.35-0.55],p < 0.001). 
This large population-based study shows an overall survival 
benefit for patients with incurable stage IV CRC who underwent 
primary tumour resection as the initial treatment after diagno-
sis, compared to patients who started systemic therapy with the 
primary tumour in situ. This result is an argument in favour of 
resection of the primary tumour, even when patients have little 
to no symptoms.
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Introduction
An increasing number of colorectal cancer (CRC) patients is diagnosed with 
synchronous metastases (stage IV).1-3 The majority of these patients are only 
eligible for treatment with palliative intent.1, 3, 4 The increasing use of palliative 
systemic therapy during the past two decades has led to a remarkable increase 
in overall survival (OS).1, 3, 5, 6
Traditionally, palliative resection of the primary tumour was preferred in stage 
IV CRC patients to prevent complications, such as bleeding, obstruction and 
perforation. Currently, a trend toward a more conservative treatment strategy 
is perceptible,2, 3 probably as a response to recent publications questioning 
the benefit of primary tumour resection.7-12 Poultsides et al. showed that 89% 
of patients treated with combination systemic therapy did not require an 
emergency intervention.12 Although refraining from surgery might be safe in 
terms of complications of the primary tumour, meta-analyses of retrospective 
data of large randomized systemic therapy trials suggest that patients 
undergoing primary tumour resection have a survival benefit compared to 
patients who are only treated with systemic therapy.13-16 This survival benefit 
might be just a reflection of selection bias, as younger and healthier patients 
are more likely to undergo surgery. Furthermore, patients with an adverse 
outcome of surgery will less often have been included in these trials. It is 
important to determine the extent of a possible survival benefit, as the impact 
of surgery on condition and quality of life has to be justified.
In the absence of randomized controlled trials, the purpose of this large 
nationwide population study was to investigate the survival of patients with 
incurable stage IV CRC who underwent an elective palliative resection of the 
primary tumour as the initial treatment after diagnosis compared to patients 
who started systemic therapy without prior primary tumour resection.
Methods
Netherlands Cancer Registry
Nationwide population-based data were extracted from the Netherlands 
Cancer Registry. This database includes all newly diagnosed cancers since 
1989, based on notification by the nationwide automated pathology 
registry and the National Registry of Hospital Discharge Diagnosis. All data 
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are being retrieved from patient files by trained registration employees of 
the Netherlands Comprehensive Cancer Centre. Classification of tumour 
characteristics occurs according to the TNM Classification of Malignant 
Tumours17 and International Classification of Diseases for Oncology (ICD-O).18 
Completeness of the Netherlands Cancer Registry is estimated to be at least 
95%.19 Follow-up consists of linking the registry to the Municipal Personal 
Records database to retrieve vital status and date of death. At the time of 
data extraction for this study, the follow-up of patients was completed up to 
December 2012.
Patient selection
We selected all patients that presented with stage IV (metastases diagnosed 
before or during the first intervention) colorectal adenocarcinoma (C18-C20) 
between 2008 and 2011.
All patients were classified as either treated with curative or palliative intent 
(Figure 1). Therapy was considered with curative intent if a metastasectomy, 
radiofrequency ablation (RFA) and/or hyperthermic intraperitoneal 
chemotherapy (HIPEC) was performed. Based on the available information, we 
were not able to determine if RFA as stand-alone treatment for metastases had 
to be classified as either curative or palliative. Furthermore, the Netherlands 
Cancer Registry does not provide treatment per metastatic lesion; thus, in 
patients with multiple metastases, it cannot be confirmed with complete 
certainty that metastasectomy was performed for all metastases. For this 
study, we therefore classified all these treatments as with curative intent. 
Treatment that did not meet the inclusion criteria for curative intent was 
considered palliative.
Within the palliative group, we identified three main treatment strategies: (i) 
therapy starting with, or consisting solely of, primary tumour resection, (ii) 
systemic therapy without prior resection of the primary and (iii) patients who 
underwent neither, who were classified as best supportive care.
As surgery, including primary tumour resection, cannot be avoided in patients 
with an acute problem undergoing emergency surgery, and the objective of 
this study was to determine the benefit of opting for a palliative resection 
prior to the start of systemic therapy, we excluded all patients who underwent 
an primary tumour resection in the acute setting as the first treatment after 
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diagnosis. We also excluded all patients for whom systemic therapy was part 
of neoadjuvant chemoradiation prior to resection of the primary tumour, 
because resection was always part of the treatment plan in these patients.
For all analyses, we compared patients who underwent a palliative elective 
resection of the primary tumour as the initial treatment after diagnosis, with 
patients who started palliative systemic therapy without prior resection. 
Subgroups of patients who underwent solely primary tumour resection or 
systemic therapy and patients who underwent resection and systemic therapy 
were analysed separately.
Data selection
The extracted data included patient, tumour and treatment characteristics. 
Socioeconomic status was estimated based on postal code of patients’ 
residence at time of diagnosis, using data on income and education from 
the Dutch Institute for Social Research. Location of the tumour was divided 
in colon (C18-C19) and rectum (C20). Morphology was divided into three 
subtypes: mucinous (ICD-O: 8480 and 8481), signet ring cell (8490) and 
non-mucinous, non-signet ring cell adenocarcinoma (adenocarcinoma not 
otherwise specified [NOS]: 8000, 8010, 8020, 8021, 8140, 8141, 8143, 8144, 
8210, 8211, 8220, 8221, 8260, 8261, 8262 and 8263). TNM stage was based 
on pathology results, supplemented with clinical stage. Date of diagnosis 
was defined as the date of first histological confirmation of malignancy, most 
often the day of endoscopic biopsy. Primary tumour resection was recorded 
as emergency, when there was an indication for intervention prior to, or within 
twelve hours after diagnosis. Systemic therapy was scored if the patient had 
received at least one regimen of chemotherapy and/or targeted therapy.
Statistical analysis
The primary endpoint of this study was OS, defined as the interval between 
date of diagnosis of the primary tumour until date of death from any cause, 
or censored at date of end of follow-up (December 31, 2012).
First, characteristics of the two treatment groups were compared using the χ2 
test. To assess the possibility of bias by baseline characteristics for resection 
of the primary tumour, both χ2 test and multivariable Cox regression analysis 
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was performed. A propensity score analysis including those characteristics 
that were significantly associated with initial primary tumour resection 
was performed to adjust for potential baseline confounding variables, and 
patients were matched 1:1.20 Because T stage and N stage were expected to 
have a high percentage of missing in the systemic therapy group, because 
only clinical, and not pathological, TNM stage would be known in this group 
(missing not at random), these were not included in the propensity score 
analysis. Patients without a matching counterpart were excluded from the 
analysis. Later, baseline characteristics of the matched groups were compared 
using χ2 test to assure no major differences persisted.
After propensity-score matching, OS were rendered according to the Kaplan-
Meier method to compare OS between the two treatment groups. The equality 
of distributions was compared using the log-rank test. A multivariable Cox 
regression model was applied to determine whether resection of the primary 
tumour is an independent prognostic factor for OS in stage IV patients.
As intervention-related mortality will be more concentrated in the direct time 
period after surgery in the resection group, while systemic therapy-related 
mortality will be distributed over a longer period of time, short-term outcomes 
are less comparable between the two groups. Therefore, a landmark analysis 
was performed in the matched groups, consisting of a logistic regression 
analysis predicting mortality within 6 months after diagnosis and conditional 
survival, including only those patients who were alive at 6 months after 
diagnosis.21
p-value < 0.05 was considered significant. For all statistical analyses, IBM 
SPSS Statistics software, Version 20.0 (IBM Corporation, Armonk, NY) was 
used.
Results
Patient selection and characteristics
Between 2008 and 2011, of the total of 10,372 patients diagnosed with a 
synchronous metastatic colorectal adenocarcinoma, 1,496 (14%) underwent 
treatment with curative intent (i.e., metastasectomy, RFA and/or HIPEC; Figure 
1). Of the remaining 8,876 patients treated with palliative intent, 2,231 patients 
(25%) received best supportive care only. Initial treatment consisted of a 
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primary tumour resection in 3,178 patients, of whom 2,746 patients (86%) were 
operated on in an elective setting. Systemic therapy without prior resection 
was the initial therapy for 3,467 patients, of whom a further 122 patients 
were excluded because their therapy was part of neoadjuvant chemoradiation 
for rectal cancer (Figure 1). Table 1 lists the patient characteristics of the 
two treatment groups (initial elective primary tumour resection, n = 2,746; 
and initial systemic therapy, n = 3,345). Initial primary tumour resection was 
followed by systemic therapy in 1,484 patients (54%), and systemic therapy 
was followed by resection in 168 patients (of which 13% in an emergency 
setting).
Figure 1. Flow diagram of patient selection. 
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In multivariable logistic regression analysis, primary tumour resection was 
more often performed in earlier years and in older patients; and tumours 
of these patients were more often located in the colon, more often of 
mucinous histology and less often metastasized to multiple organs. Data on 
differentiation, T stage  and N stage were more often unknown in patients 
who initially started systemic  therapy compared to patients who initially had 
their primary tumour resected (all p < 0.001).
Short-term outcomes
Date of surgery was missing in three out of 2,746 patients, who initially 
underwent elective primary tumour resection. Median time between 
diagnosis and surgery was 26 days, and 95% of primary tumour resection was 
performed within 78 days. The 30-day mortality rate after primary tumour 
resection was 9% (n = 236). The 30-day postoperative mortality was higher 
in patients older than 75 years (138/941 patients, 15%), and lower in patients 
below 60 years (15/504 patients, 3%), compared to patients aged 60-75 years 
(83/1,301, 6%, p < 0.001). Mortality at 30 days was significantly higher for 
colon surgery (218/2,399 patients, 9%) compared to rectal surgery (18/344 
patients, 5%, p = 0.017).
In patients who initially underwent systemic therapy, start date of systemic 
therapy was missing in 663 of 3,345 (20%), and end date of systemic therapy 
was missing in 2,547 (76%). The median time between diagnosis and start of 
systemic therapy was 34 days, and 95% of patients started on systemic therapy 
within 86 days. The median duration of systemic therapy was 105 days. The 
30-day mortality after start of systemic therapy was 9% (n = 235 of 2,682 
patients). Mortality at 30 days in patients who started with systemic therapy 
was comparable for all age groups (p = 0.344). Colon cancer compared to 
rectal cancer was significantly associated with a higher 30-day mortality after 
start of systemic therapy (10 vs. 6%, p < 0.001). 
Overall survival
Crude survival outcomes are presented in Table 2. At the end of follow-up, 
24% (n = 656) of patients who initially underwent primary tumour resection 
and 14% (n = 466) of patients who started systemic therapy without prior 
resection were still alive. The median follow-up was 17.6 months in the 
surgery group and 13.9 months in the systemic therapy group. Combined 
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median OS for all included patients was 13.5 months (95% CI 13.1-14.0). 
Crude median OS was higher for patients undergoing initial primary tumour 
resection (independently of subsequent systemic therapy) compared to all 
patients who started systemic therapy  without prior resection (16.2 months 
[95%  CI 15.4-17.1], compared  to 12.1 [95% CI 11.7-12.5]; Figure 2). Two-
year survival rates was 27% (n = 748) for patients initially undergoing 
primary tumour resection and 14% (n = 483) in the systemic therapy group. 
Subgroup analyses showed that OS was highest for patients in whom primary 
tumour resection and systemic therapy were combined (resection followed 
by systemic therapy: 20.7 months (95% CI 19.6-21.8) and systemic therapy 
followed by resection: 18.8 months (95% CI 16.1-21.4); Table 2), compared to 
patients who only underwent primary tumour resection (8.9 months [95% CI 
7.9-9.9]) or only received systemic therapy (11.9 months [95% CI 11.5-12.3]; 
Figure 2).
In univariable Cox regression analysis, primary tumour resection was 
associated with increased OS (hazard ratio [HR] of death = 0.69 [95% CI 
0.65-0.73]). Increased median OS was furthermore associated with female 
gender, younger age, a rectal primary, non-mucinous non-signet ring cell 
adenocarcinoma, a good/moderate differentiated tumour, lower T stage, 
lower N stage and single-organ metastases. In multivariable analysis, the 
survival benefit for primary tumour resection persisted with a HR of death of 
0.40 (95% CI 0.27-0.58). 
Propensity score matching
To validate the findings of the regression analyses, a propensity score was 
calculated to adjust for biases caused by baseline differences between the 
two groups. A propensity score was calculated based on year of diagnosis, 
age, location of the primary, morphology and number of organs affected by 
metastases (1 vs. >1).
The propensity score for patients with primary tumour resection was 0.52 ± 
SD 0.16 versus 0.39 ± 0.17 (p < 0.001) for systemic therapy before matching. 
After propensity score matching, the score was 0.48 ± 0.15 for patients with 
primary tumour resection and 0.47 ± 0.15 for patients with systemic therapy 
first (p = 0.31). During the propensity score matching (with a match tolerance 
of 0.01), 569 patients with initial primary tumour resection and 1,168 patients 
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with initial systemic therapy were 
excluded because no matching 
counterpart was found (Table 1).
 Median OS was 13.7 months (95% 
CI 13.2-14.2) in patients selected 
by propensity score matching, with 
17.2 months (95% CI 16.3-18.1) for 
patients initially undergoing primary 
tumour resection and 11.5 (95% 
CI 11.0-12.0) for patients treated 
with systemic therapy without prior 
resection (Table 2). Univariable Cox 
regression analysis showed that 
initial primary tumour resection was 
still significantly associated with OS 
(HR of death: 0.69 [95% CI 0.65-
0.73], p < 0.001). Table 3 depicts 
the results of a multivariable Cox 
regression analysis, which confirms 
the survival benefit for primary 
tumour resection with a HR of death 
of 0.58 (95% CI 0.47-0.72).
Landmark analysis
At the predetermined landmark 
of 6 months, 99.6% of resections 
in patients initially undergoing 
primary tumour resection had been 
performed and 99.5% of patients 
had started systemic therapy in the 
group initially treated with systemic 
therapy. After 6 months, 76.5% of 
patients in the two groups were alive 
(79.3% in the systemic therapy group 
and 73.7% in the resection group, p 
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< 0.001). Multivariable logistic regression analysis for death at 6 months after 
diagnosis showed that despite the higher postoperative 6-month mortality 
in univariable analysis, primary tumour resection was not associated with a 
higher chance of death at 6 months (odds ratio [OR] 1.27 [95% CI 0.76-2.11], 
p = 0.365; Table 4). Sensitivity analyses showed an OR of 1.00 (95% CI 1.00-
2.96) at a 5-month landmark (p = 0.049) and an OR of 1.08 (95% CI 0.67-1.74) 
at a 7-month landmark (p = 0.756; data not shown).
For patients who were alive six months after diagnosis, the median OS in the 
resection group was 22.2 months (95% CI 21.1-23.3), compared with 15.2 
months (95% CI 14.6-15.9) for patients who initially underwent systemic 
therapy (p < 0.001); 2-year survival rates were 35 and 18% (p < 0.001). In 
the Cox regression analysis (Table 4), primary tumour resection was strongly 
associated with a decreased long-term mortality (HR 0.58 [95% CI 0.47-0.72], p 
 
Table 2. Overall survival outcomes by treatment group and tumour location 
 Raw data set After propensity score matching  
In landmark 
analysis 
 N OS [95%CI] N OS [95%CI] N OS [95%CI] 
Colorectal cancer       
Overall 6,091 13.5 [13.1-14.0] 4,354 13.7 [13.2-14.2] 3,331 18.3 [17.8-18.9] 
Group A: Initial PTR 2,746 16.2 [15.4-17.1] 2,177 17.2 [16.3-18.1] 1,726 22.2 [21.1-23.3] 
Not followed by ST 1,262 8.9 [7.9-9.9] 899 9.1 [8.9-10.3] 540 21.4 [19.4-23.4] 
Subsequent ST 1,484 20.7 [19.6-21.8] 1,278 21.0 [19.8-22.2] 1,186 22.5 [21.3-23.7] 
Group B: Initial ST 3,345 12.1 [11.7-12.5] 2,177 11.5 [11.0-12.0] 1,605 15.2 [14.6-15.9] 
Not followed by PTR 3,177 11.9 [11.5-12.4] 2,050 11.2 [10.7-11.7] 1,495 14.9 [14.3-15.5] 
Subsequent PTR 168 18.8 [16.1-21.4] 127 18.8 [14.8-22.8] 110 21.2 [19.1-23.2] 
Colon cancer       
Overall 4,672 12.6 [12.2-13.1] 3,696 12.9 [12.4-13.4] 2,772 18.5 [16.9-18.1] 
Group A: Initial PTR 2,402 15.3 [14.5-16.3] 1,835 16.2 [15.2-17.2] 1,427 21.6 [20.4-22.8] 
Not followed by ST 1,045 7.4 [6.5-8.3] 695 7.1 [6.0-8.2] 375 19.1 [16.6-21.6] 
Subsequent ST 1,346 20.2 [19.1-21.3] 1,140 20.4 [19.1-21.6] 1,052 22.3 [20.9-23.6] 
Group B: Initial ST 2,270 11.0 [10.5-11.5] 1,861 11.1 [10.5-11.6] 1,345 14.6 [14.0-15.2] 
Not followed by PTR 2,119 10.6 [10.2-11.2] 1,737 10.8 [10.2-11.4] 1,236 14.3 [13.7-14.9] 
Subsequent PTR 151 18.3 [14.4-22.1] 124 18.8 [14.9-22.8] 109 21.2 [19.0-18.1] 
Rectal cancer       
Overall 1,419 17.1 [16.0-18.1] 658 19.3 [17.9-20.6] 559 21.5 [20.1-22.9] 
Group A: Initial PTR 344 22.2 [19.8-24.5] 342 22.2 [19.8-24.6] 299 25.1 [23.0-27.2] 
Not followed by ST 206 19.8 [16.5-23.1] 204 19.8 [16.6-23.0] 165 25.3 [21.8-28.9] 
Subsequent ST 138 24.8 [21.8-27.8] 138 24.8 [21.8-27.8] 134 24.8 [22.6-27.0] 
Group B: Initial ST 1,075 15.4 [14.3-16.5] 316 15.6 [13.4-17.7] 260 19.0 [17.4-20.5] 
Not followed by PTR 1,058 15.3 [14.2-16.4] 313 15.6 [13.4-17.7] 259 19.0 [17.1-20.9] 
Subsequent PTR 17 22.3 [3.4-41.2] 3 5.1 [0.0-11.8] 1 19.3 [n/a] 
ST = systemic therapy; PTR = primary tumour resection 
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< 0.001). Younger age (HR 0.88 [95% CI 0.83-0.98]), high socioeconomic status 
(HR 0.90 [95% CI 0.83-0.98]), rectal cancer (HR 0.79 [95% CI 0.71-0.87]) and 
T0-2 primary tumour (HR 0.70 [95% CI 0.53-0.94]) were also associated with 
a decreased mortality, while mucinous (HR 1.21 [95% CI 1.02-1.42]) or signet 
ring cell carcinoma (HR 1.89 [95% CI 1.42-2.50]), a poorly or undifferentiated 
tumour (HR 1.85 [95% CI 1.56-2.21]), a node-positive primary (HR 1.32 [95% 
CI 1.15-1.52]) and multiple-organ metastases (HR 1.25 [95% CI 1.16-1.34]) 
were independent prognostic factors of increased mortality.
Discussion
This is a large nationwide study to show a significant survival benefit for 
patients with stage IV CRC undergoing resection of the primary tumour, 
irrespective of subsequent systemic therapy, compared to patients treated 
with systemic therapy without prior primary tumour resection. All patients in 
this study were included from a recent cohort (2008-2011), and the survival 
benefit persisted after propensity score matching and landmark analysis 
including many important baseline characteristics.
In recent years, many studies have reported a similar survival benefit for 
patients undergoing palliative primary tumour resection.12, 14, 16, 22-29 None 
of these studies were randomized controlled trials and most were single-
centre studies with small numbers of patients. Two retrospective analyses 
of large phase III metastatic CRC studies had the advantage of predefined 
inclusion and treatment criteria and provided somewhat stronger evidence 
for a potential benefit of removing the primary tumour.16, 25 Especially in these 
studies, however, selection bias cannot be avoided as patients with severe 
postoperative morbidity or mortality were of course not eligible for inclusion 
in these systemic therapy trials. This form of selection bias is non-existent 
in the present study, although many patients were excluded for various 
other reasons. On the other hand, patients who underwent resection without 
systemic therapy were included, and it is estimated that over 95% of Dutch 
cancer patients are recorded in the NCR.19 Furthermore, only a few studies 
performed a propensity score matching to correct for differences in baseline 
characteristics,27, 29, 30 and none performed a landmark analysis. However, as 
survival is expected to be associated with the addition of a second therapy 
(i.e., systemic therapy after resection, or resection after systemic therapy), 
IMPROVED OVERALL SURVIVAL AFTER PRIMARY TUMOUR RESECTION
139
5
 
Table 3. Prognostic factors for overall survival in raw data set and after propensity score matching. 
 Raw data 
 Median OS Univariable Multivariable 
 OS [95%CI] HR[95%CI] p-value HR[95%CI] p-value 
Initial treatment   <.001 <.001 
Primary tumour resection 16.2 [15.4-17.1] 0.69 [0.65-0.73]  0.40 [0.27-0.58]  
Systemic therapy 12.1 [11.7-12.5] 1  1  
Year of incidence   .819  .065 
2008 13.6 [12.7-14.4] 1  1  
2009 13.5 [12.6-14.3] 0.98 [0.91-1.05]  0.92 [0.83-1.02]  
2010 13.7 [12.9-14.5] 0.99 [0.92-1.07]  0.87 [0.78-0.97]  
2011 13.1 [12.3-13.9] 1.02 [0.93-1.11]  0.95 [0.84-1.06]  
Gender   .015  .268 
Male 14.0 [13.4-14.6] 1  1  
Female 12.9 [12.3-13.5] 1.07 [1.01-1.13]  1.03 [0.98-1.09]  
Age   <.001  <.001 
< 60 15.6 [14.7-16.5] 0.93 [0.87-1.00]  0.94 [0.86-1.03]  
60-75 14.2 [13.6-14.8] 1  1  
> 75 10.4 [9.7-11.1] 1.32 [1.24-1.41]  1.35 [1.22-1.49]  
SES   0.066  .226 
High 14.1 [13.3-14.9] 0.95 [0.89-1.01]  0.96 [0.86-1.03]  
Intermediate 13.6 [13.0-14.2] 1  1  
Low 12.7 [11.9-13.5] 1.03 [0.96-1.10]  1.02 [0.95-1.09]  
Location   <.001  <.001 
Colon 12.6 [12.2-13.1] 1  1  
Rectum 17.1 [16.0-18.1] 0.79 [0.74-0.84]  0.75 [0.68-0.81]  
Morphology   <.001  <.001 
Mucinous 12.1 [11.1-13.0] 1.14 [1.04-1.25]  1.25 [1.07-1.45]  
Signet ring cell 7.3 [6.1-8.6] 2.10 [1.75-2.53]  1.95 [1.52-2.51]  
Adenocarcinoma NOS 13.9 [13.5-14.4] 1  1  
Differentiation   <.001  <.001 
Good/moderate 16.8 [16.0-17.6] 1  1  
Poor/undifferentiated 8.6 [7.9-9.3] 1.82 [1.69-1.97]  1.83 [1.59-2.10]  
Unknown 13.2 [12.76-13.7] 1.34 [1.25-1.42]  1.08 [0.99-1.18]  
T-stage   <.001  <.001 
T0-2 21.6 [18.8-24.4] 0.70 [0.60-0.83]  0.78 [0.62-0.98]  
T3 16.5 [15.6-17.4] 1  1  
T4 12.3 [11.7-13.1] 1.38 [1.29-1.48]  1.09 [0.97-1.22]  
Tx 11.0 [10.4-11.6] 1.66 [1.55-1.78]  1.20 [1.09-1.33]  
N-stage   <.001  .002 
N0 18.2 [16.8-19.6] 1  1  
N+ 13.4 [12.9-13.9] 1.39 [1.28-1.51]  1.23 [1.09-1.38]  
Nx 11.3 [10.6-12.1] 1.80 [1.63-1.97]  1.19 [1.05-1.34]  
Metastases   <.001  <.001 
Single-site 15.1 [14.4-15.7] 1  1  
Multiple-site 11.7 [11.2-12.2] 1.38 [1.30-1.46]  1.23 [1.14-1.32]  
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Table 3 (continuing) 
 After propensity score matching 
 Median OS Univariable  Multivariable  
 OS [95%CI] HR [95%CI] p-value HR[95%CI] p-value 
Initial treatment   <.001  <.001 
Primary tumour resection 17.2 [16.3-18.1] 0.61 [0.57-0.65]  0.58 [0.47-0.72]  
Systemic therapy 11.5 [11.0-12.0] 1  1  
Year of incidence   .478  .386 
2008 14.1 [13.1-15.2] 1  1  
2009 13.6 [12.5-14.7] 0.99 [0.90-1.08]  0.94 [0.86-1.03]  
2010 13.9 [13.0-14.7] 1.02 [0.93-1.11]  0.96 [0.87-1.05]  
2011 12.9 [12.0-13.8] 1.07 [0.96-1.18]  1.02 [0.92-1.13]  
Gender   .092  .531 
Male 14.1 [13.4-14.8] 1  1  
Female 13.1 [12.4-13.9] 1.06 [0.99-1.13]  1.02 [0.96-1.09]  
Age   <.001  <.001 
< 60 16.3 [15.2-17.3] 0.90 [0.83-0.98]  0.88 [0.81-0.96]  
60-75 14.5 [13.8-15.2] 1  1  
> 75 10.1 [9.2-11.0] 1.44 [1.33-1.56]  1.55 [1.43-1.68]  
SES   .044  .039 
High 14.7 [13.6-15.7] 0.91 [0.84-0.99]  0.90 [0.83-0.98]  
Intermediate 13.5 [12.8-14.2] 1  1  
Low 13.0 [12.0-14.0] 0.99 [0.92-1.08]  0.95 [0.88-1.04]  
Location   <.001  <.001 
Colon 12.9 [12.4-13.4] 1  1  
Rectum 19.3 [17.9-20.6] 0.71 [0.64-0.78]  0.79 [0.71-0.87]  
Morphology   <.001  <.001 
Mucinous 11.8 [10.8-12.8] 1.15 [1.03-1.28]  1.21 [1.02-1.42]  
Signet ring cell 7.5 [5.8-9.1] 1.96 [1.56-2.45]  1.89 [1.42-2.50]  
Adenocarcinoma NOS 14.1 [13.5-14.6] 1  1  
Differentiation   <.001   
Good/moderate 17.4 [16.6-18.3] 1  1 <.001 
Poor/undifferentiated 8.6 [7.7-9.4] 1.88 [1.71-2.06]  1.85 [1.56-2.21]  
Unknown 12.7 [12.1-13.3] 1.45 [1.35-1.56]  1.12 [1.00-1.26]  
T-stage   <.001  <.001 
T0-2 22.9 [18.4-27.4] 0.66 [0.54-0.80]  0.70 [0.53-0.94]  
T3 17.1 [16.1-18.1] 1  1  
T4 12.7 [11.8-13.6] 1.40 [1.28-1.52]  1.13 [0.97-1.31]  
Tx 10.8 [10.1-11.5] 1.76 [1.63-1.91]  1.21 [1.08-1.37]  
N-stage   <.001  <.001 
N0 18.7 [16.8-20.5] 1  1  
N+ 13.8 [13.1-14.4] 1.42 [1.29-1.56]  1.32 [1.15-1.52]  
Nx 11.0 [10.2-11.9] 1.90 [1.70-2.12]  1.23 [1.06-1.41]  
Metastases   <.001  <.001 
Single-site 15.3 [14.6-16.0] 1  1  
Multiple-site 11.3 [10.7-12.0] 1.42 [1.33-1.52]  1.25 [1.16-1.34]  
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there is a potential of immortal time bias, which can be at least partly resolved 
by performing a landmark analysis.31
This study only included recently treated patients between 2008 and 2011 to 
minimize variation in systemic treatment regimens. During these years, the 
advised systemic therapy regimen in The Netherlands was a combination of 
a fluoropyrimidine-containing chemotherapy and bevacizumab.32 All patients 
who underwent a metastasectomy, RFA and/or HIPEC were excluded to 
minimize the bias found in other population-based studies, where it is often 
unclear if patients who were treated with curative intent were included.22, 24 
Patients undergoing emergency resection were also excluded, mainly because 
there is no doubt of the necessity of the procedure – as an emergency resection 
is only done in patients with severe symptoms (i.e., obstruction, perforation 
and bleeding). Also, while elective patients need to be in reasonable good 
physical condition to receive systemic therapy or surgery, this is less true 
in case of emergency resection.33 As the NCR lacks data on comorbidity or 
physical condition, excluding patients who underwent emergency resection 
of the primary tumour has the advantage of selecting a group of patients in 
whom more homogeneity with regard to these areas can be assumed. On the 
other hand, many patients were excluded for from the final analyses.
The proportion of patients undergoing palliative resection was remarkable 
lower than reported in studies from North America, where two out of 
three patients underwent surgery.22, 24, 34 Previous publications from The 
Netherlands have shown a consistent trend toward systemic therapy instead 
of initial primary tumour resection as the initial treatment in stage IV CRC.2, 3 
While Poultsides et al. concluded that resection was not necessary to prevent 
complications, they did not comment on the low median OS of 13 months 
in their study population (including both curative and palliative patients) 
which is similar to the 12 months in the unselected group of systemic 
treatment-only patients in the present study.12 This survival is substantially 
lower, compared to those reached with modern regimens in clinical trials, 
but in the present study patients are unselected, and therefore survival will 
never be as high as survival of selected WHO 0-1 patients included in clinical 
trials. Patients initially undergoing resection of the primary tumour in our 
study had a remarkable higher OS of 17 months compared to 11 months in 
patients started on systemic therapy without prior resection. Patients who 
underwent primary tumour resection and were subsequently treated with 
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Table 4. Propensity-score adjusted landmark analysis to define prognostic factors for death at six 
months and overall survival in population surviving first six months 
 Died within 6 months 
 Total Univariable Multivariable 
 N(%) OR[95%CI] p-value OR[95%CI] p-value 
Initial treatment   <.001  
Primary tumour resection 451 (21) 0.73 [0.64-0.84]  1.27 [0.76-2.11] .365 
Systemic therapy 572 (26) 1  1  
Year of incidence     .586 
2008 266 (24) 1 .887 1  
2009 252 (23) 0.93 [0.76-1.13]  0.88 [0.71-1.08]  
2010 260 (23) 0.94 [0.77-1.14]  0.89 [0.72-1.10]  
2011 2011 (23) 0.95 [0.78-1.16]  0.89 [0.72-1.11]  
Gender   .095  .576 
Male 561 (23) 1  1  
Female 462 (25) 1.13 [0.98-1.30]  1.04 [0.90-1.21]  
Age   <.001  <.001 
< 60 165 (17) 0.72 [0.60-0.88]  0.67 [0.55-0.82]  
60-75 509 (22) 1  1  
> 75 349 (33) 1.79 [1.52-2.10]  1.99 [1.67-2.35]  
SES   .329  .407 
High 300 (22) 0.89 [0.75-1.06]  0.89 [0.74-1.06]  
Intermediate 420 (24) 1  1  
Low 303 (24) 1.01 [0.85-1.19]  0.93 [0.78-1.12]  
Location   <.001  <.001 
Colon 924 (25) 1  1  
Rectum 99 (15) 0.53 [0.42-0.67]  0.61 [0.47-0.78]  
Morphology   .009  .232 
Mucinous 104 (24) 1.06 [0.84-1.34]  1.18 [0.83-1.68]  
Signet ring cell 31 (38) 2.02 [1.29-3.18]  1.58 [0.87-2.88]  
Adenocarcinoma NOS 888 (23) 1  1  
Differentiation   <.001  <.001 
Good/moderate 307 (17) 1  1  
Poor/undifferentiated 282 (37) 2.96 [2.44-3.58]  3.37 [2.32-4.89]  
Unknown 434 (23) 1.60 [1.36-1.89]  1.47 [1.13-1.91]  
T-stage   <.001  .002 
T0-2 19 (11) 0.51 [0.31-0.83]  0.97 [0.51-1.84]  
T3 348 (20) 1  1  
T4 285 (25) 1.34 [1.12-1.60]  1.03 [0.73-1.45]  
Tx 371 (30) 1.73 [1.46-2.05]  1.53 [1.17-2.00]  
N-stage   <.001  .008 
N0 127 (17) 1  1  
N+ 656 (24) 1.47 [1.19-1.81]  1.65 [1.20-2.26]  
Nx 240 (28) 1.86 [1.46-2.37]  1.43 [1.04-1.98]  
Metastases   <.001  .012 
Single-site 604 (21) 1  1  
Multiple-site 419 (28) 1.48 [1.28-1.71]  1.22 [1.04-1.42]  
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Table 4. (continuing) 
 
 Survived past 6 months 
 Univariable  Multivariable  
 HR [95%CI] p-value HR[95%CI] p-value 
Initial treatment  <.001  <.001 
Primary tumour resection 0.61 [0.57-0.65]  0.58 [0.47-0.72]  
Systemic therapy 1  1  
Year of incidence  .478  .386 
2008 1  1  
2009 0.98 [0.90-1.08]  0.94 [0.86-1.03]  
2010 1.02 [0.93-1.11]  0.96 [0.87-1.05]  
2011 1.07 [0.96-1.18]  1.02 [0.92-1.13]  
Gender  .092  .531 
Male 1  1  
Female 1.06 [0.99-1.13]  1.02 [0.96-1.09]  
Age  <.001  <.001 
< 60 0.90 [0.83-0.98]  0.88 [0.81-0.96]  
60-75 1  1  
> 75 1.44 [1.33-1.56]  1.55 [1.43-1.68]  
SES  .044  .039 
High 0.91 [0.84-0.99]  0.90 [0.83-0.98]  
Intermediate 1  1  
Low 0.99 [0.92-1.08]  0.95 [0.88-1.04]  
Location  <.001  <.001 
Colon 1  1  
Rectum .071 [0.64-0.78]  0.79 [0.71-0.87]  
Morphology  <.001  <.001 
Mucinous 1.15 [1.03-1.28]  1.21 [1.02-1.42]  
Signet ring cell 1.96 [1.56-2.45]  1.89 [1.42-2.50]  
Adenocarcinoma NOS 1  1  
Differentiation  <.001  <.001 
Good/moderate 1  1  
Poor/undifferentiated 1.88 [1.71-2.06]  1.85 [1.56-2.21]  
Unknown 1.45 [1.35-1.56]  1.12 [1.00-1.26]  
T-stage  <.002  <.001 
T0-2 0.66 [0.54-0.80]  0.70 [0.53-0.94]  
T3 1  1  
T4 1.40 [1.28-1.52]  1.13 [0.97-1.31]  
Tx 1.76 [1.63-1.91]  1.21 [1.08-1.37]  
N-stage  <.001  <.001 
N0 1  1  
N+ 1.42 [1.29-1.56]  1.32 [1.15-1.52]  
Nx 1.90 [1.69-2.12]  1.23 [1.06-1.41]  
Metastases  <.001  <.001 
Single-site 1  1  
Multiple-site 1.42 [1.33-1.52]  1.25 [1.16-1.34]  
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systemic therapy had an even higher OS of 21 months. Therefore, although 
resection might not be necessary to prevent complications of the primary 
tumour, we do believe that the potential survival benefit of 4-9 months as 
reported in this study could be an important argument in favour of resection.
Patients who initially underwent resection of the primary tumour were older 
(>75 years), possibly because age limitations for surgery are less strict than 
for systemic therapy. Since postoperative mortality is especially high in elderly 
patients (15% in patients aged >75 years), careful consideration before opting 
for surgical intervention seems necessary.35 The 30-day mortality of 8.6% after 
elective resection is much higher than the 2.6-4.8% reported in population-
based studies for colorectal surgery in stage I-III CRC.36-38 The same goes 
for the 9% mortality in systemically treated patients, compared to mortality 
reported in clinical trials for metastatic CRC patients.5, 6 This might be the 
result of unselected patients who are treated in daily practice and have more 
comorbidity and/or a higher tumour load (e.g., high lactate dehydrogenase 
[LDH] or the presence of cerebral metastases) compared to patients entered 
in clinical trials. A study by Mol et al. indeed showed that patients treated 
with exactly the same chemotherapy regimen as patients within the CAIRO 
study had a significantly worse OS.39 More studies are therefore needed to 
identify predictors of postoperative mortality in stage IV CRC, to facilitate 
informed and evidence-based decision-making about what patients should 
be eligible for primary tumour resection. Interestingly, 6-month mortality 
was comparable in multivariable analysis for primary tumour resection and 
systemic therapy. Primary tumour resection was, however, strongly associated 
with improved long-term survival.
As in most observational studies, confounding by indication cannot be 
avoided. Data on clinical symptoms are not available. It can be assumed that 
patients who underwent resection more often had a symptomatic tumour and 
might therefore have more advanced disease. This is also reflected in a higher 
tumour and lymph node stage of patients who initially underwent resection, 
compared to patients treated with systemic therapy without initial resection. 
Despite these differences, OS was better in the first group.
Performance status was not available, but we do believe patients undergoing 
elective palliative resection or palliative systemic therapy to have a 
comparable performance status. The present study is also limited by the lack 
of information on tumour load and other prognostic factors such as serum 
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LDH, alkaline phosphatase, and tumour load. This bias could not be excluded 
and this influence should be further explored, preferably in a randomized 
controlled trial, as are currently being performed in several countries.40-42
There is no explanation why palliative primary tumour resection is associated 
with improved OS. Similar results have been confirmed in randomized 
controlled trials in other types of cancer, such as renal cell carcinoma and 
breast cancer.43-46 It has been hypothesized that cytoreduction might attribute 
to a better response to systemic therapy.47 A study on angiogenetic markers 
showed that the liver parenchyma adjacent to metastases had a higher 
concentration of proangiogenetic markers in patients with the primary tumour 
in situ compared to patients after primary tumour resection.48 On the other 
hand, several studies have shown that resection of a colorectal tumour results 
in enhanced growth and metabolic activity of liver metastases, at least in the 
first few weeks to months after resection.49, 50 The exact interaction between 
these protumoural and antitumoural effects needs to be studied further.
Conclusion
This study shows that resection prior to systemic therapy may lead to an 
important survival benefit for patients with stage IV CRC, independently 
of other important baseline characteristics. At present, we believe that the 
option of primary tumour resection should be especially discussed with 
young patients without comorbidity who present with incurable stage IV CRC. 
However, results from randomized controlled trials, such as the Dutch/Danish 
CAIRO4 study, that are expected in the nearby future, will hopefully give the 
final answer on this clinically relevant question.
References
1. van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt 
JH. Nationwide trends in incidence, treatment and survival of colorectal cancer 
patients with synchronous metastases. Clinical & experimental metastasis 2015; 
32(5): 457-65.
2. van der Pool AE, Damhuis RA, Ijzermans JN, et al. Trends in incidence, 
treatment and survival of patients with stage IV colorectal cancer: a population-
PART III: PALLIATIVE RESECTION OF THE PRIMARY TUMOUR
146
5
based series. Colorectal disease : the official journal of the Association of 
Coloproctology of Great Britain and Ireland 2012; 14(1): 56-61.
3. van Steenbergen LN, Elferink MA, Krijnen P, et al. Improved survival of colon 
cancer due to improved treatment and detection: a nationwide population-based 
study in The Netherlands 1989-2006. Annals of oncology : official journal of the 
European Society for Medical Oncology / ESMO 2010; 21(11): 2206-12.
4. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic 
colorectal cancer is associated with adoption of hepatic resection and improved 
chemotherapy. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 2009; 27(22): 3677-83.
5. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination 
chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal 
cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370(9582): 
135-42.
6. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab 
in metastatic colorectal cancer. The New England journal of medicine 2009; 360(6): 
563-72.
7. Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment 
strategy for patients with colorectal cancer and synchronous irresectable liver 
metastases. The British journal of surgery 2005; 92(9): 1155-60.
8. Damjanov N, Weiss J, Haller DG. Resection of the primary colorectal cancer 
is not necessary in nonobstructed patients with metastatic disease. The oncologist 
2009; 14(10): 963-9.
9. Frago R, Kreisler E, Biondo S, Salazar R, Dominguez J, Escalante E. Outcomes 
in the management of obstructive unresectable stage IV colorectal cancer. 
European journal of surgical oncology : the journal of the European Society of 
Surgical Oncology and the British Association of Surgical Oncology 2010; 36(12): 
1187-94.
10. Karoui M, Koubaa W, Delbaldo C, et al. Chemotherapy has also an effect 
on primary tumor in colon carcinoma. Annals of surgical oncology 2008; 15(12): 
3440-6.
11. Law WL, Chan WF, Lee YM, Chu KW. Non-curative surgery for colorectal 
cancer: critical appraisal of outcomes. International journal of colorectal disease 
2004; 19(3): 197-202.
IMPROVED OVERALL SURVIVAL AFTER PRIMARY TUMOUR RESECTION
147
5
12. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in 
patients with synchronous stage IV colorectal cancer receiving combination 
chemotherapy without surgery as initial treatment. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 2009; 27(20): 3379-84.
13. Cirocchi R, Trastulli S, Abraha I, et al. Non-resection versus resection for an 
asymptomatic primary tumour in patients with unresectable stage IV colorectal 
cancer. The Cochrane database of systematic reviews 2012; 8: CD008997.
14. Gresham G, Renouf DJ, Chan M, et al. Association between palliative 
resection of the primary tumor and overall survival in a population-based cohort 
of metastatic colorectal cancer patients. Annals of surgical oncology 2014; 21(12): 
3917-23.
15. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with 
stage IV colorectal cancer managed with surgical resection versus chemotherapy 
alone. World journal of surgery 2010; 34(4): 797-807.
16. Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection 
of primary tumor in patients with stage IV colorectal cancer: retrospective analysis 
of two randomized studies and a review of the literature. Annals of surgical 
oncology 2011; 18(12): 3252-60.
17. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against 
Cancer. TNM classification of malignant tumours. 7th ed. Chichester, West Sussex, 
UK ; Hoboken, NJ: Wiley-Blackwell; 2010.
18. Fritz AG. International classification of diseases for oncology : ICD-O. 3rd 
ed. Geneva: World Health Organization; 2000.
19. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. 
Completeness of cancer registration in Limburg, The Netherlands. International 
journal of epidemiology 1993; 22(3): 369-76.
20. Rubin DB. Estimating causal effects from large data sets using propensity 
scores. Annals of internal medicine 1997; 127(8 Pt 2): 757-63.
21. Dafni U. Landmark analysis at the 25-year landmark point. Circulation 
Cardiovascular quality and outcomes 2011; 4(3): 363-71.
22. Ahmed S, Leis A, Fields A, et al. Survival impact of surgical resection of 
primary tumor in patients with stage IV colorectal cancer: results from a large 
population-based cohort study. Cancer 2014; 120(5): 683-91.
23. Clancy C, Burke JP, Barry M, Kalady MF, Calvin Coffey J. A meta-analysis to 
determine the effect of primary tumor resection for stage IV colorectal cancer 
PART III: PALLIATIVE RESECTION OF THE PRIMARY TUMOUR
148
5
with unresectable metastases on patient survival. Annals of surgical oncology 
2014; 21(12): 3900-8.
24. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in 
patients who present with stage IV colorectal cancer: an analysis of surveillance, 
epidemiology, and end results data, 1988 to 2000. Annals of surgical oncology 
2005; 12(8): 637-45.
25. Faron M, Pignon JP, Malka D, et al. Is primary tumour resection associated 
with survival improvement in patients with colorectal cancer and unresectable 
synchronous metastases? A pooled analysis of individual data from four 
randomised trials. European journal of cancer 2015; 51(2): 166-76.
26. Hu CY, Bailey CE, You YN, et al. Time trend analysis of primary tumor 
resection for stage IV colorectal cancer: less surgery, improved survival. JAMA 
surgery 2015; 150(3): 245-51.
27. Ishihara S, Nishikawa T, Tanaka T, et al. Benefit of primary tumor resection in 
stage IV colorectal cancer with unresectable metastasis: a multicenter retrospective 
study using a propensity score analysis. International journal of colorectal disease 
2015; 30(6): 807-12.
28. Kaufman MS, Radhakrishnan N, Roy R, et al. Influence of palliative surgical 
resection on overall survival in patients with advanced colorectal cancer: a 
retrospective single institutional study. Colorectal disease : the official journal of 
the Association of Coloproctology of Great Britain and Ireland 2008; 10(5): 498-
502.
29. Tarantino I, Warschkow R, Worni M, et al. Prognostic Relevance of Palliative 
Primary Tumor Removal in 37,793 Metastatic Colorectal Cancer Patients: A 
Population-Based, Propensity Score-Adjusted Trend Analysis. Annals of surgery 
2015; 262(1): 112-20.
30. Yun JA, Park Y, Huh JW, et al. Risk factors for the requirement of surgical or 
endoscopic interventions during chemotherapy in patients with uncomplicated 
colorectal cancer and unresectable synchronous metastases. Journal of surgical 
oncology 2014; 110(7): 839-44.
31. Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time 
bias. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 2013; 31(23): 2963-9.
32. National Working Group on Gastrointestinal Tumors. Colorectal 
carcinoma - national guideline. 2014. http://www.oncoline.nl/richtlijn/doc/index.
php?type=pda&amp;richtlijn_ id=933.
IMPROVED OVERALL SURVIVAL AFTER PRIMARY TUMOUR RESECTION
149
5
33. Ghazi S, Berg E, Lindblom A, Lindforss U, Low-Risk Colorectal Cancer 
Study G. Clinicopathological analysis of colorectal cancer: a comparison between 
emergency and elective surgical cases. World journal of surgical oncology 2013; 
11: 133.
34. Chan TW, Brown C, Ho CC, Gill S. Primary tumor resection in patients 
presenting with metastatic colorectal cancer: analysis of a provincial population-
based cohort. American journal of clinical oncology 2010; 33(1): 52-5.
35. Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. 
Controversies of total mesorectal excision for rectal cancer in elderly patients. 
The Lancet Oncology 2008; 9(5): 494-501.
36. Gooiker GA, Dekker JW, Bastiaannet E, et al. Risk factors for excess mortality 
in the first year after curative surgery for colorectal cancer. Annals of surgical 
oncology 2012; 19(8): 2428-34.
37. Henneman D, Ten Berge MG, Snijders HS, et al. Safety of elective colorectal 
cancer surgery: non-surgical complications and colectomies are targets for quality 
improvement. Journal of surgical oncology 2014; 109(6): 567-73.
38. Iversen LH, Ingeholm P, Gogenur I, Laurberg S. Major reduction in 30-day 
mortality after elective colorectal cancer surgery: a nationwide population-based 
study in Denmark 2001-2011. Annals of surgical oncology 2014; 21(7): 2267-73.
39. Mol L, Koopman M, van Gils CW, Ottevanger PB, Punt CJ. Comparison of 
treatment outcome in metastatic colorectal cancer patients included in a clinical 
trial versus daily practice in The Netherlands. Acta oncologica 2013; 52(5): 950-5.
40. Chen G. Effectiveness study of resection of pri-mary tumor in stage IV 
colorectal cancer. . 2015. http://https//clinicaltrials.gov/ct2/show/NCT02149784.
41. Rahbari NN, Lordick F, Fink C, et al. Resection of the primary tumour 
versus no resection prior to systemic therapy in patients with colon cancer 
and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a 
randomised controlled multicentre trial (ISRCTN30964555). BMC cancer 2012; 12: 
142.
42. t Lam-Boer J, Mol L, Verhoef C, et al. The CAIRO4 study: the role of surgery 
of the primary tumour with few or absent symptoms in patients with synchronous 
unresectable metastases of colorectal cancer--a randomized phase III study of the 
Dutch Colorectal Cancer Group (DCCG). BMC cancer 2014; 14: 741.
PART III: PALLIATIVE RESECTION OF THE PRIMARY TUMOUR
150
5
43. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by 
interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-
cell cancer. The New England journal of medicine 2001; 345(23): 1655-9.
44. Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with 
synchronous metastases from renal cell carcinoma: results from the International 
Metastatic Renal Cell Carcinoma Database Consortium. European urology 2014; 
66(4): 704-10.
45. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus 
interferon-alfa-based immunotherapy compared with interferon alfa alone in 
metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358(9286): 966-
70.
46. Ruiterkamp J, Voogd AC, Bosscha K, Tjan-Heijnen VC, Ernst MF. Impact of 
breast surgery on survival in patients with distant metastases at initial presentation: 
a systematic review of the literature. Breast cancer research and treatment 2010; 
120(1): 9-16.
47. de Mestier L, Manceau G, Neuzillet C, et al. Primary tumor resection in 
colorectal cancer with unresectable synchronous metastases: A review. World 
journal of gastrointestinal oncology 2014; 6(6): 156-69.
48. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic 
bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 
438(7069): 820-7.
49. Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ. Vascular 
density in colorectal liver metastases increases after removal of the primary tumor 
in human cancer patients. International journal of cancer 2004; 112(4): 554-9.
50. Scheer MG, Stollman TH, Vogel WV, Boerman OC, Oyen WJ, Ruers TJ. 
Increased metabolic activity of indolent liver metastases after resection of a 
primary colorectal tumor. Journal of nuclear medicine : official publication, Society 
of Nuclear Medicine 2008; 49(6): 887-91.
Submitted
Jorine ‘t Lam-Boer, Jurian Rooks, Floris T.J. Ferenschild, Philip 
M. Kruyt, Koen Reijnders, Harm J.T. Rutten, Gerrit D. Slooter, 
Ernst J. Spillenaar Bilgen, Camiel Rosman, Johannes H.W. de 
Wilt
Factors associated with 30-day 
mortality after resection of the 
primary tumour in patients with 
synchronous metastatic colorectal 
cancer
6
Background. Postoperative mortality after resection of the 
primary tumour is reported high in stage IV colorectal cancer. 
Surgery of the primary tumour and all metastatic lesions is the 
cornerstone for curative treatment, but there is no consensus on 
the benefit of palliative primary tumour resection. The aim of 
this study was to explore predictors of postoperative mortality in 
metastatic colorectal cancer.
Methods. Data from all patients with synchronous metastatic 
colorectal cancer who underwent resection of the primary 
tumour (n=987) in eight Dutch hospitals (2008-2013) were 
retrospectively reviewed. All patients who died within 30 days 
were identified (n=55; 6%), and compared to a random selection 
of 110 patients who survived beyond 30 days. Multivariable 
logistic regression analysis was used to identify factors associated 
with postoperative mortality. 
Results. Deceased patients more often experienced postoperative 
complications (73% versus 39%, p<.001). In multivariable 
analysis age ≥ 75 years (OR 4.69 [95%CI 2.06-10.69]), overweight 
(body mass index >25 kg/m2, OR 2.68 [95%CI 1.21-5.93], ASA 
classification ≥III (OR 1.65 [95%CI 1.02-2.61]), a colonic primary 
(OR 6.76 [95%CI 1.83-24.90]), elevated LDH (OR 2.48 [95%CI 
1.01-6.11]) and hypoalbuminemia (OR 1.84 [95%CI 1.15-2.95]) 
were all associated with postoperative mortality. 
Conclusion. In this study, several factors were associated with an 
increased risk on postoperative mortality in synchronous stage 
IV colorectal cancer. Patients with high risk factors (e.g. elderly 
and/or overweight, high ASA classification, a colonic primary 
and abnormal LDH and/or albumin levels) should be considered 
for increased perioperative monitoring, or even refraining from 
surgery when curative treatment is not possible.
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FACTORS ASSOCIATED WITH 30-DAY MORTALITY
Introduction
Colorectal cancer (CRC) is the third most common type of cancer-related 
deaths in the developed world.1 Approximately 20-25% of all CRC patients 
will present with metastatic disease at diagnosis (synchronous metastases).2-4 
In metastatic disease, cure is only possible when resection of the primary 
tumour is accompanied by resection of all metastases. Although the rate 
of curative treatment is increasing, only a minority of patients are deemed 
eligible for surgery.5 Studies from the Netherlands demonstrated that there 
is a large variation between hospitals, but nationwide only 12% of patients 
undergo resection of the primary colorectal tumour as well as resection of 
synchronous liver metastases.6, 7 Since the majority of patients with stage IV 
CRC have non-curable disease, resection of the primary tumour seems not 
always strictly necessary. Several studies demonstrated that systemic therapy 
can be safely administered without prior resection of the primary tumour 
and the role of surgery seems limited to patients showing symptoms of 
severe anaemia, tumour perforation of large bowel obstruction.8, 9 The added 
value of resection recently gained interest again, when retrospective studies 
showed that it is associated with a survival benefit, even in asymptomatic 
patients.10-13 However, sceptics argue that postoperative mortality has been 
reported higher for metastatic CRC, compared to non-metastatic disease.3 
Until results of randomized controlled trials become available14, 15, careful 
consideration before opting for surgical intervention remains essential. 
Although previous research identified several prognostic factors of overall 
survival after palliative primary tumour resection16-19, only few studies have 
focused on short term outcomes.20-22 All of these were single-centre studies 
with very small numbers of perioperatively deceased patients and they yielded 
inconsistent results. Data from cancer registries might resolve this issue, but 
do often not provide detailed information on comorbidity or biochemical 
markers such as serum lactate dehydrogenase or carcinoembryonic antigen – 
which are known to be important risk factors in cancer treatment.23-25
The knowledge on the predictive value of such factors may help to identify 
patients at higher risk for postoperative mortality after colorectal surgery, 
and might eventually help select those patients who benefit most of primary 
tumour resection, especially when performed with palliative intend. The 
purpose of this multicentre study was to explore what patient and biochemical 
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factors are associated with increased postoperative mortality in patients with 
stage IV colorectal cancer who underwent resection of the primary tumour.
 
Methods
Study population
All Dutch cancer patients are prospectively registered in the Netherlands 
Cancer Registry (NCR). This process is done by automated notification via the 
pathology archive and the National Registry of Hospital Discharge Diagnosis, 
and ensures registration of at least 95% of patients. Using the data registered 
in the NCR, we identified all patients with synchronous metastatic CRC (TNM/
UICC stage IV), who underwent resection of the primary tumour in one of 
the eight hospitals in the Nijmegen region between 2008 and 2013 (n=987). 
Patients who underwent synchronous resections (combined resection of 
primary tumour and all metastases) were not included. A total of 55 patients 
(6%) died within 30 days after primary tumour resection. From the remaining 
842 patients who survived beyond 30 days, we randomly selected 110 patients 
(1:2 ratio), stratified to hospital, to retrieve more detailed information from 
their patient files, that was not available in the NCR database. After approval 
of the study by the Medical Ethical Committees of the participating hospitals, 
information was retrieved on patient, tumour, and treatment characteristics. 
This information included the following preoperative biochemical serum 
values: lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), 
glomerular filtration rate (GFR), thrombocyte count, neutrocyte count, 
albumin and alanine aminotransferase (ALT). Besides 30-day mortality, the 
occurrence of postoperative complications was also noted. Body mass index 
(BMI, kilograms per centimetres squared) was calculated using data on weight 
and length from the preoperative evaluation forms. Physical status was scored 
using the classification of the American Society of Anesthesiologists (ASA). 
Data on comorbidity were used to calculate Charlson Comorbidity Index (CCI).
Statistical analysis 
Continuous variables are presented as median (range) and categorical 
variables as total number (percentage). Continuous variables were compared 
using Mann Whitney U-test, and categorical variables were compared by 
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Pearson’s chi-square test. Biochemical markers were often missing (Table 2). 
To assess potential bias, the characteristics of patients with and without a 
missing value were compared as well. For all analyses, α = .05 was used as 
significance level. 
The aim of this study was to identify risk factors for postoperative mortality 
after palliative primary tumour resection. Therefore, potential risk factors 
were entered into one model (enter method), using logistic regression, 
with 30-day mortality as dichotomous outcome variable and the following 
covariates: gender (male vs. female), age, BMI, ASA score (I-II vs. III-V), 
Charlson comorbidity index, primary tumour location (colon vs. rectum), 
metastatic disease (single-organ vs. multiple-organ), GFR (decreased vs. 
normal), CEA (normal vs. elevated) and LDH (normal vs. elevated). Because 
several biochemical markers were highly correlated, only CEA, LDH and GFR 
were taken into account. Type of surgery and TNM classification were not 
considered for the model, as these cannot always be correctly determined 
preoperatively. Missing data were replaced using linear interpolation. Second, 
all variables were entered into an additional logistic regression model 
applying backward selection procedure with p-value below .05 (stepwise 
method). For all statistical analysis, IBM SPSS Statistical software, version 20.0 
(IBM Corporation, Armonk, NY) was used.
Results
Between 2008 and 2013, a total of 987 patients with synchronous metastatic 
CRC underwent resection of the primary tumour in the Nijmegen region (the 
Netherlands). The overall 30-day mortality was 5.6% (n=55).
Sample characteristics
Table 1 shows the patients and tumour characteristics of the patients who 
died within 30 days after surgery (n=55) and the random control group 
of survivors (n=110). Compared to the survivors, deceased patients were 
significantly older (median age: 77 [61-88] vs. 68 [41-87], p<.001), less often 
had a BMI within normal ranges (20-25 kg/m2: 15% vs. 45%, p=.005), had a 
higher ASA score (median sore: III [I-V] vs. II [I-V], p<.001) and more often 
had a previous medical history (CCI ≥ 1: 62% versus 42%, p=.015). The tumour 
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Table 1. Characteristics for patients who died within 30 days after surgery (n=55) and patients who 
survived beyond 30 days (n=110). 
 Total Deceased Survivors p-value 
Total 165 55 110  
Gender    .507 
Male 90 (55) 28 (51) 62 (56)  
Female 75 (45) 27 (49) 48 (44)  
     
Age 69 [41-88] 77 [61-88] 68 [41-87] <.001 
<75 years 107 (65) 25 (45) 82 (75)  
≥75 years 58 (35) 30 (55) 28 (25)  
     
BMI 25 [16-54] 26 [18-54] 24 [16-35] .012 
≤25 kg/m2 74 (45) 13 (24) 61 (55) <.001 
>25 kg/m2 58 (35) 21 (38) 37 (34)  
Unknown 33 (20) 21 (38) 12 (11)  
     
ASA  II [I-V] III [I-V] II [I-V] < .001 
I-II 94 (57) 18 (33) 76 (69) < .001 
III-V 35 (21) 18 (33) 17 (15)  
Unknown 36 (22) 19 (35) 17 (15)  
     
Charlson comorbidity index 0 [0-11] 1 [0-11] 0 [0-8] .036 
0 85 (52) 21 (38) 64 (58) .015 
≥1 80 (48) 34 (62) 46 (42)  
     
Timing of surgery    < .001 
Elective 135 (82) 36 (66) 99 (90)  
Emergency 26 (16) 15 (27) 11 (10)  
Unknown 4 (2) 0 4 (7)  
     
Location    .001 
Colon 128 (78) 51(93) 77 (70)  
Rectum 37 (22) 4 (7) 33 (30)  
     
Tumour invasion (TNM)    .431 
T1-3 106 64) 32 (58) 74 (67)  
T4 53 (32) 20 (36) 33 (30)  
Unknown 6 (4) 3 (6) 3 (3)  
     
Nodal invasion (TNM)    .191 
N0 34 (21) 15 (27) 19 (17)  
N+ 125 (76) 37 (67) 88 (80)  
Unknown 6 (4) 3 (6) 3 (3)  
     
Metastatic disease    .689 
Single organ 129 (78) 42 (76) 87 (79)  
Multiple organ 37 (22) 13 (24) 23 (21)  
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of patients who died within 30 days was more often located in the colon 
(93% versus 70%, p=.001), but there were no significant differences in tumour 
invasion, lymph node invasion and number of organs affected by metastases. 
In the group of the deceased patients, more patients underwent emergency 
surgery (27% versus 10%, p<.001).
Deceased patients more often had a decreased glomerular filtration rate 
preoperatively (25% versus 10%, p=.008), more often had an elevated 
lactate dehydrogenase (LDH, 54% versus 27%, p=.007) and more often had 
an elevated neutrocyte count (57% versus 22%, p=.02). Albumin levels were 
more often decreased in the deceased patients compared to the survivors 
(55% versus 18%, p<.001). Carcinoembryonic antigen (CEA) and liver function 
tests were not significantly associated with postoperative mortality.
Deceased patients had less often undergone neoadjuvant therapy, compared 
to survivors (chemotherapy: 2% versus 19%, p=.002; radiation in rectal cancer: 
0% versus 73%, p=.016). A larger proportion of deceased patients underwent 
 
Table 2. Biochemical variables for patients who died within 30 days after surgery (n=55) and the patients 
who survived beyond 30 days (n=110).  
Biochemical level* No. patients value is determined in Deceased Survivors χ
2-test 
Glomerular filtration rate 159 (96)   .008 
Decreased  14 (25) 10 (10)  
Normal  41 (75) 94 (90)  
Thrombocytes 142 (86)    
Decreased  37 (73) 68 (75) .348 
Normal  14 (27) 20 (22)  
Elevated  0 3 (3)  
ALT 141 (85)   .422 
Normal  42 (86) 83 (90)  
Elevated  7 (14) 9 (10)  
CEA 101 (61)   .504 
Normal  10 (34) 30 (42)  
Elevated  19 (66) 42 (58)  
LDH 98 (59)   .007 
Normal  16 (46) 46 (73)  
Elevated  19 (54) 17 (27)  
Albumin 80 (48)   < .001 
Decreased  16 (55) 9 (18)  
Normal  13 (45) 42 (82)  
Neutrocytes 60 (36)   .022 
Decreased  1 (5) 2 (4)  
Normal  9 (39) 27 (73)  
Elevated  13 (57) 8 (22)  
* Compared to the applied upper and lower limit of normality in the hospital of determination 
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emergency surgery (27% versus 10%, p<.001). There was no difference in the 
utilization of endoscopic surgery or the use of a surgical anastomosis.
Postoperative morbidity
Figure 1 shows the different complications that occurred in the postoperative 
course. Deceased patients more often experienced postoperative complications 
(73% versus 39%, p<.001). A re-intervention was performed in 29% of patients 
in the deceased group, versus 15% in the control group (p=.039). There was 
no significant difference in the occurrence of anastomotic leakage between 
deceased patients (15%) and survivors (9%, p=.389). However, deceased 
patients did more often experience complete wound dehiscence (13 versus 
4%, p=.027). The postoperative course was more often complicated by cardiac 
and pulmonary complications in deceased patients, compared to survivors 
(respectively, 15% versus 5%, p=.025; and 38% versus 10%, p<.001). The 
most common cardiac complications were acute myocardial infarction (9% 
versus 1%, p=.008) and atrial fibrillation (6% versus 4%, p=.585). The most 
common pulmonary complications were pneumonia (18% versus 8%, p=.058) 
and aspiration (9% versus 2%, p=.029). One patient in the deceased group 
experienced a pulmonary embolus.
Risk factors for postoperative mortality
Age ≥75 years (OR 4.69 [95%CI 2.06-10.69]), overweight (OR 2.68 [95%CI 
1.21-5.93]), ASA classification III-V (OR 1.65 [95%CI 1.05-2.61]), a primary 
tumour located in the colon (OR 6.76 [95%CI 1.83-24.90]), elevated LDH (OR 
2.48 [95%CI 1.01-6.11]) and decreased albumin (OR 1.84 [95%CI 1.15-2.95]) 
were significant risk factors for postoperative mortality (Table 3).
 
Discussion
This study shows that postoperative mortality within 30 days after resection of 
the primary tumour in patients with synchronous metastatic colorectal cancer 
was 5.6%. Explorative analyses show that age, BMI, ASA classification, primary 
tumour location, serum LDH and serum albumin might have a predictive value 
with regard to postoperative mortality within this group of patients.
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The observed mortality of 5.6% is comparable to results reported in the recent 
literature12, 17, 20, but higher than the 3.3% reported for all colorectal cancer 
patients in the same period in the Netherlands26. The number of patients 
who undergo curative treatment in case of stage IV CRC is increasing, but 
only a minority will undergo both resection of the primary tumour and for 
instance a liver metastasectomy.6, 7 Many patients present with incurable 
stage IV colorectal cancer and have a clinical indication for resection of the 
primary tumour because of complaints (e.g. pain, obstruction, bleeding). 
Increased postoperative mortality is an important argument against primary 
tumour resection in patients without symptoms. However, in anticipation of 
the results of ongoing randomized controlled trials14, 15, the option of primary 
tumour resection and its perioperative risks should at least be discussed with 
all patients who present with stage IV colorectal cancer.12 To better inform 
patients about their perioperative risks and the anticipated benefit, knowledge 
of risk factors of postoperative mortality is essential in these cases.
Figure 1. Postoperative morbidity outcomes for the study group (n=55) and control group 
(n=110).
PART III: PALLIATIVE RESECTION OF THE PRIMARY TUMOUR
160
6
Several studies have been published investigating determinants of postoperative 
morbidity and mortality in metastatic colon and rectal cancer.20-22 Kleespies 
et al. identified age, ASA score, pT stage and postoperative complications 
as risk factors.21 Another study identified medical complications, emergency 
operations, female sex and age as independent prognostic factors of 
postoperative mortality.22 Costi et al. failed to identify any variables associated 
with perioperative mortality in a very small and outdated patient population.20 
All of these studies included patients who underwent surgery more than a 
 
Table 3. Risk factors for postoperative mortality. 
 Enter method Stepwise method 
 OR [95%CI] p-value OR [95%CI] p-value 
Gender     
Male Reference    
Female 1.20 [0.51-2.81] .683   
Age     
< 75 years Reference  Reference  
≥ 75 years 4.14 [1.77-9.69] .001 4.69 [2.06-10.69] <.001 
BMI     
≤ 25 kg/m2 (normal weight) Reference  Reference  
> 25 kg/m2 (overweight) 2.84 [1.21-6.68] .016 2.68 [1.21-5.93] .015 
ASA classification     
I-II Reference  Reference  
III-V 1.44 [0.90-2.30] .129 1.63 [1.05-2.55] .030 
Charlson comorbidity index     
0 Reference    
≥1 1.86 [0.80-4.32] 0.146   
Emergency surgery     
No Reference    
Yes 1.44 [0.83-2.51] 0.192   
Primary tumour location     
Colon 6.74 [1.81-25.03] .004 7.27 [2.06-25.63] .002 
Rectum Reference  Reference  
Metastatic disease     
Single-organ Reference    
Multiple-organ 1.34 [0.50-3.54] .559   
GFR     
Normal Reference    
Decreased 1.14 [0.66-1.98] 0.640   
CEA     
Normal Reference    
Elevated 0.66 [0.25-1.72] 0.395   
LDH     
Normal Reference  Reference  
Elevated 2.47 [0.97-6.31] .059 2.70 [1.10-6.62] .030 
Albumin     
Normal Reference  Reference  
Decreased 2.13 [1.29-3.53] .003 2.19 [1.35-3.54] .001 
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decade ago, and results were based on very small populations.20-22 The many 
improvements in perioperative care that have been made in the last decade, 
including the introduction of fast track programs, have strongly influenced 
the outcome of colorectal surgery and might therefore have influenced the 
determinants of postoperative mortality as well.27 Furthermore, many of the 
previous reported variables cannot be used as preoperative predictors (i.e. 
complications, pT stage, emergency operation) and are thus not of use in the 
education of patients preoperatively. 
Many predictive models exist to assess operative risk for colorectal cancer 
patients overall. Age, as identified in this study as well as in previous reports 
21, 22, is a well-known risk factor and included in many of these clinical risk 
scores, such as CR-POSSUM.28, 29 ASA classification has also been proven a 
valid predictor of postoperative outcome, and is often used to assess the 
perioperative risk profile of a patient.30-32 These clinical risk scores are all 
based on data of (mainly) non-metastatic patients and may therefore not 
be applicable to metastatic patients. It is important to recognize that there 
may be specific predictors in stage IV colorectal cancer. Tumour load has 
previously been demonstrated with the occurrence of postoperative surgical 
complications.21 Measures of tumour burden include tumour invasion, size 
of the primary tumour and extend of metastasis. LDH is a biomarker of 
cellular turnover, and is commonly used as a surrogate marker of tumour 
burden.33 Although it has not been previously identified as a predictor of 
short-term mortality; it is a known prognostic factor for overall survival in 
colorectal cancer patients.34 In this study, increased LDH was associated with 
postoperative mortality as well.
Besides LDH, hypoalbuminemia was also independently associated with 
postoperative mortality. Decreased serum albumin levels have been previously 
associated with poor surgical outcome in colorectal cancer patients.35-37 
Hypoalbuminemia is often a measure of catabolic state due to the cancer, but 
is also influenced by poor nutritional status. As hypoalbuminemia also predicts 
poor prognosis in patients receiving chemotherapy, sufficient attention 
hould be given to nutritional care.38 Preoperative nutritional interventions to 
optimize a patient’s nutritional status might also be of additional value.39-41
Multiple studies have shown that there is no difference between obese and 
non-obese patients with regard to short-term surgical outcome in non-
metastatic colorectal cancer patients.42-44 However, in this study increased 
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BMI is independently associated with postoperative mortality in patients with 
metastatic disease. There is no obvious explanation for this finding, and it 
might be caused by the high number of missing data on this variable and 
the small groups of patients. Other studies should be performed to verify 
this result in larger populations, and to further investigate the underlying 
pathophysiology.
On the other hand, location of the primary tumour has been previously 
recognized as a prognostic factor in metastatic colorectal cancer, with a 
superior overall survival for left-sided tumours compared to right-sided 
tumours.45 The present study shows that location might also be a predictor 
for short-term outcome in metastatic colorectal cancer. This might in part be 
attributed to selection bias, because patients with an incurable rectal tumour 
are probably less likely to undergo surgical resection, as palliation for rectal 
cancer often involves stenting or stoma formation. 
Some limitations have to be taken into account when interpreting the 
findings of this study. First, because of the retrospective nature of this study, 
data were missing on several variables such as BMI and ASA classification, 
and data on potential curative resection of metastases is lacking because 
for these treatments patients are often treated in other hospitals. Second, 
no conclusion on the causality of associations can be made. This study must 
be considered as a primary explorative study to investigate the possible 
predictive value of several preoperatively known variables and to give 
direction to future research. Although this is the largest study on this subject 
up to date, it might still be underpowered. Other studies are necessary to 
confirm the observed associations. Strengths of this study are its regional 
design with data from eight different hospitals, and the recent study cohort 
in which applied surgical technique and perioperative care are comparable to 
the current situation, which both increase the generalizability of the results.
In conclusion, postoperative mortality after resection of the primary in 
patients with metastatic colorectal cancer is higher compared to patients 
with non-metastatic disease. Although resection of the primary tumour is 
of paramount importance in treating stage IV CRC patients with curative 
intent, there is no proven benefit of palliative primary tumour resection. 
In anticipation of the results of ongoing randomized controlled trials, 
identification of predictors of short term outcome might aid the decision 
on refraining from a colorectal procedure as a palliative treatment option. 
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Elderly patients, overweight patients and patients with a colonic primary, 
an ASA III-V classification, increased serum LDH and/or hypoalbuminemia 
might be at increased risk of postoperative mortality. For these patients, it 
might be wise to either intensify perioperative monitoring, or to refrain from 
surgery, especially if the primary tumour is asymptomatic. Further research 
is needed to identify predictors of postoperative mortality and to investigate 
the benefit of perioperative interventions to decrease the perioperative risks.
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Clinical risk score for predicting 
postoperative mortality in patients with 
stage IV colorectal cancer: a population-
based study in the Netherlands
7
Objective. It is assumed that stage IV colorectal cancer (CRC) 
patients are at increased risk of postoperative death. This study 
aims to identify predictors for postoperative mortality in patients 
with stage IV CRC compared with stage I-III disease.
Methods. Patients who underwent surgery for CRC between 
2009 and 2013 were selected from the Dutch Surgical Colorectal 
Audit, a nation-wide surgical database. Differences in postop-
erative morbidity and mortality between stage I-III (N=37,305) 
and stage IV (N=5,489) were compared with the χ²-test. A mul-
tivariable logistic regression was used to identify independent 
predictors of morbidity and mortality.
Results. Postoperative mortality was higher in stage IV patients 
compared with stage I-III patients (6% versus 4%, p<0.001). Post-
operative complications occurred in 20% of stage I-III and in 22% 
of stage IV patients (p=0.012). The postoperative mortality rate 
in stage IV CRC patients decreased from 11% in 2009 to 4% in 
2013. Emergency surgery, high ASA score, the presence of comor-
bidity, higher age, colonic localization and the presence of extra-
hepatic metastases were independent predictors of postoperative 
mortality in stage IV disease. A clinical risk score including the 
first five factors had a discriminative power of 0.75 (95% confi-
dence interval 0.73-0.78).
Conclusions. Stage IV CRC patients have an increased risk of 
postoperative mortality compared with stage I-III patients, al-
though this difference seems to be diminishing in recent years. 
Emergency surgery is the most important predictor for postoper-
ative mortality in both non-metastatic and metastatic CRC pa-
tients. A clinical risk score is presented to improve preoperative 
counselling of patients.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers and is the fourth 
most frequent cause of cancer related mortality world-wide.1, 2 Due to the 
introduction of national bowel screening programs and population ageing, 
incidence rates have increased over the years. Survival depends strongly on 
stage at presentation and surgical resection of the primary tumour is the 
cornerstone of curative treatment. In approximately 20% of CRC patients 
metastases are present at the time of diagnosis (synchronous metastases, or 
stage IV disease).3 For these patients resection of the primary tumour together 
with all metastases is the only option when aiming for cure. Unfortunately, 
only 20-30% of stage IV patients are eligible for treatment with curative 
intent.4, 5
Thirty-day postoperative mortality is a well-established parameter to 
determine perioperative outcome. Several scoring systems have been 
published to estimate the risk of postoperative mortality.6, 7 These scoring 
systems are used to counsel patients who undergo colorectal surgery. 
Previous studies have demonstrated an increased risk of postoperative 
mortality in stage IV disease.8 Moreover, postoperative morbidity is found 
to be higher in these patients.9 Since severe postoperative complications 
may delay, or even may hamper systemic therapy, medical oncologists are 
reluctant to refer patients for resection of the primary tumour in the palliative 
setting. Nevertheless, resection of the primary tumour may benefit patients 
and may improve quality of life.10-14 Insight into risk factors for postoperative 
morbidity and mortality contributes to an individualized estimation of 
the postoperative risk. This leads to a more tailored approach to patient 
management and improved patient counselling. Unfortunately, only a few 
studies have reported on postoperative morbidity and mortality in stage IV 
CRC patients.9, 15, 16
The purpose of this large nationwide study was to investigate the rate of 
postoperative morbidity and mortality after resection of the primary tumour in 
patients with metastatic CRC, compared with non-metastatic CRC. Moreover, 
predictors of postoperative mortality were identified with the aim to design a 
scoring system to improve preoperative counselling of patients.
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Methods
Data were derived from the Dutch Surgical Colorectal Audit (DSCA), a 
nationwide multidisciplinary disease-specific initiative. Approximately 97% of 
all surgical colorectal cancer patients are registered in this database. Data 
on patient, tumour and treatment characteristics, as well as 30-day outcome, 
are collected by the participating hospitals. Details on the DSCA have been 
published elsewhere.17
Patients 
All patients who underwent resection a primary colorectal tumour between 
January 2009 and December 2013 were selected from the DSCA. Patients 
with multiple synchronous primary tumours, patients younger than 18 years, 
and those with an unknown location of the primary tumour and/or unknown 
etastatic status were excluded (N=3,243) (Figure 1). Patients were separated 
into two groups according to the presence of metastases at the time of the 
colorectal surgery: patients without metastases present (stage I-III), and 
patients with synchronous metastases (stage IV). Data sets were provided 
after approval of the study protocol by the scientific review committee of the 
Dutch Institute for Clinical Auditing.
Figure 1. Flow chart of patient inclusion.
 
DSCA database 
- Colorectal cancer 
- Surgical resection 
- 2009 – 2013 
(n = 46,037) 
Excluded 
- Missing data on metastases and/or  
location of primary tumour  (n = 2,028) 
- Surgical resection (n = 1,211) 
- 2009 – 2013 (n = 4) Available for analysis 
(n = 42,794) 
Non-metastatic disease 
(Stage I-III) 
(n = 37,305, 87%) 
Metastatic disease 
(Stage IV) 
(n = 5,489, 13%) 
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Definitions
Physical condition of the patients at the time of surgery was assessed by 
the ASA Physical Status Classification. Comorbidity was scored using the 
Charlson Comorbidity Index (CCI). Classification of tumour characteristics 
was done according to the TNM Classification of Malignant Tumours and 
the International Classification of Diseases for Oncology (ICD-O-3). Location 
of the tumour was divided into colon (C18-C19) and rectum (C20). Surgical 
resections were categorized as right colectomy (both ileocaecal resection 
and right hemicolectomy), transverse resection, left hemicolectomy, 
sigmoid resection (including anterior resection), (sub)total colectomy, 
abdominoperineal resection and transanal excision. Timing of surgery was 
classified as elective, urgent (scheduled with priority, commonly within 
2 weeks, for example because of impending obstruction) and emergency 
(unscheduled surgery because of severe complications).
Postoperative complications were scored according to the classification of 
the National Surgical Complication Registry (LHCR), which is based on the 
Classification of Clavien et al. (Figure 2).18 LHCR grade I complications were 
excluded, since delay or cancellation of systemic therapy based on these 
complications would be uncommon. All deaths within 30 days of surgery were 
considered postoperative mortality.
The DSCA provides information on the organs affected by metastases, but 
not on the number of metastases present. These data are presented as single-
organ versus multiple-organ metastases, and hepatic versus non-hepatic 
metastases. No data was available on whether the procedure was performed 
with palliative or curative intent. 
 
Grade LHCR Clavien-Dindo scale 
I Temporary health disadvantage recovering without (re)operation 
Any deviation from the normal postoperative 
course without the need for intervention. 
II Full recovery after (re)operation. Requiring pharmacological treatment, including blood transfusions and total parenteral nutrition. 
III (Probably) permanent damage or function loss. 
Requiring surgical, endoscopic or radiological 
intervention. 
IV Death of a patient during admission. Life-threatening complication. 
V  Death of a patient. 
Figure 2. Classification of the Dutch National Surgical Complication Registry (LHCR) versus the 
Clavien-Dindo
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Data analysis
Continuous variables are presented as median (range) and categorical 
variables as total number (percentage). Continuous variables were compared 
using the Mann Whitney U-test, and categorical variables were compared by 
Pearson’s chi-square test. For all analyses, α = 0.05 was used as significance 
level.
The aim of this study was to develop an accurate and simple clinical risk 
score to predict postoperative 30-day mortality in patients with metastatic 
disease. First, the difference in postoperative 30-day mortality was compared 
between non-metastatic and metastatic CRC patients. Second, to determine 
if predictors were consistent between both groups, a multivariable logistic 
regression model was applied to both groups to find independent predictors 
of postoperative mortality. Factors concerning surgical treatment (except 
indication for emergency surgery) and pathology results were not considered 
for the model, as these cannot be determined preoperatively. Finally, all 
variables were entered into an additional logistic regression model applying 
backward selection procedure with p-value below 0.2 (stepwise method). The 
final model thus contains independent predictors for postoperative mortality. 
The relative weighting of each variable was based on its β-value in the logistic 
regression analysis. Predicted probabilities were calculated on the basis of 
these weighted values. We estimated the prognostic ability of the model to 
discriminate between patients with and without postoperative mortality by 
using the area under the receiver operating characteristics curve (AUROC). 
For all statistical analysis, IBM SPSS 22 (Armonk, NY: IBM Corp) was used. 
Secondary endpoints of this study included the occurrence of perioperative 
and postoperative complications (surgical or otherwise) and data on ICU stay, 
blood transfusion and duration of hospital stay.
Results
Clinicopathological characteristics
Between 2009 and 2013, 42,794 patients registered in the DSCA database 
were eligible for inclusion (Figure 1): 37,305 patients with non-metastatic 
disease (stage I-III) and 5,489 patients with synchronous metastases at 
the time of colorectal surgery (stage IV). The proportion of stage IV CRC 
decreased from 14% in 2009 to 12% in 2013 (Supplemental Figure 1, p<.001). 
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Data on clinicopathological characteristics are presented in Supplemental 
Table 1. Stage IV patients more commonly had a colonic tumour than stage 
I-III patients (79% versus 70%; p<.001). In 86% of stage IV patients metastatic 
disease was confined to one organ: 49% patients had liver-only metastasis 
and 7% of patients had lung-only metastasis. Liver metastases were present 
in 65% of stage IV patients, peritoneal metastases in 14%, lung metastases in 
12% and bone metastases in 1%.
 
Table 1. Postoperative morbidity (LHCR grade II-V) and mortality for non-metastatic (stage I-III) and 
metastatic (stage IV) colorectal cancer patients. 
 All patients Stage I-III Stage IV p-value 
 N % N % N %  
Total 42,794 100 37,305 100 5,489 100  
Median hospital stay (range) 7 (0-360) 7 (0-302) 8 (1-360) <.0001a 
Postoperative mortality 1,732 4 1,378 4 354 6 <.00001 
Perioperative complication 1,170 4 1,005 4 165 5 .038 
Postoperative morbidity 8,717 20 7,259 20 1,188 22 .012 
Reintervention 5,542 22 4,867 23 675 20 .001 
Blood transfusion 6,003 15 5,122 15 881 17 .000002 
ICU admittance 6,533 15 5,582 15 951 17 <.00001 
≤ 2 days 3,900 15 3,306 14 594 11  
> 2 days 2,171 8 1,879 8 292 5  
Type of complication        
Pulmonary 828 2 721 2 107 2 .93 
Cardiac 544 1 486 1 58 1 .13 
Thromboembolic 117 0 98 0 19 0 .27 
Infectious 511 1 453 1 58 1 .32 
Neurological 216 1 202 1 14 0 .005 
Other 768 2 659 2 109 2 .25 
Surgical complications (all) 5,376 13 4,698 13 678 12 .61 
Anastomotic leakage b 2,013 6 1,773 6 240 6 .82 
Intra-abdominal abscess 678 2 598 2 89 2 .92 
Re-bleed 266 1 228 1 38 1 .48 
Ileus 446 1 403 1 43 1 .04 
Dehiscent fascia 554 1 469 1 85 2 .08 
LHCR grade       <.00001 
Grade II 4,476 10 3,916 10 560 10  
Grade III 226 1 205 1 21 0  
Grade IV 1,371 3 1,117 3 254 5  
Unknown 2,644 6 353 6 2,291 6  
a Independent-Samples Mann Whitney U Test 
b Percentages are only calculated over the group of patients in whom an anastomosis was constructed. 
ICU = intensive care unit 
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Treatment
Stage IV patients more often experienced preoperative complications 
compared with stage I-III patients, in particular bowel obstruction (24% versus 
10%, p<.001, Supplemental Table 1). Emergency surgery was more common 
for stage IV patients (14% versus 6%, p<.001). Tumours were more often 
resected through an endoscopic procedure in non-metastatic patients than in 
patients with metastases (41% versus 23%, p<0.001). A primary anastomosis 
was created in 65% of stage I-III patients, and in 61% of stage IV patients 
(p<.001).
Postoperative results
Median hospital stay was 7 days in non-metastatic patients, and 8 days in 
metastatic patients (Table 1). A total of 1,732 patients (4%) died within 30 
days after colorectal surgery. Postoperative mortality was significantly higher 
in stage IV disease compared with stage I-III disease (6% versus 4%, p<.001). 
Stage IV patients had a slightly higher rate of perioperative and postoperative 
complications (5% versus 4%, p=.038; and 22% versus 20%, p=.012). Stage IV 
patients also more frequently required blood transfusion (17% versus 15%, 
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p<.001) and were more commonly admitted to the intensive care unit (17% 
versus 15%, p<.001). Postoperative mortality in stage IV patients decreased 
from 11% in 2009 to 3% in 2013 (p<.001; Figure 3).
Predictors of postoperative mortality
Univariate analysis showed that in patients with non-metastatic disease 
gender, higher age, BMI, higher ASA classification, higher Charlson score, a 
proximal located tumour, signet-ring cell carcinoma and advanced T-stage 
were associated with postoperative mortality (Supplemental Table 2). 
Treatment with neoadjuvant chemotherapy was also strongly associated with 
postoperative mortality (OR 4.19 [95%CI 3.17-5.54]). Patients undergoing 
emergency surgery had a 30-day mortality of 10%. Postoperative mortality 
was 2% after endoscopic procedure, compared with 5% after an open resection 
(OR 0.39 [95%CI 0.34-0.44]). Using gender, age, BMI, ASA classification, 
Charlson score, tumour location and timing of surgery, a multivariable 
logistic regression analysis was performed for stage I-III patients (Table 2). 
All factors but tumour location (OR 1.04 [95%CI 0.89-1.21]) were independent 
predictors of postoperative mortality. Of these, emergency surgery (OR 2.29 
[95%I 1.85-2.82]) and an ASA classification of III-V (OR 3.96 [95%CI 2.90-
5.39]) were the most influential. Age was also a strong independent predictor 
of postoperative mortality (OR 1.07 [95%CI 1.06-1.07]). In patients with stage 
IV disease higher age, higher ASA classification, higher Charlson score, a 
proximal located tumour, poor differentiation and advanced T-stage were 
associated with postoperative mortality (Supplemental Table 2). In contrast 
to non-metastatic disease, there was no association between gender or BMI 
and postoperative mortality. The number of metastatic sites was not related 
to postoperative mortality, whereas the presence of liver metastases was (OR 
1.29 [95%CI 1.02-1.65]). Postoperative mortality in the emergency setting was 
13%, compared to 4% in the elective setting. After endoscopic procedure 
30-day mortality was 3.5%, compared with 7.4% after an open resection (OR 
0.45 [95%CI 0.33-0.63]). Using age, ASA classification, Charlson score, tumour 
location, the presence of liver metastases 
and timing of surgery a multivariable analysis was performed, which showed 
that all aforementioned factors were independent predictors of postoperative 
mortality (Table 2). Similar to non-metastatic disease, ASA classification of 
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III-V (OR 5.64 [95%CI 2.96-10.75]) and surgery in the emergency setting (OR 
2.62 [95%CI 1.93-3.55]) were the most influential factors. The presence of 
liver metastases was also associated with an increased rate of postoperative 
mortality (OR 1.31 [95%CI 1.01-1.69]).
Clinical risk scores
Using the predictors identified previously, a clinical risk score to determine 
postoperative mortality in stage I-III patients was designed. Based on the 
multivariable analysis, each category was assigned a certain number of points 
with a maximum of 12, and the total score was compared with the clinical 
outcome of each patient. The 30-day mortality of patients with a risk score 
of 0 (n=388, 1.2%) was 0%, whereas that for patients with 12 points (n=30, 
 
Table 2. Multivariable predictors of postoperative mortality in non-metastatic (stage I-III) and 
metastatic (stage IV) colorectal cancer patients. 
 Stage I-III Stage IV 
 
Number of 
patients 
Odds ratio  
(95%CI) 
Number of 
patients 
Odds ratio  
(95%CI) 
Total 32,670  4,890  
Gender     
Male 17,950 1.42 (1.25-1.62)   
Female 14,720 1   
Age (continuous)  1.07 (1.06-1.07)  1.05 (1.03-1.06) 
BMI (continuous)  0.98 (0.97-1.00)   
ASA Classification     
I 6,673 1 962 1 
II 18,617 1.73 (1.28-2.34) 2,702 2.37 (1.25-4.48) 
III-V 7,380 3.96 (2.90-5.39) 1,226 5.64 (2.96-10.75) 
Charlson score     
0 20,853 1 3,216 1 
≥1 11,817 1.45 (1.27-1.67) 1,674 1.44 (1.11-1.86) 
Location     
Colon 22,501 1.04 (0.89-1.21) 3,867 1.77 (1.14-2.74) 
Rectum 10,169 1 1,023 1 
Timing     
Elective 29,205 1 3,480 1 
Urgent 1,881 1.68 (1.36-2.09) 727 2.03 (1.47-2.80) 
Emergency 1,584 2.29 (1.85-2.82) 683 2.62 (1.93-3.55) 
Metastasis     
Liver metastasis   3,194 1.31 (1.01-1.69) 
Non-liver metastasis   1,696 1 
95%CI = 95% confidence intervals;  ASA = American Society of Anaesthesiologists 
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 Score  
Age   
≤60 years  0 
61-65 years  1 
66-70 years  2 
71-75 years  3 
>75 years  4 
Gender   
Female  0 
Male  1 
BMI   
≤20 kg/m2  2 
20-25  kg/m2 1 
25-30  kg/m2 0 
30-35  kg/m2 0 
>35 kg/m2  1 
Charlson score   
0 0 
1 1 
≥2 2 
ASA classification   
I 0 
II 1 
III-V  3 
Timing   
Elective  0 
Urgent  1 
Emergency  2 
Maximum  13  
Figure 4. Clinical risk score to predict postoperative mortality within 30 days after resection of the 
primary tumour in (A) patients with non-metastatic colorectal cancer (stage I-III), and (B) patients 
with synchronous metastatic colorectal cancer (stage IV), with corresponding 95% confidence 
intervals.
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0.09%) was 23% (Supplemental Figure 2A). The discriminative power (area 
under ROC-curve, AUROC) was 0.77 (95%CI 0.75-0.78), which is indicative of 
fair accuracy (Supplemental Figure 3A). Figure 4A shows the predicted value 
for the clinical risk score with 95% confidence intervals in patients with stage 
I-III colorectal cancer.
Five variables that were independent predictors of postoperative mortality in 
stage IV patients – age, ASA classification, Charlson score, location and timing 
of surgery – were chosen as criteria for a clinical risk score. Data on liver 
metastasis was missing in 10% of cases, and was therefore not considered for 
the clinical risk score. Again each category was assigned a certain number of 
points with a maximum score of 16, and the total score was compared with 
the clinical outcome of each patient after primary tumour resection. The 30-
day mortality for patients with 0 points (n=124, 2.3%) was 0%, whereas for 
patients with 16 points (n=69, 1.3%) it was 35% (Supplemental Figure 2B). 
AUROC was 0.75 (95%CI 0.73-0.78, Supplemental Figure 3B). Figure 4B shows 
the predicted value for the clinical risk score with 95% confidence intervals in 
patients with stage IV CRC. 
Discussion
This study shows that stage IV CRC is associated with a higher rate of 
postoperative mortality compared with stage I-III, although the difference 
seems to be diminishing in recent years. Risk factors for postoperative 
mortality differ between stage I-III and stage IV disease. We present two 
separate clinical risk scores, based on data from a large prospective national 
database, that may help in counselling patients with CRC. 
The overall 30-day mortality following surgery for CRC of 4% in the 
Netherlands between 2009 and 2013 is comparable with results from the 
literature.19, 20 Postoperative mortality in stage IV CRC decreased from 11% 
in 2009 to 3% in 2013, which is almost comparable to that in non-metastatic 
disease. During the studied time period, we noted only a small decrease in 
the proportion of surgically treated stage IV patients, rendering it unlikely 
that this improvement in postoperative survival is mainly based on patient 
selection. 
The most profound predictor of postoperative mortality was emergency 
surgery, both in stage I-III disease and stage IV disease. The association 
181
7
CLINICAL RISK SCORE FOR PREDICTING POSTOPERATIVE MORTALITY
between emergency surgery and postoperative mortality has been 
demonstrated before.20-24 Outcome is worse since the patient’s condition 
cannot be optimized prior to surgery and a dedicated team is not always 
available in the non-elective setting. Furthermore, in most cases of emergency 
surgery, time is limited and the multidisciplinary team cannot be consulted 
prior to surgery.25 Nevertheless, multidisciplinary evaluation of patients has 
been proven to improve quality and efficacy of cancer care, especially in the 
metastatic setting.26
The presence of comorbidity, as reflected by the ASA score and Charlson 
comorbidity index, is also an important predictor of postoperative mortality. 
Comorbidity is not only an important predictor in CRC, but in other 
gastrointestinal cancers as well.27 The Charlson comorbidity index is a score 
including cardiovascular disease, chronic pulmonary disease, dementia, 
diabetes mellitus, kidney- and liver disease, HIV and connective tissue 
diseases, and has been demonstrated to strongly correlate with outcome in 
a surgical and medical setting.28-30 The ASA score expresses the operative 
risk at the moment of surgery and is therefore not one-to-one correlated 
to the comorbidity index, as it is also dependent of other variables, such as 
alcohol- or nicotine dependency or ongoing infections. ASA score has also 
been previously linked to postoperative mortality in CRC.21, 31
The results of this study are based on the Dutch Surgical Colorectal Audit 
(DSCA), a nationwide database with a high concordance to the National Cancer 
Registry.32 The advantage of population-based data over data from clinical 
studies is that the data are not subject to patient selection. Clinical studies 
often exclude patients who underwent surgery in the emergency setting, 
although they form a vast proportion in daily practice, approximating 30% 
in the current study. However, some limitations apply to data from the DSCA. 
First, data are only collected for the first 30 days postoperatively; therefore, 
data on the differences between metastatic and non-metastatic patients on 
mid- or long-term outcomes is lacking. Furthermore, previous studies have 
demonstrated the predictive value of vital parameters and biochemical serum 
values, such as haemoglobin and urea.6 These values are not available in the 
DSCA database, and their predictive value for metastatic CRC specifically has 
not been studied to date. Addition of these values to the clinical risk model 
presented in this study might increase its discriminative power. Also, as the 
DSCA was primarily intended as a surgical audit, data on CRC patients who 
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did not undergo surgery are lacking. It has been demonstrated before that 
only about half of patients with stage IV CRC undergo resection of the primary 
tumour in the Netherlands.3 Data on non-surgical patients might generate 
insight into current selection of patients for palliative resection. Finally, no 
data are available on the possible curative intent of the intervention for stage 
IV patients and whether patients underwent additional metastasectomy. This 
makes it impossible to base the clinical risk score on data from palliative 
patients alone. However, location and number of organs affected by 
metastases was not of additional value to the discriminative power of the 
clinical risk score, which might indicate that the intent of surgery does not 
influence outcome.
More and more cancer therapy is tailored to the individual patient’s need, 
aiming to improve quality of care, that better fits the patient’s needs.33-36 
Depending on histology, molecular pathology and imaging, as well as patient 
characteristics, different treatment strategies are available.37 A clinical risk 
score made up of easily accessible clinical features can assist in clinical decision 
making and in better patient counselling. Several risk scores already exist 
to predict long-term as well as short-term outcome for colorectal surgery.38 
Most of these risk scores were based on data from non-metastatic cancer 
patients, or did not differentiate between metastatic and non-metastatic CRC 
patients. However, this study shows that predictors of postoperative mortality 
differ between these groups. Therefore, data from non-metastatic patients 
cannot be extrapolated to metastatic patients. For example, BMI and gender, 
which are independent predictors in stage I-III CRC, were not associated with 
30-day mortality in stage IV cancer. Moreover, we have demonstrated the 
importance of hepatic versus non hepatic metastases for outcome in stage IV 
patients. This substantiates the need of a clinical risk score designed explicitly 
for stage IV CRC. 
In contrast to stage I-III CRC, only a subset of patients with stage IV 
disease undergo colorectal surgery.6 Resection of the primary tumour and 
all metastases is the only option for long-term survival in patients with 
synchronous metastatic CRC. However, recent studies have shown that only 
12% of patients undergo liver resection.39 In the palliative setting, the benefit 
of colorectal surgery is under debate.10, 11, 13, 40 Although we found emergency 
surgery to be the most important predictor of postoperative mortality, 
Poultsides et al. demonstrated that palliative chemotherapy without prior 
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surgery can be safely administered in the majority of patients.41 On the other 
hand, recent trials report median overall survival of over than 30 months42, 
43, hence the number of patients developing tumour complications, such as 
obstruction, is likely to increase. The present study shows that colorectal 
surgery can be safely performed in stage IV CRC patients with acceptable 
postoperative morbidity and mortality rates, especially in the elective setting. 
Therefore, when counselling a patient with stage IV CRC in the palliative 
setting, surgeons should consider both the risk of postoperative mortality for 
elective as well as emergency surgery. 
In conclusion, the presence of comorbidity and surgery in the non-elective 
setting are the most important predictors of postoperative mortality in 
both stage I-III disease and stage IV disease. While metastatic CRC used to 
be associated with high postoperative mortality after colorectal surgery, 
mortality is almost equal to stage I-III in recent years. However, it is important 
to recognize that predictors of postoperative mortality are different between 
non-metastatic and metastatic cancer – and applying conventional scoring 
systems to determine postoperative risk should be done with caution.
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Supplemental figure 1. Distribution of UICC stage in the surgical population over the years.
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Supplemental figure 2. Prevalence of risk scores and actual 30-day mortality in (A) patients with 
non-metastatic colorectal cancer (stage I-III), and (B) patients with synchronous metastatic colorectal 
cancer (stage IV).
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Supplemental figure 3. ROC curve of the clinical risk score for 30-day mortality in patients with non-
metastatic colorectal cancer (stage I-III) (above), and patients with synchronous metastatic colorectal 
cancer (stage IV) (below).
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Supplemental table 1. Patient and tumour characteristics for non-metastatic and metastatic patients. 
 All patients Stage I-III Stage IV p-value 
 N % N % N %  
Patient characteristics        
Gender       .000015 
Male 23,513 55 20,348 55 3,165 58  
Female 19,281 45 16,957 45 2,324 42  
Age        
Median (range) 71 (18-100) 71 (18-100) 68 (21-98) <.001 
≥ 75 years 15,810 37 14,219 38 1,591 29 <.00001 
BMI (kg/m2)        
Median (range) 25.6(13-59) 25.6 (13-59) 25.1 (13-53) <.001 
<20 2,020 5 1,701 5 319 6 <.00001 
20-25 14,670 34 12,640 34 2,030 37  
25-30 15,055 35 13,269 36 1,786 33  
30-35 4,705 11 4,214 11 490 9  
>35 1,317 3 1,186 3 131 2  
Unknown 5,028 12 4,295 12 733 13  
ASA Classification       .025 
I 8,674 20 7,602 20 1,072 20  
II 23,811 56 20,795 56 3,015 55  
III-V 9,879 23 8,537 23 1,342 25  
Charlson score       .022 
0 27,466 64 23,867 64 3,599 66  
≥1 1,5328 36 13,438 36 1,890 34  
Tumour characteristics        
Location        
Colon 30,431 71 26,074 70 4,357 79 <.00001 
Rectum 12,363 29 11,231 30 1,132 21  
Left-sided tumour 15,875 37 13,706 37 2,169 40 .000071 
Right-sided tumour 26,919 63 23,599 63 3,320 60  
Morphology        
Adenocarcinoma 39,000 91 34,099 91 4,901 89 <.00001 
Mucinous 1,854 4 1,573 4 281 5  
Signet ring cell 270 1 183 1 87 2  
Other 783 2 699 2 84 2  
Unknown 887 2 751 2 136 2  
Differentiation       <.00001 
Well 3,160 18 2,862 18 298 14  
Moderately 11,446 63 10,102 64 1,344 61  
Poorly 1,861 10 1,506 10 355 16  
Unknown 1,567 9 1,378 9 189 9  
T-stage       <.00001 
ypT0 598 2 650 2 48 1  
T1 2,971 7 2,905 8 66 1  
T2 8,497 20 8,138 22 359 7  
T3 24,286 57 21,108 57 3,178 58  
T4 5,801 14 4,018 11 1,783 32  
Tx 541 1 486 1 55 1  
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Supplemental table 1. (Continuing) 
 All patients Stage I-III Stage IV p-value 
 N % N % N %  
N-stage       <.00001 
N0 25,253 59 23,923 64 1,330 24  
N1 10,504 25 8,705 23 1,799 33  
N2 6,519 15 4,279 12 2,240 41  
Nx 518 1 398 1 120 2  
Metastasis        
Single-organ     4,060 86  
Multiple-organ     659 14  
Liver metastasis     3,240 65  
Non-liver metastasis     1,725 35  
Treatment characteristics        
Neoadjuvant treatment        
None 31,395 73 27,286 73 4,109 75 <.00001 
Radiation – short course 5,420 13 5,140 14 280 5  
Radiation – long course 381 1 341 1 40 1  
Chemoradiation 4,690 11 4,110 11 580 11  
Chemotherapy 878 2 411 1 467 9  
Other 30 0 17 0 13 0  
Preoperative complications        
None 28,687 68 25,672 70 3,015 55 <.00001 
Faecal peritonitis 674 2 497 1 177 1  
Abscess 446 1 369 1 77 1  
Obstruction 4,882 12 3,568 10 1,314 24  
Blood loss 5,498 13 5,015 14 483 9  
Other 2,192 5 1,822 5 370 7  
Timing       <.00001 
Elective 36,415 85 32,567 87 3,848 70  
Urgent 3,334 8 2,495 7 839 15  
Emergency 2,959 7 2,172 6 787 14  
Unknown 86 0 71 0 15 0  
Surgical resection       <.00001 
Right-sided colectomy 14,104 33 12,201 33 1,903 35  
Transverse resection 880 2 739 2 141 3  
Left-sided colectomy 3,299 8 2,826 8 473 9  
Anterior / sigmoid resection 19,037 44 16,692 45 2,345 43  
(Sub)total colectomy 879 2 765 2 114 2  
Abdominoperineal resection 3,686 9 3,358 9 328 6  
Transanal local procedure 332 1 317 1 15 0  
Unknown 577 1 407 1 170 3  
Approach       <.00001  
Open 23,417 55 19,459 52 3,958 72  
Endoscopic 16,619 39 15,383 41 1,236 23  
Converted 2,643 6 2,360 6 283 5  
Unknown 115 0 103 0 12 0  
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Supplemental table 1. (Continuing) 
 All patients Stage I-III Stage IV p-value 
 N % N % N %  
Anastomotic procedure       <.00001 
Anastomosis 27,628 65 24,289 65 3,339 61  
Defunctioning stoma 5,806 14 5,212 14 594 11  
End-ileostomy 775 2 595 2 180 3  
End-colostomy 7,938 19 6,638 18 1,300 24  
Unknown 647 2 571 2 76 1  
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Supplemental table 2. Univariable predictors of postoperative mortality in non-metastatic and 
metastatic patients. 
 Stage I-III Stage IV 
 N % OR (95%CI) p N % OR (95%CI) p 
Patient characteristics        
Gender          
Male 829 4.1 1 <.001 210 6.7 1 .50 
Female 549 3.3 0.79 (0.71-0.88)  144 6.2 0.93 (0.75-1.16)  
Age         
  1.08 (1.08-1.09) <.001  1.06 (1.05-1.07) <.001 
< 75 years 411 1.8 1 <.001 180 4.6  1 <.001 
≥ 75 years 967 6.8 4.03 (3.58-4.53)  174 11.0 2.54 (2.05-3.16)  
BMI (kg/m2)         
  .99 (.97-1.00) .058  1.00 (0.97-1.03) .90 
<20 82 4.8 1.41 (1.11-1.80)  23 7.2 1.50 (0.94-2.40)  
20-25 436 3.5 1 <.001 99 4.9 1 .52 
25-30 367 2.8 0.80 (0.69-0.92)  96 5.4 1.10 (0.83-1.47)  
30-35 124 3.0 0.85 (0.69-1.04)  23 4.7 0.96 (0.60-1.53)  
>35 49 4.1 1.20 (0.89-1.63)  7 5.3 1.09 (0.50-2.40)  
ASA Classification         
I 72 1.0 1 <.001 20 1.9 1 <.001 
II 536 2.5 2.71 (2.12-3.48)  142 4.7 2.60 (1.62-4.18)  
III-V 763 9.0 10.28 (8.05-13.11)  186 14.0 8.49 (5.31-13.57)  
Charlson score         
0 579 2.4 1 <.001 161 4.5 1 <.001 
≥1 799 6.0 2.54 (2.28-2.84)  193 10.3 2.43 (1.96-3.02)  
Tumour characteristics        
Location         
Colon 1,092 4.2 1 <.001 314 7.3 1 <.001 
Rectum 286 2.6 0.60 (0.52-0.68)  40 3.6 0.47 (0.34-0.66)  
Left-sided tumour 632 4.6 1 <.001 180 8.4 1 <.001 
Right-sided tumour 746 3.2 0.67 (0.61-0.75)  174 5.3 0.61 (0.49-0.76)  
Morphology         
Adenocarcinoma 1,263 3.7 1 .044 305 6.3 1 .83 
Mucinous 43 2.7 0.73 (0.54-0.99)  21 7.6 1.22 (0.77-1.94)  
Signet ring cell 12 6.6 1.81 (1.01-3.27)  5 5.7 0.91 (0.37-2.27)  
Other 26 3.7 1.01 (0.68-1.49)  6 7.1 1.15 (0.50-2.66)  
Differentiation         
Well 66 2.3 0.85 (0.64-1.11)  10 3.4 1.05 (0.52-2.12)  
Moderately 274 2.7 1 .18 43 3.2 1 .<.001 
Poorly 49 3.3 1.20 (0.88-1.64)  33 9.3 3.11 (1.95-4.98)  
T-stage         
ypT0 8 1.2 0.31 (0.15-0.63)  0 0.0 0.00 (0.00-∞)  
T1 85 2.9 0.75 (0.60-0.94)  0 0.0 0.00 (0.00-∞)  
T2 228 2.8 0.72 (0.62-0.84)  8 2.3 0.37 (0.18-0.75)  
T3 812 3.9 1 <.001 186 5.9 1 <.001 
T4 223 5.6 1.47 (1.26-1.71)  153 8.6 1.51 (1.21-1.89)  
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Supplemental table 2. (Continuing) 
 
 Stage I-III Stage IV 
 N % OR (95%CI) p N % OR (95%CI) p 
N-stage         
N0 858 3.6 1 .17 63 4.8 1 .026 
N1 309 3.6 0.99 (0.87-1.13)  118 6.6 1.41 (1.03-1.93)  
N2 177 4.2 1.16 (0.99-1.37)  156 7.0 1.50 (1.11-2.03)  
Metastasis         
Single-organ     228 5.7 1 .12 
Multiple-organ     47 7.2 1.29 (0.93-1.79)  
Liver metastasis     173 5.4 1 .038 
Non-liver metastasis    117 6.8 1.29 (1.02-1.65)  
Treatment characteristics        
Year of surgery         
2009 252 4.5 1 <.001 99 10.8 1 <.001 
2010 376 5.3 1.19 (1.01-1.40)  88 7.7 0.69 (0.51-0.93)  
2011 306 4.0 0.88 (0.74-1.05)  72 6.7 0.60 (0.43-0.82)  
2012 253 3.0 0.64 (0.54-0.77)  57 4.8 0.42 (0.30-0.59)  
2013 191 2.3 0.50 (0.42-0.61)  38 3.3 0.29 (0.20-0.42)  
Neoadjuvant treatment        
None 1,095 4.0 1 <.001 300 7.4 1 <.001 
Radiation  
– short course 144 2.8 0.69 (0.58-0.82)  10 3.6 0.47 (0.25-0.89)  
Radiation  
– long course 10 2.9 0.72 (0.38-1.36)  3 7.5 1.02 (0.31-3.33)  
Chemoradiation 68 1.7 0.40 (0.31-0.52)  8 1.4 0.18 (0.09-0.36)  
Chemotherapy 61 15.0 4.19 (3.17-5.54)  2 15.4 2.29 (0.51-10.38)  
Other 0 0.0 0.00 (0.00-∞)  31 6.7 0.91 (0.62-1.34)  
Preoperative complications       
None 791 3.1 1 <.001 138 4.6 1 <.001 
Faecal peritonitis 86 17.4 6.59 (5.17-8.40)  39 22.2 5.90 (3.97-8.75)  
Abscess 21 5.7 1.89 (1.21-2.95)  7 9.1 2.07 (0.94-4.59)  
Obstruction 225 6.3 2.12 (1.82-2.47)  118 9.0 2.06 (1.60-2.66)  
Blood loss 152 3.0 0.98 (0.82-1.17)  24 5.0 1.09 (0.70-1.70)  
Other 82 4.5 1.48 (1.17-1.87)  23 6.3 1.39 (0.88-2.20)  
Timing         
Elective 987 3.0 1 <.001 169 4.4 1 <.001 
Urgent 171 6.9 2.36 (2.00-2.78)  82 9.8 2.36 (1.79-3.11)  
Emergency 218 10.1 3.58 (3.08-4.18)  101 13.0 3.23 (2.49-4.19)  
Surgical resection         
Right-sided colectomy 558 4.6 1 <.001 147 7.8 1 <.001 
Transverse resection 49 6.7 1.48 (1.10-2.00)  19 13.5 1.84 (1.11-3.08)  
Left-sided colectomy 130 4.6 1.00 (0.83-1.22)  35 7.5 0.96 (0.65-1.40)  
Anterior / sigmoid 
resection 446 2.7 0.57 (0.50-0.65)  99 4.2 0.53 (0.40-0.68)  
(Sub)total colectomy 72 9.5 2.17 (1.68-2.81)  10 8.8 1.14 (0.58-2.23)  
Abdominoperineal 
resection 90 2.7 0.57 (0.46-0.72)  8 2.5 0.30 (0.14-0.61)  
Transanal local 
procedure 3 0.9 0.20 (0.06-0.62)  0 0.0 0.00 (0.00-∞)  
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Supplemental table 2. (Continuing) 
 
 Stage I-III Stage IV 
 N % OR (95%CI) p N % OR (95%CI) p 
Approach         
Open 980 5.1 1 <.001 290 7.4 1 <.001 
Endoscopic 311 2.0 0.39 (0.34-0.44)  43 3.5 0.45 (0.33-0.63)  
Converted 75 3.2 0.62 (0.49-0.78)  19 6.8 0.92 (0.57-1.48)  
Anastomotic procedure         
Anastomosis 838 3.5 1 <.001 210 6.3 1 .34 
Defunctioning stoma 165 3.2 0.92 (0.77-1.08)  32 5.4 0.85 (0.58-1.24)  
End-ileostomy 52 8.8 2.68 (2.00-3.59)  17 9.6 1.56 (0.93-2.63)  
End-colostomy 300 4.5 1.32 (1.16-1.52)  90 7.0 1.11 (0.86-1.43)  
Stoma, type unknown 4 7.3 2.18 (0.79-6.05)  1 7.1 1.14 (0.15-8.74)  
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The CAIRO4 study: the role of surgery 
of the primary tumour with few or 
absent symptoms in patients with 
synchronous unresectable metastases 
of colorectal cancer – a randomized 
phase III study of the Dutch Colorectal 
Cancer Group (DCCG)
8
Background. There is no consensus regarding resection of the 
primary tumour with few or absent symptoms in patients with 
synchronous unresectable metastatic colorectal cancer (CRC). A 
potential benefit of resection of the primary tumour is to prevent 
complications of the primary tumour in later stages of the dis-
ease. We here propose a randomized trial in order to demonstrate 
that resection of the primary tumour improves overall survival.
Methods/design. The CAIRO4 study is a multicentre, randomized, 
phase III study of the Dutch Colorectal Cancer Group (DCCG). 
Patients with synchronous unresectable metastases of CRC and 
few or absent symptoms of the primary tumour are randomized 
1:1 between systemic therapy only, and resection of the primary 
tumour followed by systemic therapy. Systemic therapy will consist 
of fluoropyrimidine-based chemotherapy in combination with 
bevacizumab. The primary objective of this study is to determine 
the clinical benefit in terms of overall survival of initial resection 
of the primary tumour. Secondary endpoints include progression 
free survival, surgical morbidity, quality of life and the number of 
patients requiring resection of the primary tumour in the control 
arm.
Discussion. The CAIRO4 study is a multicentre, randomized, 
phase III study that will assess the benefit of resection of the pri-
mary tumour in patients with synchronous metastatic CRC.
Trial registration. The CAIRO4 study is registered at clinicaltri-
als.gov (NCT01606098)
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Background
Colorectal cancer (CRC) is the third most common type of cancer in the 
Netherlands, with an incidence of more than 13,000 new cases in 2011.1 
Due to the improvement in living standard and the aging of the population, 
the incidence of CRC is increasing. Approximately 20% of patients with CRC 
present with synchronous metastases (stage IV disease, according to TNM-
classification).2 Although curative surgery, with resection of both the primary 
tumour and all metastases, is an option in some patients, the majority of 
patients with stage IV disease end up in a palliative setting.
Median survival in patients with advanced CRC without any form of treatment 
is estimated at 8 months.3 Palliative systemic treatment, consisting of cytotoxic 
chemotherapy and targeted therapy, can lead to a significant benefit in overall 
survival.4 Standard of care in the Netherlands in first-line treatment consists 
of fluoropyrimidine-based chemotherapy in combination with bevacizumab.5
To prevent complications from the primary tumour, such as obstruction or 
bleeding, or to reduce symptoms, resection of the primary tumour is often 
considered in this patient group. Retrospective data show that approximately 
50% of all patients with stage IV disease undergo resection of the primary 
tumour.2, 6 The 30-day mortality rates after surgery of the primary tumour 
for patients with stage IV disease range between 1.3-11.7%, which is higher 
than reported for elective surgery in stage I-III patients.7 However, these rates 
usually reflect both symptomatic and asymptomatic patients with a variety in 
age and comorbidity. Limited postoperative survival is furthermore associated 
with an extensive hepatic tumour load, pT4 tumours, lymphatic spread and 
R1-2 resection.8
The indication of palliative resection prior to initiation of systemic treatment in 
patients with a symptomatic primary tumour is obvious. However, in patients 
with few or absent symptoms the indication for prophylactic resection is 
under debate, and its effect on survival and quality of life is still uncertain.9 
Currently, there are no data from prospective randomized trials to assess the 
value of resection of the primary tumour in stage IV patients with mild or 
absent symptoms of their primary tumour. Retrospective analysis does not 
provide definitive answers, since usually no reliable information is provided 
on the presence of symptoms at diagnosis or the indication to perform or 
to refrain from resection of the primary tumour. Most randomized studies in 
PART III: PALLIATIVE RESECTION OF THE PRIMARY TUMOUR
200
8
metastatic CRC do not even report whether or not a resection of the primary 
tumour has been performed.10
Treatment in patients with unresectable metastatic CRC should be based on 
two objectives: first, to improve or maintain the quality of life, and, secondly, 
to prolong the survival. In patients with few or absent symptoms of the 
primary tumour, arguments both in favour and against initial resection have 
risen.
The main argument against resection of the tumour is that survival benefit 
of initial resection of the primary tumour has not yet been investigated in 
a prospective randomized trial. Therefore, surgery-related morbidity and 
mortality should be avoided.11-13 Furthermore, there is some evidence from 
preclinical and clinical data showing that resection of the primary tumour 
may have a stimulating effect on the growth of distant metastases.14 However, 
these data are mainly derived from in vitro and animal models and it remains 
unknown if and how they influence overall survival and quality of life. Also, 
it is argued that systemic treatment can safely be administered without 
prior resection of the primary tumour.15 Thus, life-prolonging systemic 
treatment would only be postponed when it is decided to perform a surgical 
intervention first.15-17 Additionally, Poultsides et al. demonstrate that most 
patients with synchronous stage IV CRC who receive upfront systemic therapy 
never require palliative surgery.15 However, the median overall survival time 
in this study was only 13 months, whereas median overall survival times of 
20-24 months have consistently been reported in the general population of 
metastatic CRC patients. Lastly, in 70% of patients who received systemic 
treatment prior to resection of the primary tumour major histological tumour 
regression was observed, suggesting that initial chemotherapy can control 
the primary tumour in the majority of patients.18
The main argument in favour of resection is that it will prevent possible 
complications of the primary tumour, such as bleeding, obstruction or 
perforation.19-21 Patients who receive initial systemic therapy without prior 
resection of the primary tumour are more likely to develop complications of 
the primary tumour.22 Furthermore, surgery can lead to more accurate staging 
of disease, as extrahepatic metastases, particularly in the peritoneal cavity, 
may be better identified by visual exploration.
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Retrospective analysis of two large randomized trials in patients with advanced 
CRC demonstrated that survival of patients with synchronous advanced CRC 
was significantly higher in patients who underwent resection of the primary 
tumour prior to study treatment, compared to patients with the primary 
tumour in situ (20.7 vs. 13.4 months, respectively).23 Symptoms which might 
be related to the primary tumour, such as nausea, vomiting and ileus did occur 
more often in the non-resection group. However, selection bias cannot be 
excluded, as the decision whether or not a patient would undergo resection 
was made prior to study entry. Therefore no data are available on patient 
characteristics that might have influenced this decision, such as resectability 
and symptomatology of the primary tumour and condition of the patient.
In summary, the available literature does not provide an outright support for 
either of the two strategies, although most support seems to exist for surgery 
of the primary first (Table 1). We therefore propose a prospective trial that 
will help provide an answer to the question which strategy is to be preferred.
Methods/design
Hypothesis
Although literature does not provide an outright support for either of the 
two strategies, most retrospective data seem to favour surgery of the primary 
tumour followed by systemic therapy over systemic therapy alone. Obviously, 
in patients with few or absent symptoms of their primary tumour, surgery 
can only be justified if a clinical benefit is shown. Therefore, we hypothesize 
 
Table 1. Data on resection versus non-resection of the primary tumour in metastatic CRC patients. 
Study Years of study Number of patients 
Median survival time 
(in months) 
p-value 
  Resection Non-resection Resection Non-resection  
Liu 20 1986-1991 57 5 11 2  
Ruo 24 1996-1999 127 103 16 9 <0.001 
Kaufman 25 1998-2003 115 69 22 3 <0.0001 
Scoggins 13 1985-1997 66 23 14.5 16.6 0.59 
Tebbutt 26 1990-1999 280 82 14 8.2 0.08 
Michel 27 1996-1999 31 23 21 14 0.718 
Benoist 16 1997-2002 32 27 23 22  
Evans 28 1999-2006 45 57 11 2 < 0.0001 
Poultsides 15 2000-2006 - 178 - 13  
Venderbosch 23 
2003-2004 
2005-2006 
258 
289 
141 
159 
16.7 
20.7 
11.4 
13.4 
< 0.0001 
<0.0001 
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that surgery of the primary tumour improves overall survival in patients with 
few or absent symptoms as evaluated by the treating physician and incurable 
stage IV CRC.
Study design
The CAIRO4 trial is an international, multicentre, randomized, phase III study. 
Patients with synchronous unresectable metastatic colorectal cancer with few 
or absent symptoms of their primary tumour are randomized 1:1 between 
systemic treatment without resection of the primary tumour, and resection of 
the primary tumour followed by systemic treatment. Treatment according to 
protocol must be initiated within four weeks after randomization. The study 
will be conducted within the network of the Dutch Colorectal Cancer Group 
(DCCG) and the Danish Colorectal Cancer Group. At least 55 Dutch hospitals 
and 5 Danish hospitals will participate in this study, including 8 university 
medical centres.
Study population
All patients who are newly diagnosed with synchronous metastatic CRC are 
eligible for participation in this trial when they meet the following inclusion 
criteria: histologically proven CRC (i.e. via colonoscopy and/or any other 
method) with a resectable primary tumour in situ and unresectable distant 
metastases without an indication for neo-adjuvant (chemo)radiation, with 
few or absent symptoms of the primary tumour, without prior systemic 
treatment for advanced disease, with age ≥ 18 years and a WHO performance 
status of 0, 1 or 2.29 Laboratory serum values obtained ≤ four weeks prior to 
randomization must show an adequate bone marrow function (Hb ≥ 6.0 mmol/L, 
absolute neutrophil count ≥ 1.5°109/L, platelets ≥ 100° 109/L), renal function 
(creatinine ≤ 1.5x upper limit of normal (ULN) and creatinine clearing ≥ 30 
ml/min using the Cockcroft formula) and liver function (bilirubin ≤ 2× ULN, 
transaminases ≤ 3× ULN in patients without hepatic metastases or ≤ 5x ULN 
in patients with presence of liver metastases). Patients must have undergone 
a computed tomography (CT) scan in the four weeks prior to randomization. 
Adequate follow-up must be expected and a written informed consent must 
be obtained before enrolment in the study.
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The following definition of few or absent symptoms is used: patients without 
signs or symptoms related to the primary tumour that require immediate 
intervention (i.e. surgery, stenting, systemic therapy or radiotherapy). The 
necessity of immediate intervention is left to the discretion of the treating 
physician. Whether or not metastases are resectable will be decided by the 
local multidisciplinary tumour board.
Exclusion criteria are: pregnancy, lactation, unresectable primary tumour, any 
condition preventing the safety or feasibility of resection of the primary tumour, 
second primary malignancy ≤ 5 years prior to randomization with the exception 
of basal cell carcinoma of the skin or adequately treated in situ carcinoma 
of any organ, any medical condition that prevents the safe administration 
of systemic treatment, previous intolerance of fluoropyrimidines, known 
dihydropyrimidine dehydrogenase deficiency, possibility of radical resection 
of all metastatic disease, uncontrolled hypertension (values ≥ 150/100 mmHg), 
use of > 3 antihypertensive drugs, significant cardiovascular disease < 1 year 
prior to randomization, chronic active infection and concurrent treatment 
with any other anti-cancer therapy as described per protocol. There are no 
exclusion criteria considering the side of metastatic disease.
Because of the higher complexity of local treatment in locally advanced rectal 
cancer, with patients often requiring neoadjuvant (chemo)radiation therapy 
and higher risk of morbidity and longer postoperative reconvalescence, 
these patients are excluded from the study. Patients with rectal cancer that 
do not require radiation therapy (i.e. rectal cancer with clinical staged T1-3 
N0, extramural invasion ≤ 5 millimetres, distance to the mesorectal fascia > 1 
millimetre5), but otherwise do meet the inclusion criteria can participate in 
the CAIRO4 study.
All patients who do not meet our inclusion criteria and/or refuse participation 
to the trial, will be asked for their consent for registration in a prospective 
database.
Interventions
Experimental arm: surgical resection prior to systemic treatment
Patients will undergo surgical resection of the primary tumour within four 
weeks of randomization, followed by systemic therapy as described for the 
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control arm. Surgical resection of the tumour should be intended as R0 
resection, and may be performed by laparoscopy or open surgery, depending 
on the preference of the surgeon. If a complete resection of the primary 
tumour cannot be performed according to the operating team, a diverting 
stoma or entero-enterostomy is strongly advised in order to prevent 
complications of obstruction during follow-up. After surgical resection, 
patients should commence palliative systemic treatment as described for the 
control group when they have sufficiently recovered, but not earlier than 4 
weeks after surgery.
Control arm: systemic treatment
Patients will receive first-line fluoropyrimidine-based chemotherapy with 
bevacizumab within four weeks of randomization. The exact chemotherapy 
schedule is to the discretion of the local investigator. Surgery of the primary 
tumour will only be performed when indicated by local signs or symptoms, 
such as obstruction or bleeding. Alternatively, if other palliative treatment 
options, such as endoscopic stenting or radiotherapy, are considered more 
suitable, either due to the nature of the symptoms or the general condition 
of the patient, they may be used.
Duration of treatment and follow-up
The systemic therapy will be continued until progression of disease or 
unacceptable toxicity, followed by salvage therapy at the discretion of 
the local investigator. In case of drug-related toxicity, this drug should be 
discontinued, while, if possible, the other drugs should be continued. If a 
treatment-free interval is considered to be in the best interest of the patients, 
this is allowed.
Patients will be evaluated with CT scans and a clinical encounter every 9–10 
weeks for response, or in between when progression is suspected. After 
permanent discontinuation of therapy, patients will be followed every 3 
months until progression or death.
If, at any time, the physicians involved in the treatment believe an intervention 
with curative intent is possible, this should be performed in any patient on the 
study. After radical resection systemic therapy will only be continued when 
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advised by a multidisciplinary board of the local treatment centre. Patients 
will remain on-study and will be included in the analysis.
Study objectives
The primary objective of this trial is to determine the clinical benefit in terms 
of overall survival of resection of the primary tumour with few or absent 
symptoms in patients with synchronous unresectable metastases of CRC 
(intention-to-treat population).
Secondary objectives include progression free survival, grade III and IV 
chemotherapy related toxicity, 30-day and 90-day surgery-related morbidity 
and mortality, quality of life, number of patients who undergo secondary 
surgery of initially unresectable metastases, number of patients who 
never receive systemic therapy in the intervention arm, interval between 
randomization and initiation of systemic treatment, and overall survival in 
patients in whom treatment according to protocol was initiated. In the control 
arm we will also determine the percentage of patients requiring resection of 
the primary tumour and the percentage of patients who require stenting or 
radiotherapy for symptom palliation. Furthermore a cost-benefit analysis will 
be performed, as well as translational research on prognostic markers.
Endpoints
The primary study endpoint is overall survival, and the study is designed to 
demonstrate a difference in median overall survival of six months between 
both arms. Six months is believed to be the minimal difference to justify a 
surgical procedure in advanced patients. Although it seems a large difference 
between the two arms, it is in line with most published data (Table 1).
Study assessment
All eligible randomized patients will be included in the analysis (intent-to-
treat). Overall survival is estimated from the date of randomization to death 
from any cause. Progression free survival is defined as the time measured from 
the day of randomization to the date of first documented progression, or death 
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from any cause. All adverse events, clinical and laboratory symptomatology 
will be graded according to NCI common toxicity criteria, version 4.0.30
Response will be assessed according to the RECIST criteria for evaluation of 
response.31 A baseline measurement should be performed within 4 weeks prior 
to the start of treatment via CT scanning. A chest X-ray may be used provided 
in case of lung metastases if the target lesion is unidimensionally measurable 
and has a diameter of > 2 cm. Ultrasound and serum carcinoembryotic antigen 
(CEA) are not considered adequate parameters for disease evaluation.
Quality of life will be measured using the EORTC-QLQ C30 and CR38 
questionnaires32, 33, with a baseline measurement within 2 weeks prior to 
randomization and every six months thereafter, until the end of the study 
treatment.
Statistical considerations
Sample size
In the control group the expected median overall survival is 13 months. In order 
to demonstrate a clinically relevant increase of 6 months in the experimental 
group, a total of 218 deaths are required (80% power, significance level 
0.05). With a recruitment rate of 12 patients per month, an accrual period of 
30 months and a follow-up period of 8 months, a total of 360 patients are 
required in order to detect a difference in median overall survival of 13 versus 
19 months with a power of 80%.
Randomization
Patients will be randomized centrally for systemic treatment versus surgery 
of the primary tumour in a 1:1 allocation ratio, stratifying for number of 
metastatic sites (1 versus more), serum lactate dehydrogenase (LDH, normal 
versus abnormal), WHO performance status (0 or 1 versus 2) and institution.
Primary analysis
An interim analysis at a significance level of 0.001 will be performed when one 
third of the events have occurred. The primary analysis will be a stratified log 
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rank test on the overall survival at a significance level of 0.049. The sample 
size of 360 (180 per group) is such that still 79.6% power is retained when 
testing a level of 0.049. Patients without recurrence and alive at the time of 
the analysis will be included as censored data.
Secondary parameters will be compared between the two arms using stratified 
log rank tests (time-to-event endpoints), chi-square tests (disease and 
outcome characteristics) and t-tests (e.g. quality of life). Regression analysis 
will be used for translational research questions.
Ethics
The study was approved by the Central Committee of Human-related Research 
and by the local ethics committees of all participating centres. The CAIRO4 
study is registered at clinicaltrial.gov (NCT01606098).34 Prior to registration 
written informed consent will be obtained in all patients, with a separate 
informed consent for the collection of samples for translational research.
An independent data monitoring committee consisting of three senior medical 
and surgical oncologists and a statistician, who are not involved in the study, 
will review the safety data on a regular basis and report their findings to the 
principal investigator. The principal investigator will report these findings to 
the ethics committee.
Discussion
Although recent publications suggest that resection of the primary tumour 
in synchronous metastatic CRC patients might not be necessary, this appears 
to be based on feasibility and not on clinical outcome. The CAIRO4 trial is 
designed to analyse the role of resection of the primary tumour in unresectable 
metastatic CRC.
This trial has been designed to evaluate two accepted treatment strategies. 
Therefore, there are no specific directives regarding type of surgery and/
or chemotherapy regimen. To the discretion of the local investigator, the 
following chemotherapy schedules are allowed: 5FU/LV, capecitabine, 
CAPOX, FOLFOX, FOLFIRI or CAPIRI.35-39 In both study arms bevacizumab will 
be added to a fluoropyrimidine containing regimen according to the Dutch 
PART III: PALLIATIVE RESECTION OF THE PRIMARY TUMOUR
208
8
national guideline.5 Bevacizumab is a targeted therapy, as it inhibits tumour 
neoangiogenesis by blocking VEGF. Tumour neoangiogenesis is a prerequisite 
for tumour growth. VEGF and VEGF-receptors have been implicated in this 
process, and have been associated with poor prognosis. Bevacizumab is 
worldwide accepted for use in first-line treatment of advanced CRC and its 
benefit has been confirmed by compelling data.40
Considering current developments, it might be expected that there will be 
a decreasing percentage of patients presenting with incurable synchronous 
metastatic CRC. The last decades have seen major improvements in both 
surgical techniques as well as effectiveness of adjuvant therapy, which has led 
to a remarkable increase in five-year survival rates.41 Although approximately 
20-25% of patients present with synchronous distant metastatic disease, 
with the development of new surgical techniques, such as liver resection, 
pulmonary metastasectomy and hyperthermic intraperitoneal chemotherapy, 
an increasing number of patients are treated with curative intent.42 In selected 
patients this could lead to five-year survival rates as high as 35-60%.43
On the other hand, only a slight increase in the proportion of stage IV disease 
was observed in the Netherlands in the last two decades.41, 44 This increase is 
probably due to an earlier and more accurate detection of distant metastases, 
because of more widely available and improved imaging techniques, such as 
magnetic resonance imaging (MRI), positron emission tomography (PET) and 
CT scanning. Although in many cases metastases might be better resectable 
when detected in an earlier stage, in others detection of unresectable 
metastases (i.e. in bone or distant lymph nodes) might lead to refraining from 
treatment with curative intent.
It can be argued that the development of nationwide screening programmes 
will lead to an earlier detection of CRC, and thus to a decreasing number 
percentage of advanced CRC.45-48 However, randomized trials show that 
the specific proportion of patients with synchronous metastatic disease 
at diagnosis did not differ between the control group and the group that 
was offered screening.45-47 Therefore, despite current developments in both 
detection and treatment of CRC, the issue of the best treatment strategy in 
patients who present with synchronous metastatic disease will still be relevant 
for future patients.
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As of August 2012, the trial accrual for the CAIRO4 study has started in the 
above mentioned centres. Taking in account the time needed to implement 
this study in all centres, we expect that in five year time the recruitment will be 
completed. This trial will provide an answer to the question if resection of the 
primary tumour with few or absent symptoms in patients with synchronous 
metastatic CRC offers a clinical benefit in terms of overall survival and quality 
of life.
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Approximately 20% of all colorectal cancer patients present with distant 
metastases at the time of first diagnosis (synchronous metastases), and 
another 20% will develop metastases during follow-up (metachronous 
metastases). Surgical resection of the primary tumour and all metastases is 
the best chance of long-term survival for patients with metastatic colorectal 
cancer (mCRC). Currently, this option is only available for a small subset of 
patients. The majority of patients are only eligible for palliative treatment 
aimed at improving and maintaining quality of life, as well as prolonging 
survival. Surgical resection can help in preventing or treating symptoms, 
such as intestinal obstruction or perforation. Furthermore, palliative 
primary tumour resection in synchronous mCRC might lead to an increase 
in survival, even when a patients experiences no symptoms of the primary 
tumour. The aim of this thesis was to give more insight in the role of the 
surgical oncologist in both curative and palliative treatment in patients with 
synchronous mCRC.In Part 1 we aim to define the concept of synchronous 
mCRC, by investigating what is commonly meant when metastases are defined 
as ‘synchronous’, as well as by studying its epidemiology. In Chapter 1 the 
use of the terms “synchronous” and “metachronous” in articles published in 
the last decade was reviewed. Only a small subset of publications on mCRC 
was found to report on the proportion of synchronous versus metachronous 
metastases. This applies to randomized controlled trials, cohort studies and 
population-based studies. No consistent definition of synchronicity could be 
distinguished with 17 different definitions in 46 studies. During recent years, 
the proportion of patients with synchronous disease included in randomized 
controlled trials increased. The median overall survival of the total study 
population in randomized controlled trials also slightly increased over time. 
However, these results were not confirmed in cohort studies or population-
based studies. This review argues that uniform definitions and consistent 
reporting of the proportion of synchronous versus metachronous metastases 
in mCRC studies is essential to gain more insight into differences in clinical 
outcome and to improve cross-study comparisons.
In Chapter 2 we studied trends in incidence, treatment and survival of mCRC 
patients with synchronous metastases in The Netherlands. We selected all 
patients who were diagnosed with colorectal cancer between 1996 and 2011 
from The Netherlands Cancer Registry. The proportion of synchronous mCRC 
patients increased during the studied time period from 19% to 23%. We also 
found a strong increase in treatment with systemic therapy (29% to 60%) and 
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metastasectomy, especially in patients with liver-only disease (5% to 18%). 
In contrast,  the proportion of mCRC patients who underwent resection of 
the primary tumour decreased (65% to 46%). During the studied time period, 
median overall survival of all synchronous mCRC increased from 7 to 12 
months, and this increase was particularly evident in patients with single-
organ metastasis. The increased survival can in part be attributed to lead time 
bias, as small metastases are currently better detectable compared to two 
decades ago. Nevertheless, the increased utilization of metastasectomy and 
systemic therapy  will have an important impact on the prolonged median 
overall survival as well. This implies that the prognosis of synchronous mCRC 
patients will become increasingly diverse depending on the applied treatment 
strategy in different subgroups. For better interpretation of study results, it is 
important to distinguish different subgroups within study populations. 
As the criteria for resectability of metastases are constantly evolving without 
clear consensus, determining which patients are eligible for liver surgery 
is difficult. However, as surgical resection of the primary tumour and all 
metastases is the best change on long-term survival for mCRC patients, the 
importance of optimal utilization of this treatment plan is unmistakable. As 
a first step to reach the most optimal situation, Part 2 focuses on how often 
liver resection is used in The Netherlands. Chapter 3 presents the results of 
a regional study on utilization of liver resection in patients with synchronous 
mCRC confined to the liver. Patients diagnosed between 2004 and 2012 
with synchronous liver-only mCRC were selected from the Eindhoven Cancer 
Registry. The proportion of patients undergoing liver resection increased 
threefold from 8% in 2004 to 24% in 2012. However, there was a wide inter-
hospital variation with a range of 14% to 34%. This study also confirmed 
the survival benefit for patients undergoing metastasectomy, with a median 
overall survival of 55 months in the selected group of patients who underwent 
liver surgery. 
The large institutional variation in the utilization of liver metastasectomy 
was confirmed in a nation-wide study using data from The Netherlands 
Cancer Registry, presented in Chapter 4. This study showed that between 
2008 and 2012, 12% of all synchronous mCRC patients with liver metastases 
underwent liver surgery. Of these patients, 58% were referred to another 
hospital before undergoing surgery. In the majority of patients (53%) liver 
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resection was performed in a university hospital or dedicated liver centre 
(39%). The proportion of patients undergoing liver resection varied from 
2% to 26% between the different hospitals. Patients first diagnosed in the 
expert centres had a higher chance of undergoing liver surgery, compared to 
patients diagnosed in a general hospital. Furthermore, we found considerable 
differences between regions in The Netherlands. These results suggest that 
more consultation between specialists, for example in the form of a national 
expert panel evaluating resectability in patients with synchronous mCRC, 
could lead to an improvement in the identification of patients who are 
eligible for liver resection, and thus might even lead to an improvement in 
overall survival.
Although the previously discussed studies show a clear increase in the 
number of patients undergoing liver resection, the majority of synchronous 
mCRC patients are only eligible for palliative treatment. Currently, the value 
of palliative primary tumour resection in synchronous mCRC patients with 
few or absent symptoms is under discussion. In Part 3 we discuss several 
aspects of palliative primary tumour resection to help provide an answer 
to this ongoing debate. In Chapter 5 we studied the association between 
palliative resection of the primary tumour and overall survival. Using data 
from The Netherlands Cancer Registry (2008-2012), we compared patients 
who underwent an elective palliative resection, whether or not followed by 
systemic therapy, to patients who started systemic therapy without prior 
resection. Median overall survival was 17 months in patients who primarily 
underwent resection, compared to 11 months in patients who started on 
systemic therapy without prior resection. Patients who underwent primary 
tumour resection and were subsequently treated with systemic therapy had 
an ever higher overall survival of 21 months. Although selection bias cannot 
be excluded, as no data are available on the presence of symptomatic tumours 
or about performance status and comorbidity of the included patients, this 
potential survival benefit of 6 months suggests that there might be a role 
for resection of the primary tumour, even when patients have little to no 
symptoms.
An important argument to refrain of palliative resection of the primary 
tumour is an increased postoperative mortality, compared to patients with 
non-metastatic disease. In Chapter 6 we explored predictors of postoperative 
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mortality that could help in the identification of high-risk patients, in whom 
resection should be carefully deliberated. Data from mCRC patients undergoing 
primary tumour resection from eight different hospitals were retrospectively 
analysed. The 30-day mortality after colorectal surgery was 6%. Multivariable 
logistic regression analysis showed that increased age, increased body 
mass index, a colonic primary, increased lactate dehydrogenase (LDH) and 
hypoalbuminemia were associated with postoperative mortality. The two 
biochemical values are known predictors in oncological care, but are not 
part of standard preoperative laboratory analysis. Determining these values 
preoperatively, in combination with patients’ age, body mass index, and the 
location of the primary tumour, might help to identify patients most suitable 
for palliative resection of the primary tumour.
The increased postoperative mortality in patients with synchronous mCRC is 
often attributed to an increased risk of postoperative morbidity. In Chapter 
7 we analysed data from the Dutch Surgical Clinical Audit, and found that 
between 2009 and 2013, patients with synchronous mCRC had a higher risk of 
postoperative mortality compared to patients with non-metastatic disease (6% 
versus 4%). Patients with mCRC also had a slightly higher risk of perioperative 
and postoperative complications, compared to non-metastatic patients (5% 
versus 4%, and 22% versus 20%), and were more often admitted to the 
Intensive Care Unit (17% versus 15%). However, postoperative mortality after 
colorectal surgery for patients with synchronous mCRC decreased strongly, 
from 11% in 2009 to 3% in 2013. We found that age, ASA classification, 
Charlson Comorbidity Index, primary tumour location and timing of surgery 
were independent predictors of postoperative mortality. Using these results, 
we propose a clinical risk score to help specialists in providing their mCRC 
patients with an individualized risk, and help them decide on whether or 
not to perform a palliative primary tumour resection in patients with few 
symptoms.
The research described in this thesis, as well as previously published articles, 
suggests that there might be a potential survival benefit for asymptomatic 
patients undergoing resection of the primary tumour. However, none of 
these studies have an randomized controlled design, and selection bias 
cannot be excluded. To get a more robust answer in the question whether 
the primary tumour should be removed, Chapter 8 contains the protocol for 
a randomized controlled study to investigate the suggested survival benefit 
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of palliative resection of the primary tumour with few or absent symptoms 
in patients with synchronous mCRC: the CAIRO4 study. The CAIRO4 study 
is an international study, which is conducted in more than 60 hospitals in 
The Netherlands and Denmark. Patients will be randomized between surgical 
resection of the primary tumour, commencing systemic therapy when they have 
sufficiently recovered, and first-line fluoropyrimidine-based chemotherapy 
with bevacizumab without prior resection of the primary tumour. Keeping in 
mind the added morbidity of surgery, including postoperative complications 
and even mortality, we believe that a survival benefit of at least six months 
should be considered clinically relevant. To demonstrate such a benefit, a 
sample size of at least 360 patients is necessary. This study aims to give the 
final answer on the clinically very relevant question whether to resect or not 
the primary tumour in patients with synchronous mCRC.
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In this thesis we present the results of several studies on the role of 
surgery in patients with mCRC. The proportion of patients presenting with 
synchronous mCRC has increased over the last decade, probably mainly due 
to improvements in imaging techniques. Although it was long believed that 
all mCRC patients were incurable, it is now generally accepted that resection 
of the primary tumour and all metastases can lead to long term survival 
and eventually cure. We found that the number of patients undergoing 
metastasectomy in The Netherlands has increased over the last two decades. 
With the rapid developments in the field of surgery, the subset of patients 
to whom this treatment strategy is applicable is changing continuously. 
Therefore, it is challenging for all colorectal surgeons to stay up to date with 
the current criteria for metastasectomy. This is reflected in a wide variation 
in the proportion of patients undergoing liver surgery, and especially in 
the difference of liver utilization between patients diagnosed in a general 
hospital and patients diagnosed in expert centres – as demonstrated in 
this thesis. The regional differences that we found also imply that even 
among specialists there is no consensus on what defines resectability. As 
the importance of optimal utilization of metastasectomy is unmistakable, 
we believe that more consultation between colorectal and hepatobiliary 
specialists is needed on both regional and national level. We expect that 
improving utilization of metastasectomy, in combination with improvements 
in both surgical and medical oncology, will lead to a decreasing number of 
patients who are only eligible for palliative systemic therapy. Better selection 
of patients might thus improve overall survival, as well as quality of life.
With regard to palliation, many symptoms caused by the primary tumour 
(i.e. obstruction, perforation, severe anaemia) or by metastatic lesions (for 
example pain or wound problems), can be prevented or treated by radiation 
and systemic therapy. As only a small subset of patients who undergo 
systemic therapy without prior resection develop complications, resection of 
the primary tumour is not indicated to prevent complications of the primary 
tumour. This is probably one of the reasons that we found a decrease in the 
number of synchronous mCRC patients who undergo resection of the primary 
tumour. Still, other benefits of resection of the primary tumour should be 
taken into account. This thesis suggests an improved overall survival for 
patients undergoing elective palliative resection of the primary tumour 
compared to patients starting systemic therapy without prior resection. This 
survival benefit seems about six months, on a median overall survival of 
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14 months for the entire group. This thesis also disproves one the most 
important counter arguments: the increased postoperative mortality in 
mCRC patients, as it shows an important decline in the postoperative risk, 
which is nowadays almost equal to that of non-metastatic patients. Clear 
predictors of postoperative mortality are identified, and can be a handheld 
in counselling patients preoperatively. Awaiting the prospective results from 
randomized controlled trials, as proposed in this thesis, we believe that all 
mCRC patients, who cannot be included in these trials, should be discussed 
in a multidisciplinary team and at least be seen by a surgical oncologist or 
colorectal surgeon to discuss the option of primary tumour resection.
Future perspectives
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The introduction of the colorectal cancer screening program in The Netherlands 
in 2013 will probably result in tumours increasingly being diagnosed in 
an early, or even precancerous stage and thus decreasing the number of 
patients presenting with metastatic colorectal cancer (mCRC). For patients 
who are diagnosed outside the screening program, further improvements in 
diagnostic tools, such as an increased availability, and improvement in quality 
will help to timely identify metastatic lesions. This will hopefully increase 
the proportion of patients undergoing curative surgery. The same applies to 
increased awareness of optimal utilization of curative treatment strategies. 
Besides these aforementioned developments, several other surgical and 
oncological options are currently investigated to increase the proportion of 
patients eligible for curative therapy even further.
Improving resectability
For patients with initially unresectable liver-only metastases, neoadjuvant 
chemotherapy can improve resectability rates. Neoadjuvant chemotherapy 
regimens should consist of at least combination chemotherapy (consisting 
of fluoropyrimidine in combination with either irinotecan or oxaliplatin), 
and patients might possibly even benefit of triple therapy.1-3 The addition 
of monoclonal antibodies has been advocated, as these regimens have been 
shown to increase response rate in first-line treatment of mCRC.4 The choice 
of either anti-EGFR therapy or anti-VEGF therapy should be based on RAS 
mutation status, as it has recently been confirmed that RAS mutation is a 
negative predictive factor for anti-EGFR therapy.5 Studies to investigate the 
optimal induction regimen for systemic therapy are ongoing, such as the 
CAIRO 5 study of the Dutch Colorectal Cancer Group (DCCG).6
The further improvement of surgical outcome using new techniques, such 
as radiofrequency ablation (RFA), transarterial chemoembolization (TACE) 
and stereotactic radiation therapy (SABR), increases the possibilities of 
metastasectomy. Optimal utilization of two-staged resections and portal vein 
embolization will further increase the number of patients eligible for curative 
treatment.
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Metastasectomy in multi-organ metastases
Several studies have shown that complete resection of  single organ mCRC 
(commonly liver and lung metastases) can improve overall survival. Multi-
organ metastases are known prognostic negative factors for overall survival, 
and complete resection of all metastases is only possible in a small subset of 
patients. Combining known techniques, such as liver and/or lung surgery with 
hyperthermic intraperitoneal chemotherapy (HIPEC), are showing promising 
results. 
However, tumour debulking is an accepted concept in treatment of other 
cancers, such as ovarian cancer, and leads to a significant survival benefit 
compared to systemic therapy alone. These findings, in combination with the 
survival benefit demonstrated for palliative resection of the primary tumour, 
have led to the hypothesis that decreasing tumour load by maximal tumour 
debulking might have an added benefit to the treatment with chemotherapy. 
This hypothesis is currently being investigated within the Orchestra Study of 
the DCCG.
Palliative systemic therapy
For patients in whom resection cannot be achieved, large trials have proven 
the benefit of systemic therapy to prolong overall survival as well as improve 
quality of life. The addition of a monoclonal antibody will increased the 
efficacy of these chemotherapeutic regimens.7 Due to the introduction 
of these targeted drugs, testing for RAS and BRAF mutations, as well as 
microsatellite instability is becoming more and more common practice. These 
molecular differences between tumours do not only affect the prognosis of 
an individual patient, but also guide the medical oncologist in choosing the 
most optimal systemic therapy. Currently, the standard first-line treatment for 
patients with RAS-mutated tumours consistent of chemotherapy (including at 
least a fluoropyrimidine, plus potentially irinotecan and/or oxaliplation) and 
bevacizumab. Patients with RAS-wild-type tumours benefit of treatment with 
anti-EGFR antibodies (cetuximab and panitumumab), although the optimal 
treatment sequence is still subject of ongoing trials.2, 5 BRAF-mutated tumours 
have an extremely poor prognosis, and due to its low prevalence, the optimal 
treatment strategy is still under debate. The best results seem to be achieved 
with triple chemotherapy in combination with bevacizumab. Intermittent 
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systemic therapy regimens have been proven less effective compared to 
maintenance therapy with regard to disease progression.8 
New prognostic and predictive biomarkers are proposed regularly. In addition 
to traditional prognostic factors, such as performance status and extent of 
disease, KRAS-mutation might also have prognostic value. Serum VEGF-A 
(vascular endothelial growth factor levels and ERCC1 (excision repair cross-
complementation group 1) expression levels are currently under investigation 
as markers to predict response to systemic therapy.9 Besides KRAS and NRAS 
mutations, the efficacy of anti-EGFR therapy is also associated with PIK3CA, 
secondary EGFR mutations and HER2 amplification. Several promising novel 
drugs are currently under investigation. BRAF inhibitors in combination with 
other monoclonal antibodies might improve outcome in a minority of patients. 
The role of immunotherapeutic drugs is also being researched. Other drugs 
currently under development target proteins from the Wnt pathway and the 
MAPK signalling cascade.7 
Centralization of care
In accordance with the trend of the last decades, surgical oncology will 
increasingly be concentrated in expert centres. The instatement of new 
(national) expert panels to aid the surgical oncologist in the decision-making 
process on rare tumours and complex cancer care, will enable patients to 
receive expert care in a setting close to home. Currently, a national liver 
expert panel, consisting of at least one radiologist and three liver surgeons, 
has been established as a part of a clinical study. Such an expert panel will 
provide more conformity on the interpretation of resectability with the aim of 
optimal utilization of liver resection.10
Tailor-made treatment
In conclusion, it is more and more recognized that treatment for cancer 
should be individualized based on genetics, tumour biology and patient-
related factors. In combination with the ongoing developments in both 
the curative and palliative setting, the variation in treatment strategies will 
become virtually endless. Clinical trials will increasingly focus on specific 
subgroups of patients with mCRC, which will make inclusion of enough 
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patients challenging. National and international collaborations are develop 
The Prospective Dutch ColoRectal Cancer cohort (PLCRC) is a prospective 
multidisciplinary nationwide observational cohort in the Netherlands in 
which all colorectal cancer patients are eligible for inclusion. Its objective 
is to register longitudinal clinical data, patient-reported outcomes and 
biomaterials in order to facilitate future research aiming to improve tailored 
treatment outcomes in colorectal cancer patients.11 For the future surgical 
oncologist it will therefore be a major challenge to translate results from 
specific clinical trials to the individual patient’s needs and wishes.
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Dikke darmkanker is een veelvoorkomende vorm van kanker, voornamelijk in 
de Westerse wereld. Jaarlijks worden er in Nederland meer dan 15.000 nieuwe 
patiënten gediagnosticeerd. Bij ongeveer 4.500 patiënten zit de tumor in 
de endeldarm (rectum); bij de anderen in de dikke darm (colon). Het aantal 
diagnoses per jaar is verdubbeld ten opzichte van het aantal patiënten in 
1990. Meer dan 5% van de mensen in Nederland zal gedurende zijn/haar leven 
dikke darmkanker ontwikkelen. Van alle mensen met dikke darmkanker heeft 
ongeveer 20% uitzaaiingen op het moment dat de kanker wordt vastgesteld 
(“synchrone uitzaaiingen”). Daarbovenop ontwikkelt nog ongeveer 20% van de 
patiënten uitzaaiingen in de loop van de ziekte (“metachrone uitzaaiingen”). 
Operatieve verwijdering van de tumor in de darm en alle uitzaaiingen is de 
beste optie voor langdurige overleving in patiënten met uitgezaaide dikke 
darmkanker. Echter, slechts een klein deel van de patiënten komt hiervoor 
momenteel in aanmerking. Het merendeel van de patiënten is ongeneeslijk 
ziek en kan alleen palliatief behandeld worden, met als belangrijkste doel 
het in stand houden of verbeteren van de kwaliteit van leven en daarnaast 
verlenging van de levensduur. Operatieve behandeling kan bij deze patiënten 
helpen in het voorkomen of behandelen van symptomen, zoals obstructie 
of perforatie van de darm. Er zijn ook aanwijzingen dat het verwijderen van 
de darmtumor leidt tot een verbetering in de overleving, zelfs bij patiënten 
zonder klachten. Het doel van dit proefschrift was het verkrijgen van meer 
inzicht in de rol van de oncologisch chirurg, zowel met het oog op de curatieve 
als de palliatieve behandeling van patiënten met synchroon uitgezaaide dikke 
darmkanker.
Deel 1 had als doel “synchroon uitgezaaide dikke darmkanker” te definiëren, 
door te kijken naar veelgebruikte definities, alsmede naar de epidemiologische 
aspecten van synchroon uitgezaaide dikke darmkanker. In Hoofdstuk 1 werd 
het gebruik van de termen “synchroon” en “metachroon” in de bestaande 
literatuur onderzocht. Het bleek dat slechts een klein deel van de publicaties die 
het afgelopen decennium verschenen zijn over uitgezaaide dikke darmkanker 
rapporteren hoeveel patiënten synchrone of metachrone uitzaaiingen 
hebben. Gedurende de onderzochte jaren, steeg het percentage patiënten 
met synchrone uitzaaiingen ten opzichte van het percentage patiënten met 
metachrone uitzaaiingen. Verder bleek er geen consensus te bestaan over 
de definitie van “synchrone uitzaaiingen”. In 46 studies werden maar liefst 
17 verschillende definities gebruikt. Onze studie benadrukt het belang van 
goede richtlijnen met betrekking tot welke gegevens gerapporteerd moeten 
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worden in publicaties over uitgezaaide dikke darmkanker en het belang van 
een algemeen geaccepteerde definitie van “synchroon”, zodat in de toekomst 
studies beter onderling vergeleken kunnen worden. Ons voorstel is om 
“synchrone uitzaaiingen” te definiëren als “uitzaaiingen die ontdekt worden 
voorafgaand aan of gelijktijdig met de tumor in de darm”. Uniformiteit op dit 
gebied kan het vergelijken van studies in de toekomst gemakkelijker maken.
In Hoofdstuk 2 onderzochten we veranderingen in de aantallen, de 
behandeling en de overleving van patiënten met synchroon uitgezaaide dikke 
darmkanker. We bestudeerden daartoe alle patiënten uit de Nederlandse 
Kanker Registratie die tussen 1996 en 2011 gediagnosticeerd werden met 
dikke darmkanker. Gedurende deze jaren nam het percentage patiënten met 
uitzaaiingen op het moment van diagnose toe van 19% naar 23%. Steeds 
meer patiënten werden behandeld met systeemtherapie (een stijging van 
29% naar 60%) en vooral patiënten met uitzaaiingen beperkt tot de lever 
ondergingen steeds vaker een metastasectomie (operatieve verwijdering 
van één of meerdere uitzaaiingen). Het aantal patiënten met uitgezaaide 
dikke darmkanker waarbij de darmtumor verwijderd werd nam echter af 
van 65% naar 46%. De mediane overleving van alle patiënten nam toe van 
7 maanden naar 12 maanden, waarschijnlijk door een betere toepassing van 
levensverlengende behandelingen zoals systeemtherapie en metastasectomie. 
De overleving nam het sterkste toe in de groep patiënten met uitzaaiingen 
die beperkt waren tot één orgaan. De prognose van synchroon uitgezaaide 
dikke darmkanker is dus sterk afhankelijk van de aard en de behandeling 
van de ziekte. Het is daarom belangrijk om in onderzoek onderscheid te 
maken tussen de verschillende subgroepen om resultaten beter te kunnen 
vergelijken en interpreteren. 
Door nieuwe ontwikkelingen op het gebied van chirurgie, zijn de criteria voor 
operatieve verwijdering van uitzaaiingen in de lever nog volop in ontwikkeling. 
Er is geen duidelijke consensus over welke patiënten in aanmerking komen 
voor een resectie. Daardoor is het voor behandelaars niet altijd duidelijk welke 
patiënten in aanmerking komen voor een leveroperatie. Omdat genezing 
voor patiënten alleen mogelijk is als zowel de darmtumor als alle uitzaaiingen 
verwijderd worden, is het wel belangrijk dat deze mogelijkheid bij iedere 
patiënt wordt overwogen. In Deel 2 ligt de focus daarom op hoe vaak en 
waar een metastasectomie wordt uitgevoerd in Nederland. In Hoofdstuk 3 
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laten we zien dat het percentage patiënten met alleen uitzaaiingen in de lever 
waarbij de uitzaaiingen operatief verwijderd worden in de regio Eindhoven 
verdrievoudigd is tussen 2004 en 2012 (van 8 naar 24%). De mediane 
overleving van deze patiënten was 55 maanden. We vonden echter ook grote 
verschillen tussen de verschillende ziekenhuizen in deze regio in het aantal 
patiënten dat geopereerd wordt aan uitzaaiingen in de lever.
Deze grote verschillen werden bevestigd in een landelijke studie, die 
beschreven staat in Hoofdstuk 4. Tussen 2008 en 2012 kreeg 12% van alle 
patiënten met naar de lever uitgezaaide dikke darmkanker een leveroperatie. 
Van alle patiënten werd 58% verwezen naar een ander ziekenhuis om daar 
geopereerd te worden. Het merendeel van de patiënten werd geopereerd 
in een academisch ziekenhuis (53%) of een niet-academisch gespecialiseerd 
levercentrum (39%). Het percentage patiënten in een ziekenhuis dat een 
leveroperatie onderging varieerde tussen 2% en 26%. Patiënten waarbij de 
kanker werd vastgesteld in een algemeen ziekenhuis hadden een lagere 
kans om leverchirurgie te ondergaan dan patiënten waarbij de kanker werd 
vastgesteld in een academisch ziekenhuis of een gespecialiseerd levercentrum. 
We denken dat meer overleg op regionaal en landelijk niveau, bijvoorbeeld 
in de vorm van een nationaal panel dat de mogelijkheid voor leverchirurgie 
per patiënt beoordeelt, ertoe kan leiden dat meer patiënten in aanmerking 
zullen komen voor een behandeling die kan leiden tot langdurige overleving.
Hoewel de eerder beschreven studies duidelijk laten zien dat er een 
toename is in het aantal patiënten dat een leveroperatie ondergaat, komt 
het merendeel van de mensen nog steeds slechts in aanmerking voor 
palliatieve behandeling. Deel 3 belicht daarom verschillende aspecten van 
de chirurgische behandeling van ongeneeslijk zieke patiënten met synchroon 
uitgezaaide dikke darmkanker. In Hoofdstuk 5 wordt de invloed van het 
chirurgisch verwijderen van de darmtumor op de overleving van ongeneeslijk 
zieke patiënten met uitgezaaide dikke darmkanker onderzocht. Met getallen 
uit de Nederlandse Kanker Registratie (2008-2012) werd de overleving van 
patiënten die een geplande palliatieve operatie, al dan niet gevolgd door 
systeemtherapie, vergeleken met patiënten die systeemtherapie kregen 
zonder dat eerst de tumor chirurgisch werd verwijderd. Patiënten die eerst 
geopereerd werden hadden een mediane overleving van 17 maanden, in 
vergelijking met 11 maanden in de niet-geopereerde groep. Patiënten die 
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zowel een operatie als systeemtherapie kregen hadden de beste overleving 
(mediaan 21 maanden). Dit potentiële overlevingsvoordeel van 6 maanden 
zou een belangrijke reden kunnen zijn om de tumor chirurgisch te verwijderen, 
zelfs als patiënten geen klachten hebben van deze tumor. Omdat er geen 
gegevens bekend zijn over de reden voor operatie, noch over de algehele 
conditie van en de aanwezigheid van comorbiditeit bij de patiënten, kan 
selectiebias echter niet uitgesloten worden.
Een belangrijke reden om geen operatie uit te voeren bij patiënten met 
uitzaaiingen is de verhoogde kans op overlijden na de operatie, in vergelijking 
met patiënten zonder uitzaaiingen. In Hoofdstuk 6 onderzochten we of 
er voorspellende factoren zijn die kunnen helpen met het inschatten van 
het risico van een resectie van de primaire tumor. Gegevens van patiënten 
met synchroon uitgezaaide dikke darmkanker werden verzameld in 8 
verschillende ziekenhuizen. In deze groep overleed 6% van de patiënten 
binnen 30 dagen na de operatie. Risicofactoren die de kans om te overlijden 
vergroten, waren een hogere leeftijd, een verhoogde body mass index (BMI), 
een tumor in de dikke darm (ten opzichte van een tumor in de endeldarm), 
verhoogd lactaat-dehydrogenase (LDH, een enzym in het bloed dat een maat 
is voor leverschade) en een verlaagd albumine (een eiwit in het bloed dat 
een maat is voor de voedingstoestand en conditie van een patiënt). Deze 
twee bloedbepalingen zijn bekende voorspellers voor de prognose van 
kankerpatiënten op de langere termijn, maar worden niet standaard bepaald 
bij een operatie. Bepaling van deze waardes voorafgaand aan de operatie 
kan, in combinatie met leeftijd, BMI en de plek van de tumor helpen om de 
risico’s van een operatie af te wegen tegen de mogelijke voordelen – en zo te 
bepalen of chirurgische verwijdering al dan niet zinvol is.
De verhoogde kans op overlijden na een operatie wordt vaak geweten aan 
een verhoogd risico op complicaties van de chirurgie. In Hoofdstuk 7 hebben 
we gegevens uit een Nederlandse chirurgische database geanalyseerd, en 
gevonden dat tussen 2009 en 2013 patiënten met synchroon uitgezaaide 
dikke darmkanker een hoger risico op overlijden hadden dan patiënten zonder 
uitzaaiingen (6% versus 4%). Patiënten met uitgezaaide dikke darmkanker 
hadden ook een iets hogere kans op complicaties tijdens of na de chirurgie, 
vergeleken met patiënten zonder uitzaaiingen (5% versus 4%, en 22% versus 
20%). Patiënten met uitgezaaide kanker gingen ook vaker naar de Intensive 
Care (17% versus 15%). Daarentegen zagen we wel een sterke afname van 
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het overlijden na een operatie over de jaren heen, van 11% in 2009 naar 
3% in 2013. Leeftijd, ASA classificatie (een classificatie van de Amerikaanse 
Vereniging van Anesthesiologen die het perioperatieve risico van een patiënt 
inschat), de Charlson Comorbiditeits Index (een score voor bijkomende 
andere ziektebeelden zoals hart- en vaatziekten, of diabetes), de plek van 
de darmtumor (dikke darm of endeldarm) en de urgentie van een operatie 
(spoed of gepland) waren onafhankelijke voorspellers van overlijden binnen 
30 dagen. Met deze factoren werd een risicoscore opgesteld die specialisten 
kan helpen om voorafgaand aan de operatie een inschatting te maken van 
het risico van de operatie, en kan helpen in de besluitvorming om wel of geen 
operatie te doen bij ongeneeslijk zieke patiënten.
Zowel het hierboven beschreven onderzoek, als eerdere publicaties, wijzen 
erop dat een operatie van een uitgezaaide dikke darmtumor de levensduur 
van een patiënt kan verlengen. Echter, in al deze studies kan een selectiebias 
niet uitgesloten worden. Om alle twijfel weg te nemen is het belangrijk om 
deze klinisch relevante vraag gerandomiseerd uit te zoeken. In Hoofdstuk 
8 wordt daarom het protocol gepresenteerd van de CAIRO4 studie: een 
studie die gerandomiseerd uitzoekt of het chirurgisch verwijderen van 
een darmtumor die weinig tot geen klachten veroorzaakt bij ongeneeslijk 
zieke patiënten leidt tot een betere overleving. De CAIRO4 studie is een 
internationale studie, die in meer dan 60 ziekenhuizen in Nederland en 
Denemarken wordt uitgevoerd. Voor de behandeling van patiënten wordt 
geloot tussen chirurgisch verwijderen van de tumor, waarna gestart wordt 
met systeemtherapie als ze voldoende hersteld zijn, of systeemtherapie 
(bestaande uit een fluoropyrimidine-behandeling met bevacizumab) zonder 
voorafgaande operatie. Gezien de duur van het herstel na een operatie alsmede 
de mogelijke complicaties en de kans op overlijden ten gevolge hiervan, zijn 
wij van mening dat een operatie minimaal 6 maanden overlevingsvoordeel 
moet opleveren. Om dit verschil aan te tonen zijn minimaal 360 patiënten 
nodig. De resultaten van deze studie worden in de komende jaren verwacht.
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Slotwoord
Dit proefschrift beschrijft de resultaten van verschillende studies naar de rol 
van de oncologisch chirurg in de behandeling van patiënten met synchroon 
uitgezaaide dikke darmkanker. Het percentage dikke darmkankerpatiënten 
met synchrone uitzaaiingen is toegenomen gedurende het afgelopen 
decennium, mogelijk door verbeteringen in beeldvormende technieken. 
Hoewel er lang gedacht werd dat patiënten met uitzaaiingen ongeneeslijk 
ziek waren, wordt nu algemeen aangenomen dat chirurgische verwijdering 
van de darmtumor en alle uitzaaiingen tot langdurige overleving en zelfs 
genezing kan lijden. Het aantal patiënten dat deze behandeling ondergaat, is 
gedurende de laatste twintig jaar gestegen. Gezien de snelle ontwikkelingen 
op dit vlak en de toenemende specialisatie van chirurgen, neemt het aantal 
patiënten dat hiervoor in aanmerking komt nog altijd toe. Dit maakt het 
moeilijk voor darmchirurgen om in te schatten of een patiënt al dan niet als 
te reseceren wordt beschouwd door een leverchirurg. Dit blijkt tevens uit 
de grote variabiliteit tussen ziekenhuizen in het percentage patiënten met 
uitgezaaide dikke darmkanker dat leverchirurgie ondergaat, waarbij met name 
de verschillen tussen algemene ziekenhuizen en gespecialiseerde levercentra 
opvallen. Omdat patiënten die geopereerd zijn aan de leveruitzaaiingen 
een aanzienlijk betere overleving hebben, is het van groot belang om deze 
verschillen te minimaliseren. De regionale verschillen die in dit proefschrift 
worden beschreven zijn ook een reflectie van het ontbreken van consensus 
op dit vlak. Gezien het feit dat de meerwaarde van chirurgische behandeling 
van de uitzaaiingen onmiskenbaar is, wordt in dit proefschrift gepleit voor 
betere samenwerking tussen darm- en leverchirurgen op regionaal en 
nationaal niveau. We verwachten dat een toename van het aantal patiënten 
dat een verwijdering van de uitzaaiingen ondergaat, in combinatie met betere 
chirurgische technieken en betere systeemtherapie, ertoe zal leiden dat het 
aantal patiënten dat als ongeneeslijk ziek wordt beschouwd zal afnemen. 
In de palliatieve situatie kunnen klachten, veroorzaakt door de darmtumor 
of door uitzaaiingen, tegenwoordig vaak voorkomen en behandeld worden 
met chemotherapie of bestraling. Het operatief verwijderen van de dikke 
darmtumor lijkt niet noodzakelijk om klachten te voorkomen, aangezien 
slechts een klein deel van de patiënten die niet geopereerd worden alsnog 
geopereerd moeten worden. Hierdoor is het aantal patiënten met synchrone 
metastasen dat een palliatieve operatieve verwijdering van de darmtumor 
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ondergaat aanzienlijk afgenomen in de laatste jaren. Aan de andere kant 
zijn er duidelijke aanwijzingen dat een dergelijke operatie een duidelijk 
overlevingsvoordeel met zich meebrengt. Het risico op overlijden is, 
zeker bij een geplande operatie, vrijwel vergelijkbaar met dat van dikke 
darmkankerpatiënten zonder uitzaaiingen. Er zijn duidelijke voorspellende 
factoren die kunnen helpen bij het inschatten van het risico voorafgaand 
aan een operatie. In afwachting van resultaten van grote studies, zoals in 
dit proefschrift wordt  voorgesteld, moeten alle patiënten met synchroon 
uitgezaaide dikke darmkanker, die niet in aanmerking komen voor deelname 
aan één van deze studies, worden besproken worden in een multidisciplinair 
overleg en gezien worden door een chirurg of oncoloog om de mogelijkheid 
van een palliatieve operatie te bespreken.
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te maken naast de kliniek – en ook voor al je persoonlijke adviezen.
Vrienden, familie en kennissen, bedankt voor jullie belangstelling en steun. 
Bedankt voor jullie geduld als ik weer een afspraak aan mij voorbij liet gaan 
en voor de broodnodige afleiding tijdens stressvolle momenten. Zonder de 
onvoorwaardelijke liefde en steun van mijn ouders had ik het nooit tot hier 
gered. Lieve Renske, bedankt voor alle uurtjes ‘nakijkwerk’. Lieve Arlieke, 
bedankt voor je hulp bij de lay-out. Zonder jullie was dit boekje nooit zo 
mooi geworden. Ik hou van jullie.
En tenslotte, een bijzonder woord van dank aan mijn fantastische gezin. 
Nina en Matthias, met jullie op schoot waren de vele late uren achter mijn 
beeldscherm een stuk minder eenzaam – mama heeft vanaf nu weer meer tijd 
voor jullie! Liefste Lennart, soms schieten woorden te kort. Je bent mijn rots.
En nu… Hora est!
